

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Adenocarcinoma With *EGFR* Mutations

Journal of Clinical Oncology

31, 3327-3334

DOI: 10.1200/jco.2012.44.2806

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Mesenchymal Stem Cells Derived from Bone Marrow of Diabetic Patients Portrait Unique Markers Influenced by the Diabetic Microenvironment. Review of Diabetic Studies, 2009, 6, 260-270. | 0.5 | 48 |
| 2 | Prise en charge thérapeutique des cancers bronchiques non à petites cellules métastatiques mutés pour l'EGFR. Revue Des Maladies Respiratoires Actualites, 2012, 4, 583-598. | 0.0 | 2 |
| 3 | Pharmacokinetics of Afatinib, a Selective Irreversible ErbB Family Blocker, in Patients with Advanced Solid Tumours. Clinical Pharmacokinetics, 2013, 52, 1101-1109. | 1.6 | 81 |
| 4 | Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives. Expert Review of Anticancer Therapy, 2013, 13, 1207-1218. | 1.1 | 13 |
| 5 | Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer. Science Translational Medicine, 2013, 5, 216ra177. | 5.8 | 438 |
| 6 | Pocket of opportunity. Nature, 2013, 503, 475-476. | 13.7 | 16 |
| 7 | Is EGF receptor tyrosine kinase inhibitor therapy in non-small-cell lung cancer patients with EGFR mutations the best option?. Lung Cancer Management, 2013, 2, 441-443. | 1.5 | 1 |
| 8 | Afatinib: First Global Approval. Drugs, 2013, 73, 1503-1515. | 4.9 | 238 |
| 9 | Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma. Critical Reviews in Oncology/Hematology, 2013, 88, 477-493. | 2.0 | 71 |
| 10 | HER2 and lung cancer. Expert Review of Anticancer Therapy, 2013, 13, 1219-1228. | 1.1 | 63 |
| 11 | Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors. Cancer Chemotherapy and Pharmacology, 2013, 72, 1213-1222. | 1.1 | 15 |
| 12 | Afatinib: new therapy option for EGFR-mutant lung cancer. Nature Reviews Clinical Oncology, 2013, 10, 551-552. | 12.5 | 72 |
| 13 | Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations. Journal of Clinical Oncology, 2013, 31, 3342-3350. | 0.8 | 285 |
| 14 | Mutation de l'EGFR, de l'étude du geste à la pratique clinique : exemplarité ou exception ?. Revue Des Maladies Respiratoires Actualites, 2013, 5, 519-537. | 0.0 | 1 |
| 15 | A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors. Investigational New Drugs, 2013, 31, 399-408. | 1.2 | 41 |
| 16 | Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy. European Respiratory Review, 2013, 22, 565-576. | 3.0 | 23 |
| 17 | Targeted Therapy for Non-Small Cell Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 907-912. | 2.5 | 25 |
| 18 | Personalizing Therapy in Advanced Non-Small Cell Lung Cancer. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 822-836. | 0.8 | 20 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Adjuvant Therapy for a 3.9â€m Adenocarcinoma of the Lung. <i>Oncologist</i> , 2013, 18, 1258-1261. | 1.9 | 0 |
| 20 | Epidermal Growth Factor Receptor Inhibition in Mutation-Positive Nonâ€“Small-Cell Lung Cancer: Is Afatinib Better or Simply Newer?. <i>Journal of Clinical Oncology</i> , 2013, 31, 3303-3306. | 0.8 | 63 |
| 21 | American Society of Clinical Oncology 2013 Top Five List in Oncology. <i>Journal of Clinical Oncology</i> , 2013, 31, 4362-4370. | 0.8 | 126 |
| 22 | New treatment strategy for patients with EGFR-mutant lung cancer. <i>Lung Cancer Management</i> , 2013, 2, 505-516. | 1.5 | 0 |
| 24 | Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy. <i>Journal of Cancer</i> , 2013, 4, 736-754. | 1.2 | 77 |
| 25 | Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors. <i>PLoS ONE</i> , 2013, 8, e84700. | 1.1 | 41 |
| 26 | Molecular Pathology of Lung Cancer: Current Status and Future Directions. <i>Tuberculosis and Respiratory Diseases</i> , 2014, 77, 49. | 0.7 | 12 |
| 27 | Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemo-naïve patients with EGFR-mutant lung adenocarcinoma. <i>OncoTargets and Therapy</i> , 2014, 7, 799. | 1.0 | 14 |
| 28 | Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data. <i>Brazilian Journal of Medical and Biological Research</i> , 2014, 47, 929-939. | 0.7 | 94 |
| 29 | Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives. <i>OncoTargets and Therapy</i> , 2014, 7, 1689. | 1.0 | 65 |
| 30 | Clinical and comparative utility of afatinib in non-small cell lung cancer. <i>Biologics: Targets and Therapy</i> , 2014, 8, 183. | 3.0 | 25 |
| 31 | Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations. <i>PLoS ONE</i> , 2014, 9, e85245. | 1.1 | 125 |
| 32 | Patients with Exon 19 Deletion Were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation after First-Line EGFR-TKIs for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e107161. | 1.1 | 142 |
| 33 | Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance. <i>Journal of Personalized Medicine</i> , 2014, 4, 297-310. | 1.1 | 16 |
| 34 | Molecular pathways and therapeutic targets in lung cancer. <i>Oncotarget</i> , 2014, 5, 1392-1433. | 0.8 | 171 |
| 35 | EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer. <i>Drug Design, Development and Therapy</i> , 2014, 8, 1595. | 2.0 | 36 |
| 36 | Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics. <i>Lung Cancer: Targets and Therapy</i> , 2014, 5, 73. | 1.3 | 3 |
| 37 | Interstitial Lung Disease Induced by Targeted Therapy for Non-Small Cell Lung Cancer: A Review of Diagnosis, Workup, and Management. <i>Journal of Palliative Care & Medicine</i> , 2014, 05, . | 0.1 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 38 | Chronic Nicotine Exposure Mediates Resistance to Egfr-Tki in Egfr-Mutated Lung Cancer Via Egfr Signal. <i>Annals of Oncology</i> , 2014, 25, v73. | 0.6 | 0 |
| 39 | Molecular Targeted Therapy in Lung Cancer. <i>Hanyang Medical Reviews</i> , 2014, 34, 37. | 0.4 | 1 |
| 40 | Management and Future Directions in Non-Small Cell Lung Cancer with Known Activating Mutations. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e353-e365. | 1.8 | 75 |
| 41 | 50 Years of Progress in the Systemic Therapy of Non-Small Cell Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , 177-189. | 1.8 | 92 |
| 42 | Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors. <i>Investigational New Drugs</i> , 2014, 32, 1311-1315. | 1.2 | 28 |
| 43 | Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 807-815. | 1.1 | 17 |
| 44 | Effect of gefitinib plus Chinese herbal medicine (CHM) in patients with advanced non-small-cell lung cancer: A retrospective case-control study. <i>Complementary Therapies in Medicine</i> , 2014, 22, 1010-1018. | 1.3 | 42 |
| 45 | Overcoming resistance to EGF receptor tyrosine kinase inhibitors in EGFR-mutated NSCLC. <i>Lung Cancer Management</i> , 2014, 3, 459-476. | 1.5 | 1 |
| 46 | Improving access to lung cancer treatment in northern Canada: the role of oral molecularly targeted agents. <i>Cmaj</i> , 2014, 186, 485-486. | 0.9 | 0 |
| 47 | Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment?. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 661-665. | 1.1 | 22 |
| 48 | Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNAActive [®]) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. <i>BMC Cancer</i> , 2014, 14, 748. | 1.1 | 101 |
| 49 | Challenges in the Management of EGFR-Mutated Non-Small Cell Lung Cancer Patients with Acquired Resistance to Tyrosine Kinase Inhibitors. <i>Oncology</i> , 2014, 87, 83-94. | 0.9 | 4 |
| 50 | Afatinib and lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1391-1406. | 1.1 | 13 |
| 51 | Management of NSCLC: focus on crizotinib. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2587-2597. | 0.9 | 15 |
| 52 | Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. <i>British Journal of Cancer</i> , 2014, 111, 1750-1756. | 2.9 | 28 |
| 53 | First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology. <i>European Respiratory Review</i> , 2014, 23, 92-105. | 3.0 | 43 |
| 54 | Targeted molecular therapies against epidermal growth factor receptor: Past experiences and challenges. <i>Neuro-Oncology</i> , 2014, 16, viii7-viii13. | 0.6 | 85 |
| 55 | Drug Monographs: Afatinib and Obinutuzumab. <i>Hospital Pharmacy</i> , 2014, 49, 237-241. | 0.4 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 56 | Is progression-free survival associated with a better health-related quality of life in patients with lung cancer? Evidence from two randomised trials with afatinib. <i>BMJ Open</i> , 2014, 4, e005762. | 0.8 | 22 |
| 57 | The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria. <i>Cancer</i> , 2014, 120, 3853-3858. | 2.0 | 9 |
| 58 | Hidden Treasures in "Ancient" Microarrays: Gene-Expression Portrays Biology and Potential Resistance Pathways of Major Lung Cancer Subtypes and Normal Tissue. <i>Frontiers in Oncology</i> , 2014, 4, 251. | 1.3 | 15 |
| 59 | Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine. <i>Frontiers in Oncology</i> , 2014, 4, 258. | 1.3 | 4 |
| 60 | Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 190. | 1.3 | 50 |
| 61 | Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies "€œ Past, Present, and Future. <i>Frontiers in Oncology</i> , 2014, 4, 233. | 1.3 | 15 |
| 62 | New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response. <i>European Respiratory Review</i> , 2014, 23, 367-378. | 3.0 | 78 |
| 63 | Updates in oncology. <i>European Respiratory Review</i> , 2014, 23, 69-78. | 3.0 | 4 |
| 64 | Afatinib with Concurrent Radiotherapy in a Patient with Metastatic Non-Small Cell Lung Cancer. <i>Oncology Research and Treatment</i> , 2014, 37, 6-6. | 0.8 | 4 |
| 65 | Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancer. <i>Future Oncology</i> , 2014, 10, 813-822. | 1.1 | 10 |
| 67 | Molecular Targets in the Treatment of Non"Small-Cell Lung Cancer: Is There Hope on the Horizon?. <i>Postgraduate Medicine</i> , 2014, 126, 139-148. | 0.9 | 12 |
| 68 | Preclinical antitumor activity of "222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2. <i>Cancer Science</i> , 2014, 105, 1040-1048. | 1.7 | 19 |
| 69 | Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2693-2708. | 0.9 | 20 |
| 70 | First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 2167-2177. | 13.9 | 2,808 |
| 71 | AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer. <i>Cancer Discovery</i> , 2014, 4, 1046-1061. | 7.7 | 1,655 |
| 72 | Dacomitinib: another option for EGFR-mutant lung cancer?. <i>Lancet Oncology</i> , The, 2014, 15, 1408-1409. | 5.1 | 6 |
| 73 | Preparing for tomorrow: Molecular diagnostics and the changing nonsmall cell lung cancer landscape. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 2-10. | 0.7 | 4 |
| 74 | Experience With Afatinib in Patients With Non-Small Cell Lung Cancer Progressing After Clinical Benefit From Gefitinib and Erlotinib. <i>Oncologist</i> , 2014, 19, 1100-1109. | 1.9 | 27 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 75 | Pharmacotherapy targeting the EGFR oncogene in NSCLC. Expert Opinion on Pharmacotherapy, 2014, 15, 2293-2305. | 0.9 | 16 |
| 76 | Clinical Pharmacogenetics. Cancer Drug Discovery and Development, 2014, , 803-821. | 0.2 | 0 |
| 77 | Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA - Journal of the American Medical Association, 2014, 311, 1998. | 3.8 | 1,386 |
| 79 | Advances in the Diagnosis and Treatment of Non-“Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2014, 13, 557-564. | 1.9 | 18 |
| 80 | Genotyping Lung Cancer Is an Investment in the Future. Journal of Clinical Oncology, 2014, 32, 3576-3577. | 0.8 | 6 |
| 81 | A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Annals of Oncology, 2014, 25, 1813-1820. | 0.6 | 162 |
| 82 | Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial. Trials, 2014, 15, 469. | 0.7 | 26 |
| 83 | Targeting the epidermal growth factor receptor in solid tumors: focus on safety. Expert Opinion on Drug Safety, 2014, 13, 535-549. | 1.0 | 30 |
| 84 | Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers. Journal of Thoracic Oncology, 2014, 9, 1669-1674. | 0.5 | 106 |
| 85 | Novel drugs against non-small-cell lung cancer. Current Opinion in Oncology, 2014, 26, 145-151. | 1.1 | 22 |
| 86 | The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma. Journal of Thoracic Oncology, 2014, 9, 1363-1369. | 0.5 | 75 |
| 87 | Meta-Analysis of First-Line Therapies in Advanced Non-“Small-Cell Lung Cancer Harboring EGFR-Activating Mutations. Journal of Thoracic Oncology, 2014, 9, 805-811. | 0.5 | 78 |
| 88 | Stereotactic Ablative Radiotherapy for Pulmonary Oligometastases and Oligometastatic Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 1426-1433. | 0.5 | 49 |
| 89 | Relationship Between EGFR Expression, EGFR Mutation Status, and the Efficacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced Non-“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 717-724. | 0.5 | 50 |
| 90 | EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression. Frontiers in Oncology, 2014, 4, 350. | 1.3 | 12 |
| 91 | Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2014, 14, 1495-1513. | 1.1 | 8 |
| 92 | Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Annals of Oncology, 2014, 25, 1681-1690. | 0.6 | 246 |
| 93 | Unintended Consequences of Expensive Cancer Therapeutics-“The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity. JAMA Otolaryngology - Head and Neck Surgery, 2014, 140, 1225. | 1.2 | 263 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 94 | The Management of Brain Metastases in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 248. | 1.3 | 54 |
| 95 | Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 256. | 1.3 | 21 |
| 96 | Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas. <i>European Respiratory Review</i> , 2014, 23, 356-366. | 3.0 | 139 |
| 97 | Afatinib in the treatment of head and neck squamous cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 135-143. | 1.9 | 20 |
| 98 | Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck. <i>Future Oncology</i> , 2014, 10, 21-40. | 1.1 | 12 |
| 99 | Less Toxic Chemotherapy Improves Uptake of All Lines of Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A 10-Year Retrospective Population-Based Review. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1180-1186. | 0.5 | 25 |
| 100 | Management of Nonhematologic Toxicities Associated With Different EGFR-TKIs in Advanced NSCLC: A Comparison Analysis. <i>Clinical Lung Cancer</i> , 2014, 15, 307-312. | 1.1 | 29 |
| 101 | Targeting Epidermal Growth Factor Receptor in the Management of Lung Cancer. <i>Seminars in Oncology</i> , 2014, 41, 101-109. | 0.8 | 19 |
| 102 | Summary Report From the 13th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting. <i>Clinical Lung Cancer</i> , 2014, 15, 16-20. | 1.1 | 1 |
| 103 | Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 713-721. | 5.1 | 157 |
| 104 | Afatinib for lung cancer: let there be light?. <i>Lancet Oncology</i> , The, 2014, 15, 133-134. | 5.1 | 4 |
| 105 | Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 135-145. | 2.0 | 12 |
| 106 | Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). <i>Lung Cancer</i> , 2014, 83, 174-181. | 0.9 | 43 |
| 107 | Prognostic and predictive biomarkers in lung cancer. A review. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 464, 347-358. | 1.4 | 77 |
| 108 | Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer. <i>Translational Respiratory Medicine</i> , 2014, 2, 2. | 3.8 | 23 |
| 109 | Beyond EGFR TKI in EGFR-mutant Non-Small Cell Lung Cancer patients: Main challenges still to be overcome. <i>Cancer Treatment Reviews</i> , 2014, 40, 723-729. | 3.4 | 19 |
| 110 | Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 213-222. | 5.1 | 1,740 |
| 111 | Pharmacokinetic Drug Interactions of Afatinib with Rifampicin and Ritonavir. <i>Clinical Drug Investigation</i> , 2014, 34, 173-182. | 1.1 | 52 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 112 | Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 759-770. | 1.1 | 47 |
| 113 | Lung cancer in never smokers: a different disease. <i>Current Respiratory Care Reports</i> , 2014, 3, 26-34. | 0.6 | 6 |
| 114 | Afatinib: A Review of Its Use in the Treatment of Advanced Non-Small Cell Lung Cancer. <i>Drugs</i> , 2014, 74, 207-221. | 4.9 | 74 |
| 115 | Novel agents and strategies for overcoming EGFR TKIs resistance. <i>Experimental Hematology and Oncology</i> , 2014, 3, 2. | 2.0 | 34 |
| 116 | Targeted therapies in gastroesophageal cancer. <i>European Journal of Cancer</i> , 2014, 50, 1247-1258. | 1.3 | 45 |
| 117 | Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer. <i>Cancer</i> , 2014, 120, 2289-2298. | 2.0 | 30 |
| 118 | ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics. <i>Cancer Cell</i> , 2014, 25, 282-303. | 7.7 | 817 |
| 119 | Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies. <i>Clinical Cancer Research</i> , 2014, 20, 2264-2275. | 3.2 | 60 |
| 120 | ABC Transporters in Multi-Drug Resistance and ADME-Tox of Small Molecule Tyrosine Kinase Inhibitors. <i>Pharmaceutical Research</i> , 2014, 31, 2237-2255. | 1.7 | 48 |
| 121 | Afatinib for the treatment of advanced non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 889-903. | 0.9 | 21 |
| 122 | Protein kinase inhibitors to treat non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1203-1213. | 0.9 | 17 |
| 123 | HER2 aberrations in cancer: Implications for therapy. <i>Cancer Treatment Reviews</i> , 2014, 40, 770-780. | 3.4 | 184 |
| 124 | EGFR Exon 19 Deletion Mutations and Systemic/Central Nervous System Miliary Metastasis: Clinical Correlations and Response to Therapy. <i>Clinical Lung Cancer</i> , 2014, 15, 387-389. | 1.1 | 7 |
| 125 | Recent Clinical Advances in Lung Cancer Management. <i>Journal of Clinical Oncology</i> , 2014, 32, 973-982. | 0.8 | 203 |
| 126 | DNA Sequencing of Cancer: What Have We Learned?. <i>Annual Review of Medicine</i> , 2014, 65, 63-79. | 5.0 | 41 |
| 127 | Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer. <i>Expert Opinion on Drug Discovery</i> , 2014, 9, 77-92. | 2.5 | 31 |
| 128 | Targeted therapy-induced diarrhea: A review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 165-179. | 2.0 | 47 |
| 129 | Biomarker enrichment strategies: matching trial design to biomarker credentials. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 81-90. | 12.5 | 147 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 130 | Refining standard practice and admitting uncertainty. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 69-70. | 12.5 | 6 |
| 131 | Efficiency of the Therascreen® RGQ PCR kit for the detection of EGFR mutations in non-small cell lung carcinomas. <i>Clinica Chimica Acta</i> , 2014, 429, 8-11. | 0.5 | 43 |
| 132 | Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer. <i>American Journal of Health-System Pharmacy</i> , 2014, 71, 1933-1938. | 0.5 | 16 |
| 133 | Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1433-1441. | 5.1 | 114 |
| 135 | Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 10176-10191. | 2.9 | 53 |
| 136 | Aspects biologiques des cancers bronchiques. <i>Revue Des Maladies Respiratoires Actualites</i> , 2014, 6, 311-319. | 0.0 | 0 |
| 138 | Anaplastic lymphoma kinase rearrangement in lung Cancer: Its biological and clinical significance. <i>Respiratory Investigation</i> , 2014, 52, 330-338. | 0.9 | 18 |
| 139 | A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2014, 50, 3136-3144. | 1.3 | 17 |
| 140 | Application of genotype-guided cancer therapy in solid tumors. <i>Pharmacogenomics</i> , 2014, 15, 79-93. | 0.6 | 21 |
| 141 | LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer. <i>Future Oncology</i> , 2014, 10, 533-540. | 1.1 | 6 |
| 142 | Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1369-1378. | 5.1 | 124 |
| 143 | Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01). <i>Lung Cancer</i> , 2014, 86, 170-173. | 0.9 | 156 |
| 144 | A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2014, 86, 207-212. | 0.9 | 47 |
| 145 | Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors. <i>Clinical Lung Cancer</i> , 2014, 15, 411-417.e4. | 1.1 | 32 |
| 146 | A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 1226-1235. | 1.2 | 9 |
| 147 | Novel agents in development for advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2014, 6, 240-253. | 1.4 | 33 |
| 148 | Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 453-468. | 1.5 | 17 |
| 149 | Design of Reversible, Cysteine-Targeted Michael Acceptors Guided by Kinetic and Computational Analysis. <i>Journal of the American Chemical Society</i> , 2014, 136, 12624-12630. | 6.6 | 204 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 150 | Prognostic Significance of Genotype and Number of Metastatic Sites in Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, 441-447. | 1.1 | 35 |
| 151 | Development of [¹⁸ F]afatinib as new TKI-PET tracer for EGFR positive tumors. <i>Nuclear Medicine and Biology</i> , 2014, 41, 749-757. | 0.3 | 39 |
| 152 | Reply to B.M. Strebel. <i>Journal of Clinical Oncology</i> , 2014, 32, 479-480. | 0.8 | 0 |
| 153 | Chemical biology approaches to target validation in cancer. <i>Current Opinion in Pharmacology</i> , 2014, 17, 87-100. | 1.7 | 36 |
| 154 | Update on systemic therapy of advanced non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1189-1203. | 1.1 | 31 |
| 155 | Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non-Small Cell Lung Cancer Cells. <i>Journal of the National Cancer Institute</i> , 2014, 106, . | 3.0 | 88 |
| 156 | Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1333-1348. | 1.9 | 48 |
| 157 | Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma. <i>Lung Cancer</i> , 2014, 86, 102-104. | 0.9 | 27 |
| 158 | New Strategies in Lung Cancer: Translating Immunotherapy into Clinical Practice. <i>Clinical Cancer Research</i> , 2014, 20, 1067-1073. | 3.2 | 52 |
| 159 | Progression-free survival as an end-point in solid tumours – Perspectives from clinical trials and clinical practice. <i>European Journal of Cancer</i> , 2014, 50, 2303-2308. | 1.3 | 32 |
| 160 | Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug-drug interactions. <i>Cancer Treatment Reviews</i> , 2014, 40, 917-926. | 3.4 | 134 |
| 161 | Targeted biopharmaceuticals for cancer treatment. <i>Cancer Letters</i> , 2014, 352, 145-151. | 3.2 | 35 |
| 162 | Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. <i>Lancet Oncology</i> , 2014, 15, 1236-1244. | 5.1 | 678 |
| 163 | Therapeutic Strategies Utilized in the Setting of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. <i>Clinical Cancer Research</i> , 2014, 20, 5898-5907. | 3.2 | 72 |
| 164 | Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?. <i>Medical Oncology</i> , 2014, 31, 78. | 1.2 | 4 |
| 166 | Lung Cancer in Older Adults. <i>Current Geriatrics Reports</i> , 2014, 3, 166-174. | 1.1 | 0 |
| 167 | Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy. <i>BMC Cancer</i> , 2014, 14, 473. | 1.1 | 20 |
| 168 | Do We Really Need Another Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in First-Line Treatment for Patients With Non-Small-Cell Lung Cancer and EGFR Mutations?. <i>Journal of Clinical Oncology</i> , 2014, 32, 859-863. | 0.8 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 169 | Afatinib-Related Nonhematologic Adverse Events: Is Common Evaluation Enough for Now?. <i>Journal of Clinical Oncology</i> , 2014, 32, 864-865. | 0.8 | 4 |
| 170 | Reply to E.R. Haspinger et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 863-864. | 0.8 | 1 |
| 171 | Targeting the Oncogenic MUC1-C Protein Inhibits Mutant EGFR-Mediated Signaling and Survival in Non-Small Cell Lung Cancer Cells. <i>Clinical Cancer Research</i> , 2014, 20, 5423-5434. | 3.2 | 60 |
| 172 | Recent advances in personalized lung cancer medicine. <i>Personalized Medicine</i> , 2014, 11, 309-321. | 0.8 | 22 |
| 173 | Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer. <i>Journal of Molecular Medicine</i> , 2014, 92, 697-707. | 1.7 | 58 |
| 174 | Afatinib, a lung cancer inhibitor of ErbB family. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2014, 387, 503-504. | 1.4 | 3 |
| 175 | Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 267-275. | 1.1 | 36 |
| 176 | Afatinib in the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1039-1047. | 1.9 | 33 |
| 177 | Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance. <i>Molecular Cancer</i> , 2014, 13, 143. | 7.9 | 55 |
| 178 | Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC. <i>Lung Cancer</i> , 2014, 84, 203-205. | 0.9 | 9 |
| 179 | Acquired resistance to TKIs in solid tumours: learning from lung cancer. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 473-481. | 12.5 | 740 |
| 180 | Understanding lung cancer molecular subtypes. <i>Clinical Practice (London, England)</i> , 2014, 11, 441-453. | 0.1 | 2 |
| 181 | Treatment algorithm in 2014 for advanced non-small cell lung cancer: Therapy selection by tumour histology and molecular biology. <i>Advances in Medical Sciences</i> , 2014, 59, 308-313. | 0.9 | 21 |
| 182 | Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies. <i>Trends in Biochemical Sciences</i> , 2014, 39, 465-474. | 3.7 | 134 |
| 183 | To Market, To Market—2013. <i>Annual Reports in Medicinal Chemistry</i> , 2014, 49, 437-508. | 0.5 | 7 |
| 184 | Emerging protein kinase inhibitors for non-small cell lung cancer. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 51-65. | 1.0 | 22 |
| 185 | Molecular targeted therapy for early-stage non-small-cell lung cancer: Will it increase the cure rate?. <i>Lung Cancer</i> , 2014, 84, 97-100. | 0.9 | 19 |
| 186 | Molecular testing in oncology: Problems, pitfalls and progress. <i>Lung Cancer</i> , 2014, 83, 309-315. | 0.9 | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 187 | Treatment of Advanced Nonâ€“Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2014, 15, 173-181. | 1.1 | 56 |
| 188 | Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. <i>Lung Cancer</i> , 2014, 84, 161-167. | 0.9 | 81 |
| 189 | Afatinib in NSCLC harbouring EGFR mutations. <i>Lancet Oncology</i> , The, 2014, 15, e148-e149. | 5.1 | 7 |
| 190 | Bevacizumab in Non-small Cell Lung Cancer: An Overview of Practice in the Era of Molecular Testing. <i>Clinical Oncology</i> , 2014, 26, 468-472. | 0.6 | 3 |
| 191 | A REVELation in non-small-cell lung cancer treatment?. <i>Lancet</i> , The, 2014, 384, 640-642. | 6.3 | 5 |
| 192 | Precision Medicine in Oncology Standard of Care. <i>Seminars in Oncology Nursing</i> , 2014, 30, 100-108. | 0.7 | 1 |
| 194 | Afatinib in the treatment of EGFR mutation-positive NSCLC â€“ A network meta-analysis. <i>Lung Cancer</i> , 2014, 85, 230-238. | 0.9 | 47 |
| 195 | DISRUPT: A randomised phase 2 trial of ombrabulin (AVE8062) plus a taxaneâ€“platinum regimen as first-line therapy for metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 85, 224-229. | 0.9 | 23 |
| 196 | Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. <i>Cancer Treatment Reviews</i> , 2014, 40, 990-1004. | 3.4 | 70 |
| 197 | Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations. <i>Radiology and Oncology</i> , 2014, 48, 361-368. | 0.6 | 15 |
| 198 | Review of the current targeted therapies for non-small-cell lung cancer. <i>World Journal of Clinical Oncology</i> , 2014, 5, 576. | 0.9 | 59 |
| 199 | Efficacy of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Patients with/without EGFR-Mutation: Evidence Based on Recent Phase III Randomized Trials. <i>Medical Science Monitor</i> , 2014, 20, 2666-2676. | 0.5 | 18 |
| 200 | Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 285. | 0.4 | 30 |
| 201 | How Sensitive Are Epidermal Growth Factor Receptorâ€“Tyrosine Kinase Inhibitors for Squamous Cell Carcinoma of the Lung Harboring EGFR Geneâ€“Sensitive Mutations?. <i>Journal of Thoracic Oncology</i> , 2014, 9, e19-e20. | 0.5 | 6 |
| 202 | Afatinib: rationale for use in non-small-cell lung cancer based on clinical trial data. <i>Clinical Investigation</i> , 2014, 4, 55-61. | 0.0 | 1 |
| 203 | Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Nonâ€“Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1385-1392. | 0.5 | 45 |
| 204 | Advanced EGFR Mutation-Positive Nonâ€“Small-Cell Lung Cancer: Case Report, Literature Review, and Treatment Recommendations. <i>Cancer Control</i> , 2014, 21, 67-73. | 0.7 | 16 |
| 205 | NCCN Working Group Report: Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1629-1649. | 2.3 | 18 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 206 | Interview: Changing advanced lung cancer into chronic disease. <i>Lung Cancer Management</i> , 2014, 3, 23-28. | 1.5 | 1 |
| 207 | Targeted therapy for lung cancer: reviewing the cost and its effect on treatment decisions. <i>Lung Cancer Management</i> , 2014, 3, 477-489. | 1.5 | 0 |
| 208 | The Difference of Clinical Characteristics Between Patients With Exon 19 Deletion and Those With L858R Mutation in Nonsmall Cell Lung Cancer. <i>Medicine (United States)</i> , 2015, 94, e1949. | 0.4 | 22 |
| 209 | Experience with targeted next generation sequencing for the care of lung cancer: Insights into promises and limitations of genomic oncology in day-to-day practice. <i>Cancer Treatment Communications</i> , 2015, 4, 174-181. | 0.4 | 24 |
| 210 | Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 883-889. | 0.5 | 55 |
| 211 | Towards manageable toxicities from targeted lung cancer treatment. <i>Lung Cancer Management</i> , 2015, 4, 279-287. | 1.5 | 0 |
| 212 | Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1268-1278. | 0.5 | 58 |
| 213 | Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2015, 10, 738-746. | 0.5 | 70 |
| 214 | Novel targeted agents for the treatment of lung cancer in China. <i>Cancer</i> , 2015, 121, 3089-3096. | 2.0 | 10 |
| 215 | Implementation of modern therapy approaches and research for non-small cell lung cancer in Japan. <i>Respirology</i> , 2015, 20, 199-208. | 1.3 | 4 |
| 216 | The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer. <i>Journal of Internal Medicine</i> , 2015, 278, 545-570. | 2.7 | 46 |
| 217 | Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure. <i>Journal of Thoracic Oncology</i> , 2015, 10, e115-e118. | 0.5 | 5 |
| 218 | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1754-1761. | 0.5 | 145 |
| 220 | Non-small-cell lung cancer. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15048. | 18.1 | 11 |
| 222 | Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer. <i>Experimental Hematology and Oncology</i> , 2015, 5, 24. | 2.0 | 20 |
| 224 | FDG-PET/CT as a Predictor of Outcome in EGFR-Mutant Non-small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1131-1132. | 0.5 | 0 |
| 225 | PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1364-1369. | 0.5 | 16 |
| 226 | Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1553-1559. | 0.5 | 137 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 227 | SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015. <i>Clinical and Translational Oncology</i> , 2015, 17, 1020-1029. | 1.2 | 43 |
| 228 | Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough. <i>Chinese Journal of Cancer</i> , 2015, 34, 310-9. | 4.9 | 13 |
| 229 | Targeted Therapy for Cancer in the Genomic Era. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 294-298. | 1.0 | 40 |
| 230 | Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis. <i>Journal of Translational Medicine</i> , 2015, 13, 257. | 1.8 | 26 |
| 231 | Cardiac safety of afatinib: a review of data from clinical trials. <i>Cardio-Oncology</i> , 2015, 1, 3. | 0.8 | 15 |
| 232 | Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib. <i>Cancer</i> , 2015, 121, 3212-3220. | 2.0 | 160 |
| 233 | Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors. <i>Biomarker Insights</i> , 2015, 10s3, BMI.S22430. | 1.0 | 29 |
| 234 | Transformation to Small Cell Lung Cancer as an Acquired Resistance Mechanism in EGFR-mutant Lung Adenocarcinoma: A Case Report of Complete Response to Etoposide and Cisplatin. <i>Tumori</i> , 2015, 101, e96-e98. | 0.6 | 18 |
| 235 | Long Progression-free Survival with Afatinib in a Patient with EGFR-unknown Lung Adenocarcinoma after Erlotinib Failure: A Case Report. <i>Tumori</i> , 2015, 101, e64-e66. | 0.6 | 2 |
| 236 | Adequacy of Malignant Pleural Effusion for Epidermal Growth Factor Receptor Mutation Analysis Using the Pyrosequencing Method. <i>Pleura (Thousand Oaks, Ventura County, Calif)</i> , 2015, 2, 237399751561658. | 0.2 | 2 |
| 237 | Epidermal Growth Factor Receptor-Mutant Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 371-377. | 1.0 | 40 |
| 238 | Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). <i>Cancer</i> , 2015, 121, 2253-2261. | 2.0 | 21 |
| 239 | Long progression-free survival with afatinib in a patient with heavily pretreated lung adenocarcinoma without common activating EGFR mutations. <i>Lung Cancer Management</i> , 2015, 4, 263-269. | 1.5 | 1 |
| 240 | Cumulative meta-analysis of epidermal growth factor receptor-tyrosine kinase inhibitors as first-line therapy in metastatic non-small-cell lung cancer. <i>Anti-Cancer Drugs</i> , 2015, 26, 995-1003. | 0.7 | 15 |
| 241 | The Evolution of Therapies in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2015, 7, 1815-1846. | 1.7 | 107 |
| 242 | Histologic Classification of Non-Small-Cell Lung Cancer over Time: Reducing the Rates of Not-Otherwise-Specified. <i>Current Oncology</i> , 2015, 22, 164-170. | 0.9 | 28 |
| 243 | The distinctive nature of adenocarcinoma of the lung. <i>OncoTargets and Therapy</i> , 2015, 8, 2399. | 1.0 | 16 |
| 244 | Prognostic impact of initial maximum standardized uptake value of 18F-FDG PET/CT on treatment response in patients with metastatic lung adenocarcinoma treated with erlotinib. <i>OncoTargets and Therapy</i> , 2015, 8, 3749. | 1.0 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 245 | Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples. <i>Oncotarget</i> , 2015, 6, 30850-30858. | 0.8 | 72 |
| 246 | Detection of Molecular Markers of Cancer Through the Use of Biosensors. <i>Biology and Medicine (Aligarh)</i> , 0, s2, . | 0.3 | 2 |
| 247 | Afatinib for the treatment of metastatic non-small cell lung cancer. <i>Cancer Management and Research</i> , 2015, 7, 75. | 0.9 | 31 |
| 248 | Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients. <i>Oncotarget</i> , 2015, 6, 34300-34308. | 0.8 | 70 |
| 249 | miRNAs and resistance to EGFR TKIs in EGFR-mutant non-small cell lung cancer: beyond traditional mechanisms of resistance. <i>E-cancermedicalscience</i> , 2015, 9, 569. | 0.6 | 12 |
| 250 | Combating Acquired Resistance to Tyrosine Kinase Inhibitors in Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e165-e173. | 1.8 | 16 |
| 251 | Outcome of Crizotinib Treatment in a Young Woman with Heavily Pretreated ROS1-positive Lung Cancer. <i>Tumori</i> , 2015, 101, e103-e106. | 0.6 | 3 |
| 252 | Defining the Role of Tyrosine Kinase Inhibitors in Early Stage Non-Small Cell Lung Cancer. <i>Journal of Cancer</i> , 2015, 6, 568-574. | 1.2 | 18 |
| 253 | Dacomitinib in lung cancer: a "lost generation"; EGFR tyrosine-kinase inhibitor from a bygone era?. <i>Drug Design, Development and Therapy</i> , 2015, 9, 5641. | 2.0 | 24 |
| 254 | Diagnosing Lung Cancer in the 21st Century: Are We Ready to Meet the Challenge of Individualized Care?. <i>Current Oncology</i> , 2015, 22, 272-278. | 0.9 | 8 |
| 255 | Missense Mutations in Exons 18-24 of EGFR in Hepatocellular Carcinoma Tissues. <i>BioMed Research International</i> , 2015, 2015, 1-7. | 0.9 | 10 |
| 256 | Profile of neratinib and its potential in the treatment of breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2015, 7, 147. | 1.0 | 44 |
| 257 | Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0119135. | 1.1 | 38 |
| 258 | Magnitude of the Benefit of Progression-Free Survival as a Potential Surrogate Marker in Phase 3 Trials Assessing Targeted Agents in Molecularly Selected Patients with Advanced Non-Small Cell Lung Cancer: Systematic Review. <i>PLoS ONE</i> , 2015, 10, e0121211. | 1.1 | 16 |
| 259 | Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach. <i>PLoS ONE</i> , 2015, 10, e0139074. | 1.1 | 50 |
| 260 | Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors. <i>OncoTargets and Therapy</i> , 2015, 8, 1137. | 1.0 | 21 |
| 261 | Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer. <i>Jornal Brasileiro De Pneumologia</i> , 2015, 41, 365-375. | 0.4 | 31 |
| 262 | Ultra High Performance Liquid Chromatography Method for the Determination of Two Recently FDA Approved TKIs in Human Plasma Using Diode Array Detection. <i>Journal of Analytical Methods in Chemistry</i> , 2015, 2015, 1-6. | 0.7 | 26 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 263 | Effects of Activating Mutations on EGFR Cellular Protein Turnover and Amino Acid Recycling Determined Using SILAC Mass Spectrometry. <i>International Journal of Cell Biology</i> , 2015, 2015, 1-8. | 1.0 | 26 |
| 264 | Combination of EGFR-TKI and Platinum-based Therapy for EGFR-mutated Non-small Cell Lung Cancer. <i>Japanese Journal of Lung Cancer</i> , 2015, 55, 871-878. | 0.0 | 0 |
| 266 | Research Progress in Head and Neck Squamous Cell Carcinoma: Best Abstracts of ICHNO 2015. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e323-e328. | 1.8 | 5 |
| 267 | Targeted Therapies for Non-Small Cell Lung Cancer: An Update on Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Inhibitors. <i>Clinical Journal of Oncology Nursing</i> , 2015, 19, 734-742. | 0.3 | 3 |
| 268 | A Phase III Study Comparing Gefitinib and Inserted Platinum-doublet Chemotherapy with Gefitinib as a First-line Treatment for Patients with Advanced Non-squamous Non-small Cell Lung Cancer Harboring EGFR Activating Mutations. <i>Japanese Journal of Lung Cancer</i> , 2015, 55, 879-884. | 0.0 | 1 |
| 269 | A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives. <i>Oncotarget</i> , 2015, 6, 26814-26825. | 0.8 | 152 |
| 270 | Comprehensive analysis of targetable oncogenic mutations in chinese cervical cancers. <i>Oncotarget</i> , 2015, 6, 4968-4975. | 0.8 | 44 |
| 271 | RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. <i>Nature Communications</i> , 2015, 6, 6377. | 5.8 | 498 |
| 272 | Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors. <i>Drug Resistance Updates</i> , 2015, 20, 12-28. | 6.5 | 103 |
| 273 | EGFR: The Paradigm of an Oncogene-Driven Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2221-2226. | 3.2 | 72 |
| 274 | Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations. <i>International Journal of Clinical Oncology</i> , 2015, 20, 1122-1129. | 1.0 | 12 |
| 276 | Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGFR receptor tyrosine kinase inhibitors: a comparative meta-analysis. <i>Future Oncology</i> , 2015, 11, 1109-1122. | 1.1 | 18 |
| 277 | The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. <i>Clinical Cancer Research</i> , 2015, 21, 3924-3933. | 3.2 | 459 |
| 278 | Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. <i>Lancet Oncology</i> , The, 2015, 16, 830-838. | 5.1 | 786 |
| 279 | EGFR mutations in lung cancer: from tissue testing to liquid biopsy. <i>Future Oncology</i> , 2015, 11, 1611-1623. | 1.1 | 82 |
| 280 | EGFR mutations and EGFR tyrosine kinase inhibitors. <i>Lancet Oncology</i> , The, 2015, 16, 746-748. | 5.1 | 3 |
| 281 | Genomic medicine and targeted therapy for solid tumors. <i>Journal of Surgical Oncology</i> , 2015, 111, 38-42. | 0.8 | 13 |
| 282 | New Discoveries for the Treatment of Lung Cancer and the Role of Small Biopsy Material. , 2015, , 129-154. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 283 | Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity. <i>Archives of Toxicology</i> , 2015, 89, 1227-1240. | 1.9 | 42 |
| 284 | Crizotinib in the management of advanced-stage non-small-cell lung cancer. <i>Future Oncology</i> , 2015, 11, 735-745. | 1.1 | 16 |
| 285 | Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance. <i>Therapeutic Advances in Respiratory Disease</i> , 2015, 9, 242-250. | 1.0 | 42 |
| 286 | Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non-Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses. <i>Journal of Clinical Oncology</i> , 2015, 33, 1008-1014. | 0.8 | 179 |
| 287 | EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors. <i>Clinical Cancer Research</i> , 2015, 21, 3913-3923. | 3.2 | 318 |
| 288 | Targeting EGFR in lung cancer: Lessons learned and future perspectives. <i>Molecular Aspects of Medicine</i> , 2015, 45, 67-73. | 2.7 | 42 |
| 289 | Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung. <i>Future Oncology</i> , 2015, 11, 2175-2191. | 1.1 | 5 |
| 290 | Case 17-2015. <i>New England Journal of Medicine</i> , 2015, 372, 2137-2147. | 13.9 | 6 |
| 291 | Experience with erlotinib in the treatment of non-small cell lung cancer. <i>Therapeutic Advances in Respiratory Disease</i> , 2015, 9, 146-163. | 1.0 | 25 |
| 292 | Necitumumab for non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1231-1239. | 1.4 | 14 |
| 293 | Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1370-1374. | 0.5 | 25 |
| 295 | Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib. <i>Cancer Science</i> , 2015, 106, 1377-1384. | 1.7 | 62 |
| 296 | Afatinib for the treatment of non-small cell lung cancer. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 1357-1364. | 0.5 | 1 |
| 297 | Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. <i>Annals of Oncology</i> , 2015, 26, vii83. | 0.6 | 0 |
| 298 | Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3. <i>Cancer Science</i> , 2015, 106, 1202-1211. | 1.7 | 99 |
| 299 | New insights into the molecular profile of lung adenocarcinoma and implications for therapy. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 361-364. | 1.1 | 1 |
| 300 | Targeted therapies: detrimental treatment for nonsmall cell lung cancer without driver mutations. <i>European Respiratory Journal</i> , 2015, 46, 19-21. | 3.1 | 1 |
| 301 | Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 739-750. | 1.1 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 302 | Evaluation of Safety and Efficacy of Salvage Therapy With Sunitinib, Docetaxel (Tyxan) and Cisplatinum Followed by Maintenance Vinorelbine for Unresectable/Metastatic Nonsmall Cell Lung Cancer. <i>Medicine (United States)</i> , 2015, 94, e2303. | 0.4 | 5 |
| 303 | Cancers bronchiques non À petites cellules mutÃ©s ou rÃ©arrangÃ©s : de la premiere Ã la Ã©niÃ©me ligne. <i>Revue Des Maladies Respiratoires Actualites</i> , 2015, 7, 497-505. | 0.0 | 0 |
| 304 | BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1396-1403. | 0.5 | 76 |
| 305 | Une population spÃ©ciale : les sujets Ã©gÃ©s. <i>Revue Des Maladies Respiratoires Actualites</i> , 2015, 7, 524-530. | 0.0 | 0 |
| 306 | Advances in Molecular Biology of Lung Disease. <i>Chest</i> , 2015, 148, 1063-1072. | 0.4 | 18 |
| 307 | Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 206-219. | 2.0 | 22 |
| 308 | EGFR-Mutated Breast Metastasis of Lung Adenocarcinoma: A Case Report. <i>Case Reports in Oncology</i> , 2015, 8, 164-168. | 0.3 | 6 |
| 309 | Developing biomarker-specific end points in lung cancer clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 135-146. | 12.5 | 43 |
| 310 | EGFR T790M resistance mutation in non-small-cell lung carcinoma. <i>Clinica Chimica Acta</i> , 2015, 444, 81-85. | 0.5 | 61 |
| 311 | Raising the Bar for Antineoplastic Agents: How to Choose Threshold Values for Superiority Trials in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 1036-1043. | 3.2 | 31 |
| 312 | Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902. <i>Annals of Oncology</i> , 2015, 26, 888-894. | 0.6 | 97 |
| 313 | Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. <i>Lung Cancer</i> , 2015, 88, 63-69. | 0.9 | 78 |
| 314 | Interstitial Lung Disease Arising From Erlotinib Treatment in a Caucasian Patient. <i>Clinical Lung Cancer</i> , 2015, 16, e1-e3. | 1.1 | 8 |
| 315 | Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. <i>EMBO Reports</i> , 2015, 16, 280-296. | 2.0 | 200 |
| 316 | Current and Future Approaches in the Management of Non-Small-Cell Lung Cancer Patients With Resistance to EGFR TKIs. <i>Clinical Lung Cancer</i> , 2015, 16, 252-261. | 1.1 | 27 |
| 317 | The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. <i>Cancer</i> , 2015, 121, E1-6. | 2.0 | 55 |
| 318 | Addressing the Right Targets in Oncology. <i>Journal of Biomolecular Screening</i> , 2015, 20, 305-317. | 2.6 | 14 |
| 319 | Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. <i>Lancet Oncology</i> , The, 2015, 16, 141-151. | 5.1 | 1,369 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 320 | Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations. <i>Lung Cancer</i> , 2015, 87, 311-317. | 0.9 | 56 |
| 321 | Adaptive stress signaling in targeted cancer therapy resistance. <i>Oncogene</i> , 2015, 34, 5599-5606. | 2.6 | 57 |
| 322 | The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (<i>EGFR</i>) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials. <i>Oncologist</i> , 2015, 20, 307-315. | 1.9 | 51 |
| 323 | What is the best strategy for targeting EGF receptors in non-small-cell lung cancer?. <i>Future Oncology</i> , 2015, 11, 153-167. | 1.1 | 22 |
| 324 | Nit-Picking around second line in EGFR NSCLC: just an academic effort. <i>Annals of Oncology</i> , 2015, 26, 448-450. | 0.6 | 0 |
| 325 | Systemic Chemotherapy. , 2015, , 307-318. | | 0 |
| 326 | Complex Decisions for First-Line and Maintenance Treatment of Advanced Wild-Type Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2015, 20, 299-306. | 1.9 | 11 |
| 327 | Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. <i>Clinical Cancer Research</i> , 2015, 21, 3631-3639. | 3.2 | 236 |
| 328 | Erlotinib-associated rash in patients with <i>EGFR</i> mutation-positive non-small-cell lung cancer treated in the EURTAC trial. <i>Future Oncology</i> , 2015, 11, 421-429. | 1.1 | 9 |
| 329 | EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 197-206. | 1.1 | 26 |
| 330 | Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2015, 20, 659-667. | 1.0 | 2 |
| 331 | Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2015, 17, 103-112. | 1.2 | 23 |
| 332 | Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 461-477. | 1.3 | 31 |
| 333 | Advances in target therapy in lung cancer. <i>European Respiratory Review</i> , 2015, 24, 23-29. | 3.0 | 28 |
| 334 | EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs. <i>Clinical Cancer Research</i> , 2015, 21, 5305-5313. | 3.2 | 164 |
| 335 | What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 306-317. | 2.0 | 27 |
| 336 | Using large-scale genomics data to identify driver mutations in lung cancer: methods and challenges. <i>Pharmacogenomics</i> , 2015, 16, 1149-1160. | 0.6 | 15 |
| 337 | C5-substituted pyrido[2,3-d]pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFR ^{T790M} mutant. <i>MedChemComm</i> , 2015, 6, 1693-1697. | 3.5 | 31 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 338 | Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 213-227. | 2.0 | 51 |
| 339 | A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors. <i>Future Oncology</i> , 2015, 11, 1479-1491. | 1.1 | 7 |
| 340 | Prolonged survival with erlotinib followed by afatinib in a caucasian smoker with metastatic, poorly differentiated large cell carcinoma of the lung: a case report. <i>Cancer Biology and Therapy</i> , 2015, 16, 1434-1437. | 1.5 | 5 |
| 341 | Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 2472-2480. | 0.8 | 94 |
| 342 | Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients. <i>Clinical and Translational Oncology</i> , 2015, 17, 727-736. | 1.2 | 20 |
| 343 | Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL). TJ ETQ 1 1 0.784314.org/Overlock10T | 1.0 | 10 |
| 344 | Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 897-907. | 5.1 | 389 |
| 345 | EGFR Mutations in Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2015, 1, 146. | 3.4 | 33 |
| 346 | Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction. <i>Lung Cancer</i> , 2015, 89, 280-286. | 0.9 | 18 |
| 347 | Routine Clinical Mutation Profiling of Non-Small Cell Lung Cancer Using Next-Generation Sequencing. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 913-921. | 1.2 | 28 |
| 348 | EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models. <i>Medical Oncology</i> , 2015, 32, 205. | 1.2 | 27 |
| 349 | Biomarker Testing in Non-Small Cell Lung Cancer: A Clinician's Perspective. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 448-450. | 1.2 | 6 |
| 350 | Entinostat (SNDX-275) for the treatment of non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1101-1109. | 1.9 | 37 |
| 351 | Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK. <i>Drugs</i> , 2015, 75, 1335-1348. | 4.9 | 104 |
| 352 | Current practice in and considerations for personalized medicine in lung cancer: From the patient's molecular biology to patient values and preferences. <i>Maturitas</i> , 2015, 82, 94-99. | 1.0 | 14 |
| 353 | Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib. <i>BioDrugs</i> , 2015, 29, 167-183. | 2.2 | 59 |
| 354 | Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation. <i>Lung Cancer</i> , 2015, 90, 65-70. | 0.9 | 42 |
| 355 | First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. <i>Annals of Oncology</i> , 2015, 26, 1883-1889. | 0.6 | 616 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 356 | Cancer modelling in the NGS era – Part I: Emerging technology and initial modelling. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 274-307. | 2.0 | 9 |
| 357 | Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. <i>Clinical Cancer Research</i> , 2015, 21, 3196-3203. | 3.2 | 427 |
| 358 | Emerging treatment for advanced lung cancer with EGFR mutation. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 597-612. | 1.0 | 22 |
| 359 | Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. <i>Lancet Oncology</i> , The, 2015, 16, 990-998. | 5.1 | 353 |
| 360 | Chemotherapy for lung cancer: still alive!. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 609-610. | 0.6 | 1 |
| 361 | Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2014-2022. | 1.9 | 45 |
| 362 | Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2015, 20, 967-974. | 1.9 | 73 |
| 363 | Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany. <i>Pharmacoeconomics</i> , 2015, 33, 1215-1228. | 1.7 | 23 |
| 364 | Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. <i>Cancer Research</i> , 2015, 75, 2489-2500. | 0.4 | 266 |
| 365 | Management of egfr tkî€”Induced Dermatologic Adverse Events. <i>Current Oncology</i> , 2015, 22, 123-132. | 0.9 | 63 |
| 366 | The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer. <i>Oncologist</i> , 2015, 20, 1058-1068. | 1.9 | 56 |
| 367 | Importance of ethnicity and smoking status in EGFR gene testing in lung cancers. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 686-686. | 0.5 | 0 |
| 369 | Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Journal of Clinical Oncology</i> , 2015, 33, 1666-1673. | 0.8 | 99 |
| 370 | Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 88, 74-79. | 0.9 | 157 |
| 371 | Overcoming Resistance to Targeted Therapy for Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 1760-1761. | 13.9 | 24 |
| 372 | Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients. <i>Lung Cancer</i> , 2015, 88, 282-288. | 0.9 | 51 |
| 373 | Gefitinib and Erlotinib in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis of Toxicity and Efficacy of Randomized Clinical Trials. <i>Oncologist</i> , 2015, 20, 400-410. | 1.9 | 123 |
| 374 | AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 1689-1699. | 13.9 | 1,802 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 375 | Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma. <i>Thoracic Cancer</i> , 2015, 6, 224-226. | 0.8 | 1 |
| 376 | Rociletinib in <i>EGFR</i> -Mutated Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 1700-1709. | 13.9 | 615 |
| 377 | Disease flare after gefitinib discontinuation. <i>Respiratory Investigation</i> , 2015, 53, 68-72. | 0.9 | 10 |
| 379 | Maintenance chemotherapy in advanced NSCLC: A population-based assessment of eligibility. <i>Lung Cancer</i> , 2015, 87, 296-302. | 0.9 | 2 |
| 380 | Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2015, 16, 325-333. | 1.1 | 65 |
| 381 | Precision Therapy for Lung Cancer: Tyrosine Kinase Inhibitors and Beyond. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2015, 27, 36-48. | 0.4 | 8 |
| 382 | Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR -mutated lung cancer via an EGFR signal. <i>Lung Cancer</i> , 2015, 88, 16-23. | 0.9 | 31 |
| 383 | Impact of Specific Epidermal Growth Factor Receptor (<i>EGFR</i>) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in <i>EGFR</i> -Mutant Lung Cancer: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2015, 33, 1958-1965. | 0.8 | 280 |
| 384 | Pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with different EGFR genotypes. <i>Tumor Biology</i> , 2015, 36, 861-869. | 0.8 | 8 |
| 385 | A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [¹¹ C]erlotinib and [¹⁸ F]afatinib in lung cancer-bearing mice. <i>EJNMMI Research</i> , 2015, 5, 14. | 1.1 | 38 |
| 386 | The epidermal growth factor receptor (EGFR) in lung cancer. <i>Translational Respiratory Medicine</i> , 2015, 3, 1. | 3.8 | 34 |
| 387 | Beyond EGFR and ALK inhibition: Unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 401-411. | 3.4 | 40 |
| 388 | Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 97-110. | 1.0 | 7 |
| 389 | Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors. <i>Future Oncology</i> , 2015, 11, 1259-1274. | 1.1 | 10 |
| 390 | Addressing the unmet need in lung cancer: The potential of immuno-oncology. <i>Cancer Treatment Reviews</i> , 2015, 41, 465-475. | 3.4 | 30 |
| 391 | Refining the treatment of NSCLC according to histological and molecular subtypes. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 511-526. | 12.5 | 247 |
| 392 | Association of <i>EGFR</i> L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. <i>JAMA Oncology</i> , 2015, 1, 149. | 3.4 | 224 |
| 393 | Chemical Proteomics Uncovers EPHA2 as a Mechanism of Acquired Resistance to Small Molecule EGFR Kinase Inhibition. <i>Journal of Proteome Research</i> , 2015, 14, 2617-2625. | 1.8 | 48 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 394 | Present standards and future perspectives in the treatment of metastatic non-small cell lung cancer. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 173-182. | 2.7 | 6 |
| 395 | Emerging paradigms in targeted treatments for Asian patients with NSCLC. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1167-1176. | 0.9 | 16 |
| 396 | Beyond the Vascular Endothelial Growth Factor Axis: Update on Role of Imaging in Nonantiangiogenic Molecular Targeted Therapies in Oncology. <i>American Journal of Roentgenology</i> , 2015, 204, 919-932. | 1.0 | 10 |
| 397 | Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2015, 9, 255-268. | 1.0 | 24 |
| 398 | Differences in the survival of patients with recurrent versus de novo metastatic <i>KRAS</i> mutant and <i>EGFR</i> mutant lung adenocarcinomas. <i>Cancer</i> , 2015, 121, 2078-2082. | 2.0 | 15 |
| 399 | Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell-Free DNA from Patients with Advanced Non-Small Cell Lung Cancer. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 265-272. | 1.2 | 185 |
| 400 | Crizotinib Therapy for Advanced Lung Adenocarcinoma and a <i>ROS1</i> Rearrangement: Results From the EUROS1 Cohort. <i>Journal of Clinical Oncology</i> , 2015, 33, 992-999. | 0.8 | 326 |
| 401 | Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1000-1007. | 0.8 | 206 |
| 402 | Incidence and risk of xerosis with targeted anticancer therapies. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 656-667. | 0.6 | 39 |
| 403 | Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer. <i>Future Oncology</i> , 2015, 11, 385-397. | 1.1 | 29 |
| 404 | Lafatinib, un nouveau médicament dans le cancer bronchique. <i>Actualites Pharmaceutiques</i> , 2015, 54, 42-45. | 0.0 | 0 |
| 405 | Molecularly Targeted Therapies in Non-Small-Cell Lung Cancer Annual Update 2014. <i>Journal of Thoracic Oncology</i> , 2015, 10, S1-S63. | 0.5 | 119 |
| 406 | Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. <i>Lancet Oncology</i> , 2015, 16, e165-e172. | 5.1 | 685 |
| 407 | Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2015, 27, 102-107. | 1.1 | 11 |
| 408 | Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in EGFR FISH-Positive Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 665-672. | 0.5 | 28 |
| 409 | Inhibition of β -Catenin Enhances the Anticancer Effect of Irreversible EGFR-TKI in EGFR-Mutated Non-small-cell Lung Cancer with a T790M Mutation. <i>Journal of Thoracic Oncology</i> , 2015, 10, 93-101. | 0.5 | 44 |
| 410 | Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)-Pretreated Non-Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease. <i>Journal of Thoracic Oncology</i> , 2015, 10, 156-163. | 0.5 | 238 |
| 411 | Organoid development in cancer genome discovery. <i>Current Opinion in Genetics and Development</i> , 2015, 30, 42-48. | 1.5 | 58 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 412 | PET/CT characterization of non-small-cell lung cancer heterogeneity. <i>Nuclear Medicine Communications</i> , 2015, 36, 411-413. | 0.5 | 0 |
| 413 | Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2015, 27, 94-101. | 1.1 | 126 |
| 414 | Improvement in Lung Cancer Outcomes With Targeted Therapies: An Update for Family Physicians. <i>Journal of the American Board of Family Medicine</i> , 2015, 28, 124-133. | 0.8 | 28 |
| 415 | Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors. <i>Future Oncology</i> , 2015, 11, 1245-1257. | 1.1 | 66 |
| 416 | Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (<sc>NSCLC</sc>). <i>Respirology</i> , 2015, 20, 370-378. | 1.3 | 119 |
| 417 | Management of EGFR mutated nonsmall cell lung carcinoma patients. <i>European Respiratory Journal</i> , 2015, 45, 1132-1141. | 3.1 | 36 |
| 418 | Subsolid pulmonary nodules: CT pathologic correlation using the 2011 IASLC/ATS/ERS classification. <i>Clinical Imaging</i> , 2015, 39, 344-351. | 0.8 | 8 |
| 419 | Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1327-1336. | 1.1 | 11 |
| 420 | Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1427-1440. | 1.5 | 36 |
| 421 | Targeted therapy in cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 1113-1132. | 1.1 | 139 |
| 422 | Predictive biomarkers in precision medicine and drug development against lung cancer. <i>Chinese Journal of Cancer</i> , 2015, 34, 295-309. | 4.9 | 34 |
| 423 | Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. <i>Lancet Oncology</i> , 2015, 16, e447-e459. | 5.1 | 325 |
| 424 | Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 263-273. | 1.4 | 47 |
| 425 | Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations. <i>Lung Cancer</i> , 2015, 90, 307-313. | 0.9 | 23 |
| 426 | Alopecia in patients treated with molecularly targeted anticancer therapies. <i>Annals of Oncology</i> , 2015, 26, 2496-2502. | 0.6 | 48 |
| 427 | Nonsense and missense mutation of mitochondrial ND6 gene promotes cell migration and invasion in human lung adenocarcinoma. <i>BMC Cancer</i> , 2015, 15, 346. | 1.1 | 55 |
| 428 | Divergent epidermal growth factor receptor mutation patterns between smokers and non-smokers with lung adenocarcinoma. <i>Lung Cancer</i> , 2015, 90, 472-476. | 0.9 | 14 |
| 429 | Failures in Phase III: Causes and Consequences. <i>Clinical Cancer Research</i> , 2015, 21, 4552-4560. | 3.2 | 70 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 431 | Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors. <i>Oncologist</i> , 2015, 20, 1167-1174. | 1.9 | 59 |
| 432 | Next-generation sequencing and empowering personalised cancer medicine. <i>Drug Discovery Today</i> , 2015, 20, 1470-1475. | 3.2 | 22 |
| 433 | Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I-III A. <i>European Respiratory Review</i> , 2015, 24, 340-355. | 3.0 | 27 |
| 434 | Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2015, 113, 1413-1420. | 2.9 | 18 |
| 435 | Radiotherapy of non-small-cell lung cancer in the era of EGFR gene mutations and EGF receptor tyrosine kinase inhibitors. <i>Future Oncology</i> , 2015, 11, 2329-2342. | 1.1 | 15 |
| 436 | Cytotoxic metabolites from the endophytic fungus <i>Penicillium chermesinum</i> : discovery of a cysteine-targeted Michael acceptor as a pharmacophore for fragment-based drug discovery, bioconjugation and click reactions. <i>RSC Advances</i> , 2015, 5, 70595-70603. | 1.7 | 47 |
| 437 | Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects. <i>Lung Cancer</i> , 2015, 90, 1-7. | 0.9 | 14 |
| 439 | Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance. <i>Cancer Medicine</i> , 2015, 4, 1621-1632. | 1.3 | 48 |
| 440 | Pharmacogenomics in the treatment of lung cancer: an update. <i>Pharmacogenomics</i> , 2015, 16, 1751-1760. | 0.6 | 6 |
| 441 | Targeted therapy in the treatment of uterine serous carcinoma. <i>Pharmacogenomics</i> , 2015, 16, 97-99. | 0.6 | 5 |
| 442 | Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress. <i>Current Treatment Options in Oncology</i> , 2015, 16, 51. | 1.3 | 9 |
| 443 | Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly. <i>Drugs and Aging</i> , 2015, 32, 907-916. | 1.3 | 9 |
| 444 | Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs. <i>Pharmacological Research</i> , 2015, 102, 123-131. | 3.1 | 51 |
| 445 | Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. <i>British Journal of Cancer</i> , 2015, 113, 1519-1528. | 2.9 | 94 |
| 446 | A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). <i>Annals of Oncology</i> , 2015, 26, 1547-1573. | 0.6 | 635 |
| 447 | Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach. <i>Future Oncology</i> , 2015, 11, 489-500. | 1.1 | 20 |
| 448 | Entrectinib: a potent new TRK, ROS1, and ALK inhibitor. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1493-1500. | 1.9 | 117 |
| 449 | Considerations on the management of EGF receptor-TKIs for brain metastases in EGFR-mutant lung carcinoma patients. <i>Lung Cancer Management</i> , 2015, 4, 43-49. | 1.5 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 450 | Management of pulmonary toxicity associated with targeted anticancer therapies. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1695-1707. | 1.5 | 15 |
| 451 | Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel. Future Oncology, 2015, 11, 267-277. | 1.1 | 17 |
| 452 | A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours. European Journal of Cancer, 2015, 51, 2275-2284. | 1.3 | 25 |
| 453 | Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2015, 33, 3488-3515. | 0.8 | 606 |
| 454 | Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer. Future Oncology, 2015, 11, 2525-2540. | 1.1 | 25 |
| 455 | Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States. Value in Health, 2015, 18, 774-782. | 0.1 | 61 |
| 456 | Practical Value of Molecular Pathology in Stage III Lung Cancer: Implications for the Clinical Surgeon. Annals of Surgical Oncology, 2015, 22, 3459-3465. | 0.7 | 5 |
| 457 | The future of immunotherapy in the treatment of lung cancer. Lung Cancer Management, 2015, 4, 57-73. | 1.5 | 2 |
| 458 | Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. Lung Cancer, 2015, 89, 287-293. | 0.9 | 29 |
| 459 | EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. Cancer Discovery, 2015, 5, 1155-1163. | 7.7 | 94 |
| 460 | EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2015, 76, 835-841. | 1.1 | 40 |
| 461 | Modernizing Eligibility Criteria for Molecularly Driven Trials. Journal of Clinical Oncology, 2015, 33, 2815-2820. | 0.8 | 80 |
| 462 | Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy. Therapeutic Advances in Medical Oncology, 2015, 7, 274-290. | 1.4 | 20 |
| 463 | Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?. Expert Opinion on Biological Therapy, 2015, 15, 1553-1566. | 1.4 | 22 |
| 464 | Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the "Hispanic paradox". Lung Cancer, 2015, 90, 161-166. | 0.9 | 50 |
| 465 | Casting a wide net: HSP90 inhibition to circumvent resistance to TKIs in EGFR-mutated and ALK-rearranged NSCLC. Lung Cancer Management, 2015, 4, 5-8. | 1.5 | 0 |
| 466 | Renal toxicity of anticancer agents targeting HER2 and EGFR. Journal of Nephrology, 2015, 28, 647-657. | 0.9 | 33 |
| 467 | Role of circulating-tumor DNA analysis in non-small cell lung cancer. Lung Cancer, 2015, 90, 128-134. | 0.9 | 80 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|----------|-----------|
| 468 | Overcoming Resistance Without the Risk of Reaction: Use of Afatinib and Panitumumab in Two Cases of Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer With T790M Mutations. <i>Clinical Lung Cancer</i> , 2015, 16, e97-e99. | 1.1 | 3 |
| 469 | Oncogenic Alterations in <i>ERBB2/HER2</i> Represent Potential Therapeutic Targets Across Tumors From Diverse Anatomic Sites of Origin. <i>Oncologist</i> , 2015, 20, 7-12. | 1.9 | 69 |
| 470 | Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. <i>Neuro-Oncology</i> , 2015, 17, 296-302. | 0.6 | 72 |
| 471 | Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials. <i>Journal of Chemotherapy</i> , 2015, 27, 40-51. | 0.7 | 56 |
| 472 | Rationale and Study Design of the IRENE-Trial (NVALT-16): A Phase II Trial to Evaluate Iressa Rechallenge in Advanced NSCLC Patients With an Activating EGFR Mutation Who Responded to an EGFR-TKI Used As First-Line or Previous Treatment. <i>Clinical Lung Cancer</i> , 2015, 16, 60-66. | 1.1 | 13 |
| 473 | Optimizing the Sequence of Anti-EGFR-Targeted Therapy in EGFR-Mutant Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 542-552. | 1.9 | 28 |
| 474 | Pharmacogenomic biomarkers for personalized cancer treatment. <i>Journal of Internal Medicine</i> , 2015, 277, 201-217. | 2.7 | 57 |
| 475 | Pragmatic issues in biomarker evaluation for targeted therapies in cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 197-212. | 12.5 | 162 |
| 476 | PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. <i>British Journal of Cancer</i> , 2015, 112, 95-102. | 2.9 | 515 |
| 478 | Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2016, Volume 7, 91-97. | 1.3 | 7 |
| 479 | Safe and successful treatment with afatinib in three postoperative non-small cell lung cancer patients with recurrences following gefitinib/erlotinib-induced hepatotoxicity. <i>Journal of Medical Investigation</i> , 2016, 63, 149-151. | 0.2 | 6 |
| 480 | Lung cancer with concurrent <i>EGFR</i> mutation and <i>ROS1</i> rearrangement: a case report and review of the literature. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4301-4305. | 1.0 | 21 |
| 481 | Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2016, 9, 929. | 1.0 | 13 |
| 482 | Detection of the T790M mutation of <i>EGFR</i> in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR). <i>Tj ETQq1 1 0.784314 rgeT /Overlo</i> | 0.784314 | 6 |
| 483 | Precision medicine in lung cancer: the battle continues. <i>Journal of Thoracic Disease</i> , 2016, 8, 2991-2993. | 0.6 | 4 |
| 484 | Targeted therapies and immunotherapy in non-small-cell lung cancer. <i>Ecancermedicalsecience</i> , 2016, 10, 648. | 0.6 | 29 |
| 485 | In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma. <i>Drug Design, Development and Therapy</i> , 2016, 10, 1299. | 2.0 | 13 |
| 486 | New targeted treatments for non-small-cell lung cancer – role of nivolumab. <i>Biologics: Targets and Therapy</i> , 2016, Volume 10, 103-117. | 3.0 | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 487 | Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 31-38. | 0.7 | 26 |
| 488 | Biopsy Procedures and Molecular Testing Utilization and Related Costs in Patients with Metastatic Lung Cancer. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 1194-1203. | 0.5 | 9 |
| 489 | Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer. Oncotarget, 2016, 7, 3884-3896. | 0.8 | 34 |
| 490 | Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine kinase inhibitors (TKIs) and evidence in favor or against their use with concurrent cranial radiotherapy. Translational Lung Cancer Research, 2016, 5, 588-598. | 1.3 | 28 |
| 491 | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future. Translational Lung Cancer Research, 2016, 5, 563-578. | 1.3 | 30 |
| 492 | Targeted Therapy in Brain Metastases: Ready for Primetime?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e123-e130. | 1.8 | 35 |
| 493 | Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma. Oncotarget, 2016, 7, 45237-45248. | 0.8 | 25 |
| 494 | Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?. Journal of Thoracic Disease, 2016, 8, E217-E220. | 0.6 | 9 |
| 495 | Afatinib in lung cancer harboring EGFR mutation in the LUX-Lung trials: six plus three is greater than seven?. Translational Lung Cancer Research, 2016, 5, 446-449. | 1.3 | 6 |
| 496 | Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors. Translational Lung Cancer Research, 2016, 5, 401-412. | 1.3 | 56 |
| 497 | Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?â€”current evidence and future perspectives. Translational Lung Cancer Research, 2016, 5, 628-636. | 1.3 | 15 |
| 498 | Metastatic lung cancer in the age of targeted therapy: improving long-term survival. Translational Lung Cancer Research, 2016, 5, 727-730. | 1.3 | 14 |
| 499 | Non-Small-Cell Lung Cancer Treatment. Juntendo Medical Journal, 2016, 62, 7-12. | 0.1 | 1 |
| 500 | Lazarus response to treatment of patients with lung cancer and oncogenic mutations in the intensive care unit. Journal of Thoracic Disease, 2016, 8, E1455-E1461. | 0.6 | 8 |
| 501 | Are there any differences in genomic characterization of non-small cell lung cancer between African Americans and Whites?. Journal of Thoracic Disease, 2016, 8, E1517-E1519. | 0.6 | 1 |
| 502 | Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements. Translational Lung Cancer Research, 2016, 5, 331-337. | 1.3 | 56 |
| 503 | Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice. Oncotarget, 2016, 7, 28748-28760. | 0.8 | 95 |
| 504 | EGFR Mutation Analysis of Circulating Tumor DNA Using an Improved PNA-LNA PCR Clamp Method. Canadian Respiratory Journal, 2016, 2016, 1-7. | 0.8 | 28 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 505 | Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer. <i>Oncotarget</i> , 2016, 7, 71013-71035. | 0.8 | 69 |
| 506 | Osimertinib making a breakthrough in lung cancer targeted therapy. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5489-5493. | 1.0 | 53 |
| 507 | Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives. <i>Pharmacogenomics and Personalized Medicine</i> , 2016, Volume 9, 65-77. | 0.4 | 25 |
| 508 | Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5461-5473. | 1.0 | 41 |
| 509 | The prevalence of <i>EGFR</i> mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. <i>Oncotarget</i> , 2016, 7, 78985-78993. | 0.8 | 500 |
| 510 | An update on clinical oncology for the non-oncologist. <i>Einstein (Sao Paulo, Brazil)</i> , 2016, 14, 294-299. | 0.3 | 2 |
| 511 | Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC. <i>Frontiers in Oncology</i> , 2016, 6, 112. | 1.3 | 23 |
| 512 | Discordance of Mutation Statuses of Epidermal Growth Factor Receptor and K-ras between Primary Adenocarcinoma of Lung and Brain Metastasis. <i>International Journal of Molecular Sciences</i> , 2016, 17, 524. | 1.8 | 28 |
| 513 | EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2132. | 1.8 | 48 |
| 514 | ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations. <i>Respiratory Research</i> , 2016, 17, 105. | 1.4 | 10 |
| 515 | Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 807. | 0.9 | 10 |
| 516 | Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. <i>OncoTargets and Therapy</i> , 2016, 9, 3711. | 1.0 | 98 |
| 517 | Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 3867-3872. | 2.0 | 41 |
| 518 | Overcoming Resistance to EGFR Inhibitors in NSCLC. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 99-105. | 0.4 | 15 |
| 519 | The role of pembrolizumab in the treatment of advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2016, 4, 215-215. | 0.7 | 13 |
| 520 | The Current Situation and Problems of Re-biopsy in Non-small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations. <i>Japanese Journal of Lung Cancer</i> , 2016, 56, 331-336. | 0.0 | 0 |
| 521 | Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer. <i>Oncotarget</i> , 2016, 7, 49948-49960. | 0.8 | 95 |
| 524 | Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study. <i>Lung Cancer</i> , 2016, 101, 1-8. | 0.9 | 118 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 525 | Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2016, 28, 115-121. | 1.1 | 21 |
| 526 | Evolving Landscape of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Journal of Clinical Oncology</i> , 2016, 34, 3233-3234. | 0.8 | 0 |
| 527 | Targeted therapies for treatment of non-small cell lung cancer—Recent advances and future perspectives. <i>International Journal of Cancer</i> , 2016, 138, 2549-2561. | 2.3 | 155 |
| 528 | Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1484-1499. | 1.0 | 75 |
| 529 | Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1693-1701. | 0.9 | 16 |
| 530 | Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2980-2987. | 0.8 | 444 |
| 531 | Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles. <i>Archiv Der Pharmazie</i> , 2016, 349, 573-593. | 2.1 | 29 |
| 532 | Circulating Biomarkers in Non-Small-Cell Lung Cancer: Current Status and Future Challenges. <i>Clinical Lung Cancer</i> , 2016, 17, 507-516. | 1.1 | 43 |
| 533 | Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer. , 2016, 166, 71-83. | | 14 |
| 534 | Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small cell lung cancer. <i>Biomedical Chromatography</i> , 2016, 30, 1150-1154. | 0.8 | 33 |
| 535 | First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. <i>The Cochrane Library</i> , 2016, , CD010383. | 1.5 | 146 |
| 536 | A phase I study of nedaplatin, pemetrexed and thoracic intensity-modulated radiotherapy for inoperable stage III lung adenocarcinoma. <i>BMC Cancer</i> , 2016, 16, 775. | 1.1 | 2 |
| 537 | Resistance to Targeted Therapies Against Adult Brain Cancers. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016, , . | 0.1 | 4 |
| 538 | Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma. <i>Open Medicine (Poland)</i> , 2016, 11, 68-77. | 0.6 | 10 |
| 539 | Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors. <i>Oncologist</i> , 2016, 21, 1483-1491. | 1.9 | 64 |
| 540 | Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors. <i>Journal of Biomedical Science</i> , 2016, 23, 86. | 2.6 | 41 |
| 542 | Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial. <i>Targeted Oncology</i> , 2016, 11, 619-629. | 1.7 | 15 |
| 543 | Safety profiles of first-line therapies for metastatic non-squamous non-small-cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 837-851. | 1.0 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 544 | Immune checkpoint inhibitors in lung cancer: past, present and future. <i>Future Oncology</i> , 2016, 12, 1151-1163. | 1.1 | 26 |
| 545 | The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. <i>Journal of Thoracic Oncology</i> , 2016, 11, 946-963. | 0.5 | 173 |
| 546 | Treatment of EGFR-Mutant Lung Cancers After Progression in Patients Receiving First-Line EGFR Tyrosine Kinase Inhibitors. <i>JAMA Oncology</i> , 2016, 2, 948. | 3.4 | 30 |
| 547 | Progression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Phase III Randomized Controlled Trials Evaluating the First-Line Chemotherapy for Advanced, Locally Advanced, and Recurrent Non-Small Cell Lung Carcinoma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1574-1585. | 0.5 | 22 |
| 548 | Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1988-1997. | 1.9 | 16 |
| 549 | Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR. <i>Future Medicinal Chemistry</i> , 2016, 8, 853-878. | 1.1 | 15 |
| 550 | BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 461-465. | 1.1 | 37 |
| 551 | Specialty pharmacy services for patients receiving oral medications for solid tumors. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 775-796. | 0.5 | 14 |
| 552 | Safety of gefitinib in non-small cell lung cancer treatment. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 993-1000. | 1.0 | 14 |
| 553 | New oncogenes drivers in lung cancer—new therapeutic targets. <i>Current Pulmonology Reports</i> , 2016, 5, 49-56. | 0.5 | 0 |
| 554 | Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence. <i>Therapeutic Advances in Respiratory Disease</i> , 2016, 10, 256-264. | 1.0 | 17 |
| 555 | Pre-Emptive or Reactive Treatment of Cutaneous Rash Induced by Epidermal Growth Factor Receptor Inhibitors: Does It Matter?. <i>Journal of Clinical Oncology</i> , 2016, 34, 774-776. | 0.8 | 0 |
| 556 | Next-Generation Sequencing and Immunotherapy Biomarkers: A Medical Oncology Perspective. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 245-248. | 1.2 | 11 |
| 557 | Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. <i>Lancet Oncology</i> , The, 2016, 17, 577-589. | 5.1 | 950 |
| 558 | Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2016, 9, 34. | 6.9 | 231 |
| 559 | Radiation recall pneumonitis induced by epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced nonsmall-cell lung cancer. <i>Journal of the Chinese Medical Association</i> , 2016, 79, 248-255. | 0.6 | 32 |
| 560 | Q787Q EGFR Polymorphism as a Prognostic Factor for Lung Squamous Cell Carcinoma. <i>Oncology</i> , 2016, 90, 289-298. | 0.9 | 9 |
| 561 | Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2219-2231. | 1.4 | 49 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 562 | Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?. <i>Drugs</i> , 2016, 76, 831-840. | 4.9 | 13 |
| 563 | Identification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016, 142, 559. | 1.2 | 37 |
| 564 | The Frequency of EGFR Mutation in Lung Adenocarcinoma and the Efficacy of Tyrosine Kinase Inhibitor Therapy in a Hungarian Cohort of Patients. <i>Pathology and Oncology Research</i> , 2016, 22, 755-761. | 0.9 | 3 |
| 565 | EGFR Fusions as Novel Therapeutic Targets in Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 601-611. | 7.7 | 97 |
| 568 | Linking the Price of Cancer Drug Treatments to Their Clinical Value. <i>Clinical Drug Investigation</i> , 2016, 36, 579-589. | 1.1 | 5 |
| 570 | Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA. <i>Clinical Cancer Research</i> , 2016, 22, 5772-5782. | 3.2 | 279 |
| 571 | Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. <i>Annals of Oncology</i> , 2016, 27, 2103-2110. | 0.6 | 159 |
| 572 | Challenge of Prognostic Uncertainty in the Modern Era of Cancer Therapeutics. <i>Journal of Clinical Oncology</i> , 2016, 34, 3605-3608. | 0.8 | 72 |
| 573 | Resisting Resistance: Targeted Therapies in Lung Cancer. <i>Trends in Cancer</i> , 2016, 2, 350-364. | 3.8 | 162 |
| 575 | Clinical analysis of patients treated with afatinib for advanced non-small cell lung cancer: A Nagano Lung Cancer Research Group observational study. <i>Respiratory Investigation</i> , 2016, 54, 462-467. | 0.9 | 7 |
| 579 | The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 1229-1241. | 1.0 | 9 |
| 580 | Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 941-947. | 1.1 | 6 |
| 581 | Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2253-2266. | 0.9 | 26 |
| 582 | A decrease in D-dimer concentration and an occurrence of skin rash as iatrogenic events and complementary predictors of survival in lung cancer patients treated with EGFR tyrosine kinase inhibitors. <i>Pharmacological Reports</i> , 2016, 68, 1140-1148. | 1.5 | 13 |
| 584 | Metastatic Lung Cancer: Emerging Therapeutic Strategies. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016, 37, 736-749. | 0.8 | 1 |
| 585 | Immunotherapy for Lung Cancer: No Longer an Abstract Concept. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016, 37, 771-782. | 0.8 | 12 |
| 586 | EGFR as a Pharmacological Target in EGFR -Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?. <i>Trends in Pharmacological Sciences</i> , 2016, 37, 887-903. | 4.0 | 76 |
| 587 | Divide and Conquer to Treat Lung Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1892-1893. | 13.9 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 588 | Treatments and outcomes of advanced/recurrent non-small cell lung cancer harboring the EGFR T790M mutation: a retrospective observational study of 141 patients in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 1135-1142. | 0.6 | 3 |
| 589 | Efficacy of platinum-based combination chemotherapy in advanced lung adenocarcinoma harboring sensitive epidermal growth factor receptor (EGFR) mutations with acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI). <i>Cancer Treatment and Research Communications</i> , 2016, 9, 48-55. | 0.7 | 7 |
| 590 | Sensitivities to various epidermal growth factor receptor tyrosine kinase inhibitors of uncommon EGFR mutations L861Q and S768I: What is the optimal epidermal growth factor receptor tyrosine kinase inhibitor?. <i>Cancer Science</i> , 2016, 107, 1134-1140. | 1.7 | 78 |
| 591 | LUX-Lung 7: is there enough data for a final conclusion?. <i>Lancet Oncology</i> , The, 2016, 17, e266-e267. | 5.1 | 0 |
| 592 | Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations. <i>Journal of Clinical Oncology</i> , 2016, 34, 3258-3266. | 0.8 | 153 |
| 593 | Systematic analysis of design and stratification for phase III trials in first-line advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2016, 7, 66-71. | 0.8 | 2 |
| 594 | Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER 2 oncogene alterations. <i>Cancer Science</i> , 2016, 107, 45-52. | 1.7 | 71 |
| 595 | Epidermal Growth Factor Receptor Mutations and Prognosis in Pathologic N1-N2 Pulmonary Adenocarcinoma. <i>Annals of Thoracic Surgery</i> , 2016, 102, 1821-1828. | 0.7 | 14 |
| 596 | Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. <i>Cancer Science</i> , 2016, 107, 1179-1186. | 1.7 | 305 |
| 597 | Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2022-2026. | 0.5 | 73 |
| 598 | Mechanisms of resistance to EGFR-targeted drugs: lung cancer. <i>ESMO Open</i> , 2016, 1, e000060. | 2.0 | 325 |
| 599 | Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2066-2081. | 0.5 | 49 |
| 600 | New and emerging targeted treatments in advanced non-small-cell lung cancer. <i>Lancet</i> , The, 2016, 388, 1012-1024. | 6.3 | 381 |
| 601 | Management of Lung Cancer in the Elderly. <i>Cancer Treatment and Research</i> , 2016, 170, 251-284. | 0.2 | 10 |
| 602 | Risk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis. <i>Future Oncology</i> , 2016, 12, 2741-2753. | 1.1 | 8 |
| 603 | Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity. <i>Investigational New Drugs</i> , 2016, 34, 797-799. | 1.2 | 12 |
| 604 | The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer. <i>SpringerPlus</i> , 2016, 5, 1244. | 1.2 | 12 |
| 605 | Targeted Therapies for Lung Cancer. <i>Cancer Treatment and Research</i> , 2016, 170, 165-182. | 0.2 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 606 | Resistance to Therapy. <i>Cancer Treatment and Research</i> , 2016, 170, 183-202. | 0.2 | 10 |
| 607 | Stratified Treatment in Lung Cancer. <i>Oncology Research and Treatment</i> , 2016, 39, 760-766. | 0.8 | 13 |
| 608 | Afatinib: A Review in Advanced Non-Small Cell Lung Cancer. <i>Targeted Oncology</i> , 2016, 11, 825-835. | 1.7 | 33 |
| 609 | Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment. <i>British Journal of Cancer</i> , 2016, 115, 1504-1512. | 2.9 | 55 |
| 610 | Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1283-1288. | 1.3 | 2 |
| 611 | Novel immunotherapy in the treatment of advanced non-small cell lung cancer. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1571-1581. | 1.3 | 21 |
| 612 | Crizotinib: from discovery to accelerated development to front-line treatment. <i>Annals of Oncology</i> , 2016, 27, iii35-iii41. | 0.6 | 36 |
| 613 | Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer. <i>Oncologist</i> , 2016, 21, 964-973. | 1.9 | 45 |
| 614 | The safety of afatinib for the treatment of non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1563-1572. | 1.0 | 15 |
| 615 | Recomendaciones SEPAR de diagnóstico y tratamiento del cáncer de pulmón de células no pequeñas. <i>Archivos De Bronconeumología</i> , 2016, 52, 2-62. | 0.4 | 12 |
| 616 | Recomendaciones SEPAR de diagnóstico y tratamiento del cáncer de pulmón de células no pequeñas. <i>Archivos De Bronconeumología</i> , 2016, 52, 2-62. | 0.4 | 25 |
| 618 | Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2016, 17, 1643-1652. | 5.1 | 533 |
| 619 | Profile of the <i>therascreen</i> ® <i>EGFR</i> RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 1251-1257. | 1.5 | 17 |
| 620 | Therapeutic value of EGFR inhibition in CRC and NSCLC: 15...years of clinical evidence. <i>ESMO Open</i> , 2016, 1, e000088. | 2.0 | 85 |
| 621 | The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. <i>ESMO Open</i> , 2016, 1, e000066. | 2.0 | 17 |
| 622 | Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients. <i>BMC Cancer</i> , 2016, 16, 864. | 1.1 | 41 |
| 623 | Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients. <i>Scientific Reports</i> , 2016, 6, 36458. | 1.6 | 75 |
| 624 | Complete remission of liver metastasis in a lung cancer patient with epidermal growth factor mutation achieved with <i>cotinib</i> . <i>Thoracic Cancer</i> , 2016, 7, 681-683. | 0.8 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 625 | Targeting the KRAS Pathway in Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2016, 21, 1450-1460. | 1.9 | 101 |
| 626 | Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer. <i>Scientific Reports</i> , 2016, 6, 31636. | 1.6 | 10 |
| 627 | Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy. , 2016, 2016, 1268-1271. | | 15 |
| 628 | SUV_{max} and Tumour Location in PET-CT Predict Oncogene Status in Lung Cancer. <i>Oncology Research and Treatment</i> , 2016, 39, 681-686. | 0.8 | 6 |
| 629 | A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds. <i>Journal of Visualized Experiments</i> , 2016, , e53885. | 0.2 | 20 |
| 630 | Survival of Patients with Advanced Non-Small Cell Lung Cancer Enrolled in Clinical Trials. <i>Oncology</i> , 2016, 91, 185-193. | 0.9 | 19 |
| 631 | Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2016, 27, v1-v27. | 0.6 | 1,351 |
| 632 | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer. <i>Oncology</i> , 2016, 91, 26-34. | 0.9 | 13 |
| 633 | Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment. <i>Medicine (United States)</i> , 2016, 95, e3998. | 0.4 | 30 |
| 634 | Best Practices in Treatment Selection for Patients with Advanced NSCLC. <i>Cancer Control</i> , 2016, 23, 2-14. | 0.7 | 7 |
| 635 | A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in <i>EGFR</i>-Mutant Nonâ€“Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. <i>Clinical Cancer Research</i> , 2016, 22, 6010-6020. | 3.2 | 100 |
| 636 | A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies. <i>Journal of Translational Medicine</i> , 2016, 14, 83. | 1.8 | 18 |
| 637 | Targeting EGFR and ALK in NSCLC: current evidence and future perspective. <i>Lung Cancer Management</i> , 2016, 5, 79-90. | 1.5 | 1 |
| 638 | Necitumumab in squamous non-small-cell lung cancer: how to move forward?. <i>Annals of Oncology</i> , 2016, 27, 1374-1376. | 0.6 | 0 |
| 639 | Scientific Advances Shaping the Future Roles of Oncology Nurses. <i>Seminars in Oncology Nursing</i> , 2016, 32, 87-98. | 0.7 | 13 |
| 640 | Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 1005-1009. | 1.1 | 14 |
| 641 | Pharmacologic Costs of Tyrosine Kinase Inhibitors in First-Line Therapy for Advanced Nonâ€“Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations: A Review of Pivotal Phase III Randomized Controlled Trials. <i>Clinical Lung Cancer</i> , 2016, 17, 91-94. | 1.1 | 6 |
| 642 | Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 176-187. | 1.4 | 25 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 643 | Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1140-1152. | 0.5 | 64 |
| 644 | The use of biomarkers in the treatment of non-small cell lung cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 25-36. | 0.4 | 2 |
| 645 | Targeted Therapy and Immunotherapy for Lung Cancer. <i>Surgical Oncology Clinics of North America</i> , 2016, 25, 601-609. | 0.6 | 99 |
| 646 | Methodology of health-related quality of life analysis in phase III advanced non-small-cell lung cancer clinical trials: a critical review. <i>BMC Cancer</i> , 2016, 16, 122. | 1.1 | 40 |
| 647 | IKBKE Is a Substrate of EGFR and a Therapeutic Target in Non-Small Cell Lung Cancer with Activating Mutations of EGFR. <i>Cancer Research</i> , 2016, 76, 4418-4429. | 0.4 | 29 |
| 648 | Ethics of Clinical Trials in Low-Resource Settings: Lessons From Recent Trials in Cancer Medicine. <i>Journal of Global Oncology</i> , 2016, 2, 1-3. | 0.5 | 8 |
| 649 | Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress. <i>Future Oncology</i> , 2016, 12, 355-372. | 1.1 | 16 |
| 650 | Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2016, 10, 485-491. | 1.0 | 12 |
| 651 | Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3375-3382. | 0.8 | 741 |
| 652 | Effect of renal function on pemetrexed-induced haematotoxicity. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 183-189. | 1.1 | 9 |
| 653 | Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib. <i>Anti-Cancer Drugs</i> , 2016, 27, 251-253. | 0.7 | 4 |
| 654 | Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC). <i>Surgery Today</i> , 2016, 46, 25-37. | 0.7 | 30 |
| 655 | Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 357-366. | 5.1 | 125 |
| 656 | Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 2871-2881. | 1.4 | 25 |
| 657 | Radiographic patterns and survival of patients with early and late brain metastases in EGFR wild type and mutant non small cell lung cancer. <i>Journal of Neuro-Oncology</i> , 2016, 127, 525-533. | 1.4 | 11 |
| 658 | Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. <i>Annals of Oncology</i> , 2016, 27, 423-429. | 0.6 | 51 |
| 659 | Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study. <i>Targeted Oncology</i> , 2016, 11, 167-174. | 1.7 | 16 |
| 660 | Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography. <i>Journal of Clinical Oncology</i> , 2016, 34, 91-101. | 0.8 | 146 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 661 | Drugâ€‘diagnostic co-development: challenges and issues. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 187-204. | 1.5 | 4 |
| 662 | Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer. <i>Lung Cancer</i> , 2016, 91, 36-40. | 0.9 | 38 |
| 663 | Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/ gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. <i>Annals of Oncology</i> , 2016, 27, 417-423. | 0.6 | 122 |
| 664 | Comparing Patient-Derived Xenograft and Computational Response Prediction for Targeted Therapy in Patients of Early-Stage Large Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2167-2176. | 3.2 | 16 |
| 665 | Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 576-592. | 1.4 | 43 |
| 666 | Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. <i>Therapeutic Advances in Respiratory Disease</i> , 2016, 10, 113-129. | 1.0 | 125 |
| 667 | Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1-11. | 0.8 | 72 |
| 668 | The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. <i>Immunotherapy</i> , 2016, 8, 479-488. | 1.0 | 136 |
| 669 | FDA Approval of Gefitinib for the Treatment of Patients with Metastatic <i>EGFR</i> Mutationâ€‘Positive Nonâ€‘Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1307-1312. | 3.2 | 173 |
| 670 | Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis. <i>Lung Cancer</i> , 2016, 94, 46-53. | 0.9 | 60 |
| 671 | 2015 and human cancer: back to overall survival. <i>Future Oncology</i> , 2016, 12, 1751-1754. | 1.1 | 0 |
| 672 | A Potent Derivative of Indolizino[6,7-b]Indole for Treatment of Human Nonâ€‘Small Cell Lung Cancer Cells. <i>Neoplasia</i> , 2016, 18, 199-212. | 2.3 | 17 |
| 673 | Clinical applications of stereotactic radiation therapy for oligometastatic cancer patients: a disease-oriented approach. <i>Journal of Radiation Research</i> , 2016, 57, i58-i68. | 0.8 | 30 |
| 674 | Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 393-403. | 1.9 | 3 |
| 675 | Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. <i>Lung Cancer</i> , 2016, 93, 59-68. | 0.9 | 103 |
| 676 | Skin problems and EGFR-tyrosine kinase inhibitor. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 291-298. | 0.6 | 82 |
| 677 | The Evolving Role of Nivolumab in Nonâ€‘Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2016, 17, 161-168. | 1.1 | 13 |
| 678 | Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 107-116. | 2.0 | 92 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 679 | Strategies to Improve Outcomes of Patients with EGFR-Mutant Non-Small Cell Lung Cancer: Review of the Literature. <i>Journal of Thoracic Oncology</i> , 2016, 11, 174-186. | 0.5 | 77 |
| 682 | Efficacy of chemotherapy in epidermal growth factor receptor (EGFR) mutated metastatic pulmonary adenocarcinoma patients who had acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI). <i>Journal of Chemotherapy</i> , 2016, 28, 50-58. | 0.7 | 9 |
| 683 | therascreen [®] EGFR RGQ PCR Kit: A Companion Diagnostic for Afatinib and Gefitinib in Non-Small Cell Lung Cancer. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 191-198. | 1.6 | 15 |
| 684 | Personalized Medicine in Respiratory Disease. <i>Advances in Protein Chemistry and Structural Biology</i> , 2016, 102, 115-146. | 1.0 | 20 |
| 686 | First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. <i>Journal of Thoracic Oncology</i> , 2016, 11, 380-390. | 0.5 | 300 |
| 687 | BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients. <i>Lung Cancer</i> , 2016, 95, 73-81. | 0.9 | 16 |
| 688 | Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer. <i>Molecular BioSystems</i> , 2016, 12, 1552-1563. | 2.9 | 6 |
| 689 | Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 767-776. | 1.1 | 118 |
| 690 | Laying the Groundwork to Confront the Final Frontier of CNS Metastasis in NSCLC with Targetable Driver Mutations. <i>Journal of Thoracic Oncology</i> , 2016, 11, 281-283. | 0.5 | 1 |
| 691 | Being molecular in the molecular age. <i>Annals of Oncology</i> , 2016, 27, 367-368. | 0.6 | 1 |
| 692 | The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 383-390. | 1.1 | 58 |
| 693 | Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 989-993. | 0.9 | 19 |
| 694 | Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. <i>Journal of Thoracic Oncology</i> , 2016, 11, 556-565. | 0.5 | 268 |
| 695 | Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 547-556. | 1.0 | 9 |
| 696 | First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2016, 2, 305. | 3.4 | 201 |
| 697 | Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel. <i>European Journal of Health Economics</i> , 2016, 17, 855-863. | 1.4 | 22 |
| 698 | Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects. <i>Supportive Care in Cancer</i> , 2016, 24, 301-309. | 1.0 | 11 |
| 699 | Risk of elevated transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: a meta-analysis. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 223-234. | 1.0 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 700 | Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents. <i>Annals of Oncology</i> , 2016, 27, 373-378. | 0.6 | 50 |
| 701 | Safety and efficacy of targeted agents monotherapy in advanced NSCLC. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 143-155. | 1.3 | 1 |
| 702 | Molecular and Histological Changes in Post-Treatment Biopsies of Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Study. <i>Targeted Oncology</i> , 2016, 11, 157-166. | 1.7 | 9 |
| 703 | siRNA delivered by EGFR-specific scFv sensitizes EGFR-TKI-resistant human lung cancer cells. <i>Biomaterials</i> , 2016, 76, 196-207. | 5.7 | 26 |
| 704 | Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 426-435. | 3.2 | 46 |
| 705 | Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses. <i>Clinical Cancer Research</i> , 2016, 22, 1103-1110. | 3.2 | 326 |
| 706 | Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 143-151. | 2.0 | 27 |
| 707 | EGFR mutation testing of lung cancer patients – Experiences from Vestfold Hospital Trust. <i>Acta Oncologica</i> , 2016, 55, 149-155. | 0.8 | 9 |
| 708 | Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis. <i>Targeted Oncology</i> , 2016, 11, 41-47. | 1.7 | 15 |
| 709 | Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 461-476. | 0.5 | 26 |
| 710 | Biology of Lung Cancer. , 2016, , 912-926.e6. | | 1 |
| 711 | Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small cell lung cancer receiving first-line gefitinib or erlotinib treatment. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e189-e194. | 0.7 | 47 |
| 712 | Principles of Kinase Inhibitor Therapy for Solid Tumors. <i>Annals of Surgery</i> , 2017, 265, 311-319. | 2.1 | 10 |
| 713 | EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib. <i>Journal of Thoracic Oncology</i> , 2017, 12, 884-889. | 0.5 | 24 |
| 714 | A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. <i>British Journal of Cancer</i> , 2017, 116, 568-574. | 2.9 | 155 |
| 715 | Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. <i>Lung Cancer</i> , 2017, 104, 119-125. | 0.9 | 41 |
| 716 | Real-World EQ5D Health Utility Scores for Patients With Metastatic Lung Cancer by Molecular Alteration and Response to Therapy. <i>Clinical Lung Cancer</i> , 2017, 18, 388-395.e4. | 1.1 | 23 |
| 717 | Developments in pharmacotherapy for treating metastatic non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 151-163. | 0.9 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 718 | Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib. <i>Current Oncology Reports</i> , 2017, 19, 4. | 1.8 | 15 |
| 719 | <i>MET</i> Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of <i>EGFR</i>-mutant Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 506-515. | 1.9 | 52 |
| 720 | Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures. , 2017, 174, 1-21. | | 123 |
| 721 | Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 171-180. | 1.0 | 8 |
| 722 | Accuracy of transbronchial biopsy as a rebiopsy method for patients with relapse of advanced non-small-cell lung cancer after systemic chemotherapy. <i>BMJ Open Respiratory Research</i> , 2017, 4, e000163. | 1.2 | 7 |
| 723 | The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer. <i>Scientific Reports</i> , 2017, 7, 40374. | 1.6 | 43 |
| 724 | Osimertinib for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 225-231. | 0.9 | 4 |
| 725 | Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptor-mutated lung cancer receiving tyrosine kinase inhibitors as first-line treatment. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 304-313. | 0.7 | 13 |
| 726 | Osimertinib in Pretreated T790M-Positive Advanced Nonâ€“Small-Cell Lung Cancer: AURA Study Phase II Extension Component. <i>Journal of Clinical Oncology</i> , 2017, 35, 1288-1296. | 0.8 | 470 |
| 727 | Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2017, 25, 1713-1739. | 1.0 | 125 |
| 728 | Pulsatile Erlotinib in EGFR-Positive Nonâ€“Small-Cell Lung Cancer Patients With Leptomeningeal and Brain Metastases: ReviewÂofÂthe Literature. <i>Clinical Lung Cancer</i> , 2017, 18, 354-363. | 1.1 | 44 |
| 729 | Treatment options for EGFR mutant NSCLC with CNS involvementâ€“Can patients BLOOM with the use of next generation EGFR TKIs?. <i>Lung Cancer</i> , 2017, 108, 29-37. | 0.9 | 37 |
| 730 | Amplification of EGFR Wild-Type Alleles in Nonâ€“Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors. <i>Cancer Research</i> , 2017, 77, 2078-2089. | 0.4 | 126 |
| 731 | Successful treatment with gefitinib after Stevensâ€“Johnson syndrome associated with afatinib therapy in a patient with adenocarcinoma of the lung. <i>International Cancer Conference Journal</i> , 2017, 6, 38-41. | 0.2 | 5 |
| 732 | Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 783-791. | 1.2 | 36 |
| 733 | EGFR TKI combination with immunotherapy in non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 465-469. | 1.0 | 156 |
| 735 | Biological determinants of radioresistance and their remediation in pancreatic cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 69-92. | 3.3 | 65 |
| 736 | Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990â€“2015: Progress and Opportunities. <i>Oncologist</i> , 2017, 22, 304-310. | 1.9 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 737 | EGFR inhibition in NSCLC: New findings and opened questions?. Critical Reviews in Oncology/Hematology, 2017, 112, 126-135. | 2.0 | 22 |
| 738 | Association between PD-L1 expression and driven gene status in NSCLC: A meta-analysis. European Journal of Surgical Oncology, 2017, 43, 1372-1379. | 0.5 | 29 |
| 739 | Integrating liquid biopsies into the management of cancer. Nature Reviews Clinical Oncology, 2017, 14, 531-548. | 12.5 | 1,375 |
| 740 | China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016) Tj ETQq1 1,0784314 rgBT /Ove 0.7 34 | 0.7 | 34 |
| 741 | Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR -Mutated Lung Cancer. Journal of Thoracic Oncology, 2017, 12, e81-e84. | 0.5 | 41 |
| 742 | Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer. Lung Cancer, 2017, 108, 75-82. | 0.9 | 37 |
| 743 | Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer. Targeted Oncology, 2017, 12, 153-161. | 1.7 | 31 |
| 745 | Surrogate endpoints for overall survival in lung cancer trials: a review. Expert Review of Anticancer Therapy, 2017, 17, 447-454. | 1.1 | 21 |
| 746 | Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges. European Journal of Cancer, 2017, 78, 16-23. | 1.3 | 108 |
| 747 | Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine. CNS Oncology, 2017, 6, 139-151. | 1.2 | 12 |
| 748 | EGFR T790M mutation testing within the osimertinib AURA Phase I study. Lung Cancer, 2017, 109, 9-13. | 0.9 | 20 |
| 749 | Analyzing epidermal growth factor receptor mutation status changes in advanced non-small cell lung cancer at different sampling timepoints of blood within one day. Thoracic Cancer, 2017, 8, 312-319. | 0.8 | 12 |
| 750 | Assessment of the External Validity of the National Comprehensive Cancer Network and European Society for Medical Oncology Guidelines for Non-Small-Cell Lung Cancer in a Population of Patients Aged 80 Years and Older. Clinical Lung Cancer, 2017, 18, 460-471. | 1.1 | 25 |
| 751 | Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design. Oncologist, 2017, 22, 700-708. | 1.9 | 11 |
| 752 | Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1061-1070. | 0.5 | 240 |
| 753 | Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities. Clinical Lung Cancer, 2017, 18, 651-659. | 1.1 | 164 |
| 754 | Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance. European Journal of Medicinal Chemistry, 2017, 142, 32-47. | 2.6 | 119 |
| 755 | The Role of Radiotherapy in Epidermal Growth Factor Receptor Mutation-positive Patients with Oligoprogression: A Matched-cohort Analysis. Clinical Oncology, 2017, 29, 568-575. | 0.6 | 42 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 756 | Synthesis of 2-substituted quinazolines by CsOH-mediated direct aerobic oxidative cyclocondensation of 2-aminoarylmethanols with nitriles in air. <i>Green Chemistry</i> , 2017, 19, 2945-2951. | 4.6 | 67 |
| 757 | Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation. <i>Clinical Lung Cancer</i> , 2017, 18, 698-705.e2. | 1.1 | 29 |
| 758 | Treatment of <i>KRAS</i> -Mutant Non-Small Cell Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1835. | 3.8 | 12 |
| 759 | <i>AJRCCM</i> : 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1150-1160. | 2.5 | 75 |
| 760 | Uncommon EGFR mutations in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 109, 137-144. | 0.9 | 120 |
| 761 | Efficacy and safety of osimertinib in a Japanese compassionate use program. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 625-629. | 0.6 | 12 |
| 762 | Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence. <i>Medical Oncology</i> , 2017, 34, 105. | 1.2 | 47 |
| 763 | Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. <i>ESMO Open</i> , 2017, 2, e000168. | 2.0 | 48 |
| 764 | Epidermal Growth Factor Receptor Mutated Advanced Non-Small Cell Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 83-99. | 0.9 | 10 |
| 765 | Systemic Treatment of Brain Metastases. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 157-176. | 0.9 | 8 |
| 766 | Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 357-364. | 1.9 | 65 |
| 767 | Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 31-44. | 0.9 | 6 |
| 768 | Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 143-155. | 1.1 | 26 |
| 769 | Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials. <i>JAMA Oncology</i> , 2017, 3, e171029. | 3.4 | 70 |
| 770 | Optimal management of EGFR -mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy. <i>Lung Cancer</i> , 2017, 110, 7-13. | 0.9 | 40 |
| 771 | Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer. <i>Targeted Oncology</i> , 2017, 12, 563-569. | 1.7 | 71 |
| 772 | Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib. <i>Oncologist</i> , 2017, 22, 1075-1083. | 1.9 | 31 |
| 773 | Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma. <i>Npj Precision Oncology</i> , 2017, 1, . | 2.3 | 70 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 775 | Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A. <i>BMC Cancer</i> , 2017, 17, 281. | 1.1 | 31 |
| 776 | EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of AOsimeritinib. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1247-1256. | 0.5 | 48 |
| 777 | Clinical sequencing using a nextâ€generation sequencingâ€based multiplex gene assay in patients with advanced solid tumors. <i>Cancer Science</i> , 2017, 108, 1440-1446. | 1.7 | 57 |
| 778 | Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy. <i>Medical Oncology</i> , 2017, 34, 121. | 1.2 | 12 |
| 779 | Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. <i>Lancet Oncology</i> , The, 2017, 18, 887-894. | 5.1 | 108 |
| 780 | Scientific Advances in Thoracic Oncology 2016. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1183-1209. | 0.5 | 40 |
| 781 | Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. <i>Journal of the National Cancer Institute</i> , 2017, 109, . | 3.0 | 196 |
| 782 | Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 413-423. | 0.8 | 21 |
| 783 | Drug-biomarker co-development in oncology â€“ 20 years and counting. <i>Drug Resistance Updates</i> , 2017, 30, 48-62. | 6.5 | 48 |
| 784 | An LCâ€MS/MS method for quantification of AC0010, a novel mutant-selective epidermal growth factor receptor (EGFR) inhibitor, and its metabolites in human plasma and the application to a pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 141, 9-18. | 1.4 | 4 |
| 785 | Management of afatinib-induced stomatitis. <i>Molecular and Clinical Oncology</i> , 2017, 6, 603-605. | 0.4 | 11 |
| 786 | Challenging the Paradigm: EGFR wild-type benefit from an EGFR inhibitor in NSCLC. <i>Cancer Treatment and Research Communications</i> , 2017, 11, 10-16. | 0.7 | 1 |
| 787 | PUB062 Risk Factors of Brain Metastasis during the Course of EGFR-TKIs Therapy for Patients with EGFR-Mutated Advanced Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1484. | 0.5 | 0 |
| 788 | Targeted Treatment of Brain Metastases. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 37. | 2.0 | 28 |
| 789 | A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib. <i>Lung Cancer</i> , 2017, 108, 154-160. | 0.9 | 18 |
| 790 | Expression of Neuroendocrine Factor VGF in Lung Cancer Cells Confers Resistance to EGFR Kinase Inhibitors and Triggers Epithelial-to-Mesenchymal Transition. <i>Cancer Research</i> , 2017, 77, 3013-3026. | 0.4 | 42 |
| 791 | Vulvar Squamous Cell Carcinoma (VSCC) as Two Diseases: HPV Status Identifies Distinct Mutational Profiles Including Oncogenic Fibroblast Growth Factor Receptor 3. <i>Clinical Cancer Research</i> , 2017, 23, 4501-4510. | 3.2 | 45 |
| 792 | Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with epidermal growth factor receptor gene mutation-positive lung cancer. <i>Molecular and Clinical Oncology</i> , 2017, 6, 3-6. | 0.4 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 793 | Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 201-216. | 1.4 | 30 |
| 794 | Effect of Sustained Elevated Gastric pH Levels on Gefitinib Exposure. <i>Clinical Pharmacology in Drug Development</i> , 2017, 6, 517-523. | 0.8 | 13 |
| 795 | Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 431-436. | 1.6 | 2 |
| 796 | SBRT for oligoprogressive oncogene addicted NSCLC. <i>Lung Cancer</i> , 2017, 106, 50-57. | 0.9 | 49 |
| 797 | Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. <i>Respiratory Investigation</i> , 2017, 55, 181-183. | 0.9 | 4 |
| 798 | Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 106, 138-144. | 0.9 | 15 |
| 799 | Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation. <i>Molecular Cancer Research</i> , 2017, 15, 915-928. | 1.5 | 37 |
| 800 | Complete Tumor Response with Afatinib 20Âmg Daily in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report. <i>Clinical Drug Investigation</i> , 2017, 37, 581-585. | 1.1 | 2 |
| 801 | Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection. <i>Biomedicine and Pharmacotherapy</i> , 2017, 90, 24-37. | 2.5 | 45 |
| 802 | The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR -mutant NSCLC Patients. EORTC 1613. <i>Clinical Lung Cancer</i> , 2017, 18, 583-588. | 1.1 | 84 |
| 803 | Osimertinib or Platinumâ€Pemetrexed in <i>EGFR</i> T790Mâ€Positive Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 629-640. | 13.9 | 2,631 |
| 804 | A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients withâacquired EGFRâTKI resistance. <i>Cancer Medicine</i> , 2017, 6, 154-162. | 1.3 | 82 |
| 805 | Clinical Outcome of ALK -Positive Nonâ€Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). <i>Journal of Thoracic Oncology</i> , 2017, 12, 681-688. | 0.5 | 58 |
| 806 | Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR -Mutated Nonâ€Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 633-643. | 0.5 | 122 |
| 807 | Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR -Mutated Nonâ€Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 612-623. | 0.5 | 203 |
| 808 | EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. <i>British Journal of Cancer</i> , 2017, 116, 175-185. | 2.9 | 76 |
| 809 | Systemic therapy of brain metastases: nonâ€small cell lung cancer, breast cancer, and melanoma. <i>Neuro-Oncology</i> , 2017, 19, i1-i24. | 0.6 | 171 |
| 810 | Circulating exosomal microRNAâ€96 promotes cell proliferation, migration and drug resistance by targeting LMO7. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 1228-1236. | 1.6 | 121 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 811 | Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 1-4. | 1.1 | 14 |
| 812 | Current Trends in Cancer Therapy. , 2017, , 1-24. | | 7 |
| 813 | New data on clinical decisions in NSCLC patients with uncommon EGFR mutations. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 51-55. | 1.0 | 16 |
| 814 | Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016. <i>Journal of Clinical Oncology</i> , 2017, 35, 243-252. | 0.8 | 19 |
| 815 | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 324-332.e1. | 1.1 | 33 |
| 816 | Afatinib successfully treated leptomeningeal metastasis during erlotinib treatment in a patient with EGFR mutant (Exon18:G719S) lung adenocarcinoma as a second-line chemotherapy. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e531-e533. | 0.7 | 6 |
| 817 | Precision oncology: neither a silver bullet nor a dream. <i>Pharmacogenomics</i> , 2017, 18, 1525-1539. | 0.6 | 21 |
| 818 | Understanding and targeting resistance mechanisms in NSCLC. <i>Nature Reviews Cancer</i> , 2017, 17, 637-658. | 12.8 | 679 |
| 819 | Predictors of EGFR mutation and factors associated with clinical tumor stage at diagnosis: Experience of the INSIGHT study in Poland. <i>Oncology Letters</i> , 2017, 14, 5611-5618. | 0.8 | 7 |
| 820 | Highly sensitive detection of epidermal growth factor receptor in lung cancer cells by aptamer-based target/probe-mediated cyclic signal amplification. <i>Chemical Communications</i> , 2017, 53, 11496-11499. | 2.2 | 18 |
| 821 | Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2017, 18, 1454-1466. | 5.1 | 877 |
| 822 | Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 4832-4837. | 1.0 | 19 |
| 823 | Selection of non-small cell lung cancer patients for intercalated chemotherapy and tyrosine kinase inhibitors. <i>Radiology and Oncology</i> , 2017, 51, 241-251. | 0.6 | 3 |
| 824 | A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations. <i>Clinical Cancer Research</i> , 2017, 23, 7467-7473. | 3.2 | 26 |
| 825 | Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study. <i>ESMO Open</i> , 2017, 2, e000214. | 2.0 | 30 |
| 826 | Gefitinib: an orphan drug for non-small cell lung cancer. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 899-906. | 0.5 | 2 |
| 828 | Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1179-1187. | 1.1 | 24 |
| 829 | Cancer: Towards a general theory of the target. <i>BioEssays</i> , 2017, 39, 1700059. | 1.2 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 830 | T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non-Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2563-2571. | 1.9 | 19 |
| 831 | An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 933-942. | 1.5 | 5 |
| 832 | First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. <i>Annals of Oncology</i> , 2017, 28, 2443-2450. | 0.6 | 236 |
| 833 | The RAS-related GTPase RHOB confers resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer via an AKT-dependent mechanism. <i>EMBO Molecular Medicine</i> , 2017, 9, 238-250. | 3.3 | 30 |
| 834 | Tracking MET de-addiction in lung cancer: A road towards the oncogenic target. <i>Cancer Treatment Reviews</i> , 2017, 60, 1-11. | 3.4 | 29 |
| 835 | Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers. <i>Lung Cancer</i> , 2017, 112, 195-199. | 0.9 | 9 |
| 836 | External quality assessment for EGFR mutations in Italy: improvements in performances over the time. <i>ESMO Open</i> , 2017, 2, e000160. | 2.0 | 8 |
| 837 | Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature. <i>Pharmacoeconomics</i> , 2017, 35, 1195-1209. | 1.7 | 16 |
| 838 | Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. <i>Lung Cancer</i> , 2017, 113, 51-58. | 0.9 | 16 |
| 839 | Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status. <i>Scientific Reports</i> , 2017, 7, 8483. | 1.6 | 6 |
| 840 | EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma. <i>Medical Oncology</i> , 2017, 34, 175. | 1.2 | 5 |
| 841 | Case series on the association between blood levels and side effects of afatinib maleate. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 545-553. | 1.1 | 6 |
| 842 | Icotinib versus whole-brain irradiation in patients with EGFR -mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 707-716. | 5.2 | 159 |
| 843 | Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 117, 38-47. | 2.0 | 85 |
| 844 | Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib. <i>Lung Cancer</i> , 2017, 111, 84-87. | 0.9 | 71 |
| 845 | Lung cancer as a paradigm for precision oncology in solid tumours. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 221-233. | 1.4 | 14 |
| 846 | Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant advanced non-small-cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 2017, 28, 2451-2457. | 0.6 | 58 |
| 848 | Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?. <i>Lung Cancer</i> , 2017, 111, 6-11. | 0.9 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 849 | Inhibition of histone deacetylases sensitizes EGF receptor- TK inhibitor-resistant non-small cell lung cancer cells to erlotinib <i>in vitro</i> and <i>in vivo</i> . <i>British Journal of Pharmacology</i> , 2017, 174, 3608-3622. | 2.7 | 34 |
| 850 | Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysis. <i>Cancer Treatment Reviews</i> , 2017, 59, 117-122. | 3.4 | 61 |
| 851 | Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations – Still a daily challenge. <i>European Journal of Cancer</i> , 2017, 83, 266-278. | 1.3 | 22 |
| 852 | Brain metastases in non-small cell lung cancer patients on epidermal growth factor receptor tyrosine kinase inhibitors: symptom and economic burden. <i>Journal of Medical Economics</i> , 2017, 20, 1136-1147. | 1.0 | 21 |
| 853 | Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1588-1594. | 0.5 | 21 |
| 854 | Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets. <i>ESMO Open</i> , 2017, 2, e000200. | 2.0 | 31 |
| 856 | TRIM59 is a novel potential prognostic biomarker in patients with non-small cell lung cancer: A research based on bioinformatics analysis. <i>Oncology Letters</i> , 2017, 14, 2153-2164. | 0.8 | 21 |
| 857 | Lung cancer as a cardiotoxic state: a review. <i>Medical Oncology</i> , 2017, 34, 159. | 1.2 | 12 |
| 858 | Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 791-805. | 1.0 | 4 |
| 859 | Osimertinib-induced interstitial lung disease in a patient with non-small cell lung cancer pretreated with nivolumab: A case report. <i>Molecular and Clinical Oncology</i> , 2017, 7, 383-385. | 0.4 | 19 |
| 860 | Clinical analysis of NSCLC patients reveals lack of association between EGFR mutation and TET1 downregulation. <i>Cancer Gene Therapy</i> , 2017, 24, 373-380. | 2.2 | 6 |
| 861 | EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice. <i>European Respiratory Journal</i> , 2017, 50, 1700514. | 3.1 | 20 |
| 862 | Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations. <i>Scientific Reports</i> , 2017, 7, 6595. | 1.6 | 29 |
| 863 | A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib. <i>Journal of Thoracic Oncology</i> , 2017, 12, e200-e202. | 0.5 | 25 |
| 864 | Deciphering unclassified tumors of non-small-cell lung cancer through radiomics. <i>Computers in Biology and Medicine</i> , 2017, 91, 222-230. | 3.9 | 16 |
| 865 | Personalised medicine for nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2017, 26, 170066. | 3.0 | 37 |
| 866 | Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges. <i>Cancer</i> , 2017, 123, 4800-4807. | 2.0 | 19 |
| 868 | A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 114, 96-102. | 0.9 | 146 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 869 | Quantification of plasma EGFR mutations in patients with lung cancers: Comparison of the performance of ARMS-Plus and droplet digital PCR. <i>Lung Cancer</i> , 2017, 114, 31-37. | 0.9 | 22 |
| 870 | Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β -blockers. <i>Science Translational Medicine</i> , 2017, 9, . | 5.8 | 96 |
| 871 | Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1600-1609. | 5.1 | 282 |
| 872 | Adherence to surveillance guidelines in resected NSCLC: Physician compliance and impact on outcomes. <i>Lung Cancer</i> , 2017, 112, 176-180. | 0.9 | 3 |
| 873 | Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 1281-1288. | 1.5 | 8 |
| 874 | Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations. <i>Lung Cancer</i> , 2017, 110, 56-62. | 0.9 | 82 |
| 875 | Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2017, 111, 23-29. | 0.9 | 160 |
| 876 | Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies. <i>Oncologist</i> , 2017, 22, 762-767. | 1.9 | 56 |
| 877 | Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 779-786. | 1.1 | 27 |
| 878 | Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. <i>Annals of Oncology</i> , 2017, 28, 270-277. | 0.6 | 425 |
| 879 | PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges. <i>Cancer Letters</i> , 2017, 405, 29-37. | 3.2 | 93 |
| 880 | Evolution of anti-HER2 therapies for cancer treatment. <i>Cancer Treatment Reviews</i> , 2017, 59, 1-21. | 3.4 | 73 |
| 881 | Efficacy and Safety Results of the Afatinib Expanded Access Program. <i>Oncology and Therapy</i> , 2017, 5, 103-110. | 1.0 | 5 |
| 882 | Recent advances in targeted advanced lung cancer therapy in the elderly. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 787-797. | 1.1 | 13 |
| 883 | Adverse kidney effects of epidermal growth factor receptor inhibitors. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1089-1097. | 0.4 | 38 |
| 884 | Quantitative proteomics in lung cancer. <i>Journal of Biomedical Science</i> , 2017, 24, 37. | 2.6 | 75 |
| 885 | Osimertinib-related skin and mucosal adverse events. <i>Cancer Treatment and Research Communications</i> , 2017, 12, 53-55. | 0.7 | 1 |
| 886 | Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-“Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials. <i>Clinical Lung Cancer</i> , 2017, 18, e333-e340. | 1.1 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 887 | Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression. <i>Oncologist</i> , 2017, 22, 3-11. | 1.9 | 34 |
| 888 | Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 843-853. | 1.4 | 51 |
| 889 | The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized-controlled trials of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating epidermal growth factor receptor mutations. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 5-8. | 0.7 | 5 |
| 890 | Capilliposide from <i>Lysimachia capillipes</i> inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 100-109. | 2.8 | 14 |
| 891 | Pulmonary Resection for Synchronous M1b-cStage IV Non-Small Cell Lung Cancer Patients. <i>Annals of Thoracic Surgery</i> , 2017, 103, 1594-1599. | 0.7 | 14 |
| 892 | Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2017, 70, 12-21. | 1.3 | 36 |
| 893 | Treatment of brain metastases in the modern genomic era. , 2017, 170, 64-72. | | 40 |
| 894 | Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. <i>Annals of Oncology</i> , 2017, 28, 278-284. | 0.6 | 43 |
| 895 | Targeting MET in Lung Cancer: Will Expectations Finally Be MET?. <i>Journal of Thoracic Oncology</i> , 2017, 12, 15-26. | 0.5 | 299 |
| 896 | Targeting the Gatekeeper: Osimertinib in <i>EGFR T790M</i> Mutation "Positive Non" Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 618-622. | 3.2 | 35 |
| 897 | Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403. <i>Clinical Lung Cancer</i> , 2017, 18, 241-244. | 1.1 | 9 |
| 898 | Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 461-469. | 0.6 | 19 |
| 899 | Lung cancer: current therapies and new targeted treatments. <i>Lancet</i> , The, 2017, 389, 299-311. | 6.3 | 2,267 |
| 900 | Clinical Pharmacokinetics and Pharmacodynamics of Afatinib. <i>Clinical Pharmacokinetics</i> , 2017, 56, 235-250. | 1.6 | 138 |
| 901 | Prognostic value of <i>EGFR</i> mutations in surgically resected pathological stage I lung adenocarcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e204-e211. | 0.7 | 22 |
| 902 | A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR -Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib. <i>Journal of Thoracic Oncology</i> , 2017, 12, 102-109. | 0.5 | 40 |
| 903 | Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 663-673. | 2.5 | 24 |
| 904 | Survival of Asian Females With Advanced Lung Cancer in the Era of Tyrosine Kinase Inhibitor Therapy. <i>Clinical Lung Cancer</i> , 2017, 18, e35-e40. | 1.1 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 905 | First-line Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors for EGFR Mutant Non-small Cell Lung Cancer: And the Winner isâ€¦. Clinical Oncology, 2017, 29, e1-e4. | 0.6 | 4 |
| 906 | Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations. Annals of Oncology, 2017, 28, 136-141. | 0.6 | 72 |
| 907 | Phase 2 Study of Erlotinib in Combination WithÂ€Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With NonÂ€Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. Clinical Lung Cancer, 2017, 18, 34-42.e2. | 1.1 | 29 |
| 908 | Challenges in Facing the Lung Cancer Epidemic and Treating Advanced Disease in Latin America. Clinical Lung Cancer, 2017, 18, e71-e79. | 1.1 | 23 |
| 909 | Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic NonÂ€Small-Cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 96-99. | 1.1 | 10 |
| 910 | A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2017, 79, 17-27. | 1.1 | 6 |
| 911 | Intercalated Chemotherapy and Epidermal Growth Factor Receptor Inhibitors for Patients With Advanced NonÂ€Small-cell Lung Cancer: A Systematic Review and Meta-analysis. Clinical Lung Cancer, 2017, 18, 23-33.e1. | 1.1 | 12 |
| 912 | The End of Nihilism: Systemic Therapy of Advanced NonÂ€Small Cell Lung Cancer. Annual Review of Medicine, 2017, 68, 153-168. | 5.0 | 24 |
| 913 | Targeting <i>EGFR</i> mutation in non-small-cell lung cancer: challenges and future perspectives. Future Oncology, 2017, 13, 201-204. | 1.1 | 3 |
| 914 | Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients. Cancer Biology and Therapy, 2017, 18, 883-887. | 1.5 | 14 |
| 915 | Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: ProposalÂ€from the Bench. Journal of Thoracic Oncology, 2017, 12, 27-35. | 0.5 | 24 |
| 916 | Gene expression of MAGEÂ€A3 and PRAME tumor antigens and EGFR mutational status in Taiwanese nonÂ€small cell lung cancer patients. Asia-Pacific Journal of Clinical Oncology, 2017, 13, e212-e223. | 0.7 | 16 |
| 917 | Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer. The Cochrane Library, 2017, , . | 1.5 | 0 |
| 918 | ASCO update: lung cancer. Memo - Magazine of European Medical Oncology, 2017, 10, 224-227. | 0.3 | 19 |
| 919 | Molecular Testing in Lung Cancer. , 2017, , 287-303. | | 2 |
| 920 | Paradigm shift in cancer treatment: Cancer treatment as a metabolic disease â€ fusion of Eastern and Western medicine. Journal of Traditional Chinese Medical Sciences, 2017, 4, 322-327. | 0.1 | 2 |
| 921 | A pH-induced conformational switch in a tyrosine kinase inhibitor identified by electronic spectroscopy and quantum chemical calculations. Scientific Reports, 2017, 7, 16271. | 1.6 | 3 |
| 922 | Prise en charge du CBNPC chez les sujets Ã¢gÃ©s. Revue Des Maladies Respiratoires Actualites, 2017, 9, 299-307. | 0.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 923 | Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis. <i>Current Medical Science</i> , 2017, 37, 864-872. | 0.7 | 4 |
| 924 | A novel ARMS-based assay for the quantification of EGFR mutations in patients with lung adenocarcinoma. <i>Oncology Letters</i> , 2018, 15, 2905-2912. | 0.8 | 17 |
| 925 | Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program. <i>Annals of Oncology</i> , 2017, 28, 2715-2724. | 0.6 | 72 |
| 926 | Do patients with reduced or excellent performance status derive the same clinical benefit from novel systemic cancer therapies? A systematic review and meta-analysis. <i>ESMO Open</i> , 2017, 2, e000225. | 2.0 | 24 |
| 927 | Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancer—Transformed <i>EGFR</i> Mutant Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2017, 1, 1-7. | 1.5 | 8 |
| 929 | Il Costo Degli Eventi Avversi Associati ad Afatinib, Erlotinib e Gefitinib Nel Trattamento del Tumore del Polmone non a Piccole Cellule con Mutazione EGFR. <i>Global & Regional Health Technology Assessment</i> , 2017, 4, grhta.5000270. | 0.2 | 5 |
| 930 | Real-world experience of afatinib as a first-line therapy for advanced <i>EGFR</i> mutation-positive lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 90430-90443. | 0.8 | 63 |
| 931 | Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients. <i>Oncotarget</i> , 2017, 8, 64600-64606. | 0.8 | 22 |
| 932 | Concurrent T790M and L858R mutations in treatment-naïve metastatic non-small-cell lung cancer: A therapeutic challenge—Current treatment strategies and promising therapies of the future in a nutshell. <i>Asian Journal of Oncology</i> , 0, 03, 087-091. | 0.2 | 0 |
| 933 | Feasibility of molecular testing in a multicenter study with geographical variation in India: Epidermal growth factor receptor mutation as a model molecular test. <i>Asian Journal of Oncology</i> , 2017, 03, 039-044. | 0.2 | 3 |
| 934 | Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations. <i>Journal of Thoracic Disease</i> , 2017, 9, 2923-2934. | 0.6 | 23 |
| 935 | Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come. <i>Ecanermedicalscience</i> , 2017, 11, 787. | 0.6 | 34 |
| 936 | Epidemiological features of lung giant cell carcinoma and therapy for patients with EGFR mutations based on case reports and the surveillance, epidemiology, and end results (SEER) database. <i>Oncotarget</i> , 2017, 8, 25323-25333. | 0.8 | 12 |
| 937 | Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2473-2482. | 1.0 | 42 |
| 939 | Treating <i>EGFR</i> mutation resistance in non-small cell lung cancer—role of osimertinib. <i>The Application of Clinical Genetics</i> , 2017, Volume 10, 49-56. | 1.4 | 25 |
| 940 | Beyond chemotherapy for advanced disease—the role of EGFR and PD-1 inhibitors. <i>Translational Andrology and Urology</i> , 2017, 6, 848-854. | 0.6 | 12 |
| 941 | Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2420. | 1.8 | 102 |
| 942 | Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors. <i>Oncotarget</i> , 2017, 8, 105103-105114. | 0.8 | 27 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 944 | Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. <i>Frontiers in Medicine</i> , 2016, 3, 76. | 1.2 | 74 |
| 945 | Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. <i>Frontiers in Medicine</i> , 2017, 4, 39. | 1.2 | 18 |
| 946 | Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 38. | 1.3 | 14 |
| 947 | Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine. <i>Frontiers in Oncology</i> , 2017, 7, 50. | 1.3 | 30 |
| 948 | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib. <i>Frontiers in Oncology</i> , 2017, 7, 97. | 1.3 | 12 |
| 949 | Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 113. | 1.3 | 46 |
| 950 | Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 222. | 1.3 | 5 |
| 951 | Genetic Characterization of Brain Metastases in the Era of Targeted Therapy. <i>Frontiers in Oncology</i> , 2017, 7, 230. | 1.3 | 43 |
| 952 | Interstitial Lung Disease Induced by Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer. <i>Internal Medicine</i> , 2017, 56, 2325-2328. | 0.3 | 12 |
| 953 | Phase I study of combined therapy with vorinostat and gefitinib to treat <i>BIM</i> deletion polymorphism-associated resistance in <i>EGFR</i>-mutant lung cancer (VICTROY-I): a study protocol. <i>Journal of Medical Investigation</i> , 2017, 64, 321-325. | 0.2 | 7 |
| 954 | <i>Yin-Cold</i> or <i>Yang-Heat</i> Syndrome Type of Traditional Chinese Medicine Was Associated with the Epidermal Growth Factor Receptor Gene Status in Non-Small Cell Lung Cancer Patients: Confirmation of a TCM Concept. <i>Evidence-based Complementary and Alternative Medicine</i> , 2017, 2017, 1-7. | 0.5 | 24 |
| 955 | Chinese Medicine Treatment for Afatinib-Induced Paronychia. <i>Case Reports in Oncological Medicine</i> , 2017, 2017, 1-6. | 0.2 | 5 |
| 956 | Impact of Cytological Sampling on EGFR Mutation Testing in Stage III-IV Lung Adenocarcinoma. <i>Lung Cancer International</i> , 2017, 2017, 1-5. | 1.2 | 6 |
| 957 | Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 655-668. | 0.7 | 11 |
| 958 | New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2513-2526. | 1.0 | 33 |
| 959 | Role of afatinib in the treatment of advanced lung squamous cell carcinoma. <i>Clinical Pharmacology: Advances and Applications</i> , 2017, Volume 9, 147-157. | 0.8 | 7 |
| 960 | Durable complete remission of poor performance status metastatic lung adenocarcinoma patient treated with second-line erlotinib: a case report. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4347-4354. | 1.0 | 3 |
| 961 | Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291). <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1757-1766. | 1.0 | 18 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 962 | AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?. <i>Annals of Translational Medicine</i> , 2017, 5, S14-S14. | 0.7 | 5 |
| 963 | Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. <i>Lung Cancer: Targets and Therapy</i> , 2017, Volume 8, 109-125. | 1.3 | 49 |
| 964 | Frequency and clinical relevance of EGFR mutations and EML4–ALK translocations in octogenarians with non-small cell lung cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5179-5186. | 1.0 | 7 |
| 965 | Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy. <i>Oncotarget</i> , 2017, 8, 66491-66503. | 0.8 | 2 |
| 966 | Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4989-4995. | 1.0 | 19 |
| 967 | Assessing the relationship between toxicity and economic cost of oncological target agents: A systematic review of clinical trials. <i>PLoS ONE</i> , 2017, 12, e0183639. | 1.1 | 2 |
| 968 | Treatment in EGFR-mutated Non-small Cell Lung Cancer: How to Block the Receptor and overcome Resistance Mechanisms. <i>Tumori</i> , 2017, 103, 325-337. | 0.6 | 12 |
| 969 | Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. <i>Nature Communications</i> , 2017, 8, 410. | 5.8 | 117 |
| 970 | Addressing the challenges of applying precision oncology. <i>Npj Precision Oncology</i> , 2017, 1, 28. | 2.3 | 43 |
| 971 | Development and validation of a patient-reported questionnaire assessing systemic therapy induced diarrhea in oncology patients. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 249. | 1.0 | 6 |
| 972 | The clinical efficacy of Afatinib 30Âmg daily as starting dose may not be inferior to Afatinib 40Âmg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations. <i>BMC Pharmacology & Toxicology</i> , 2017, 18, 82. | 1.0 | 34 |
| 973 | Significance of Neutrophil-to-lymphocyte Ratio in Western Advanced EGFR-mutated Non-small Cell Lung Cancer Receiving a Targeted Therapy. <i>Tumori</i> , 2017, 103, 443-448. | 0.6 | 18 |
| 974 | Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity. <i>Internal Medicine</i> , 2017, 56, 2895-2898. | 0.3 | 7 |
| 975 | Molecular characterization of circulating tumor cells in lung cancer: moving beyond enumeration. <i>Oncotarget</i> , 2017, 8, 109818-109835. | 0.8 | 5 |
| 976 | Improving Molecular Testing and Personalized Medicine in Non-Small-Cell Lung Cancer in Ontario. <i>Current Oncology</i> , 2017, 24, 103-110. | 0.9 | 30 |
| 977 | EGFR T790M: revealing the secrets of a gatekeeper. <i>Lung Cancer: Targets and Therapy</i> , 2017, Volume 8, 147-159. | 1.3 | 23 |
| 978 | Osimertinib â€œ effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors. <i>Wspolczesna Onkologia</i> , 2017, 3, 254-258. | 0.7 | 8 |
| 979 | Sequential treatment of tyrosine kinase inhibitor and platinum-based doublet chemotherapy on EGFR mutant non-small cell lung cancer: a meta-analysis of randomized controlled clinical trials. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1279-1284. | 1.0 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 980 | Preventive effect of kampo medicine (hangeshashin-to, TJ-14) plus minocycline against afatinib-induced diarrhea and skin rash in patients with non-small cell lung cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5107-5113. | 1.0 | 17 |
| 981 | EGFR G796D mutation mediates resistance to osimertinib. <i>Oncotarget</i> , 2017, 8, 49671-49679. | 0.8 | 90 |
| 982 | Managing Resistance to EGFR- and ALK-Targeted Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 607-618. | 1.8 | 16 |
| 983 | Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic Drugs. <i>Journal of Oncology Practice</i> , 2017, 13, e653-e665. | 2.5 | 31 |
| 984 | Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNAâ€“Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis. <i>JCO Precision Oncology</i> , 2017, 1, 1-15. | 1.5 | 31 |
| 985 | EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. <i>Oncotarget</i> , 2017, 8, 75712-75726. | 0.8 | 119 |
| 986 | Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with nonâ€“small cell lung cancer harboring EGFR mutations. <i>Oncotarget</i> , 2017, 8, 68123-68130. | 0.8 | 63 |
| 987 | Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival of Advanced Non-Small Cell Lung Cancer Harboring Mutant Epidermal Growth Factor Receptor. <i>World Journal of Oncology</i> , 2017, 8, 180-187. | 0.6 | 20 |
| 988 | Effect of TW37 on the growth of H1975 EGFRâ€“TKIâ€“resistant lung cancer cells and its underlying mechanisms. <i>Molecular Medicine Reports</i> , 2018, 17, 2509-2514. | 1.1 | 0 |
| 989 | Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy. <i>Journal of Thoracic Disease</i> , 2017, 9, 2142-2158. | 0.6 | 92 |
| 990 | Moving more potent and less toxic options to the frontline in the management of advanced lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 2812-2818. | 0.6 | 1 |
| 991 | Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis. <i>Translational Lung Cancer Research</i> , 2017, 6, S21-S34. | 1.3 | 9 |
| 992 | Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401875507. | 1.4 | 13 |
| 993 | Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Nonâ€“Small-cell Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2018, 19, e361-e372. | 1.1 | 17 |
| 994 | Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies. <i>Cancer Treatment Reviews</i> , 2018, 65, 1-10. | 3.4 | 225 |
| 995 | Overview of current systemic management of EGFR-mutant NSCLC. <i>Annals of Oncology</i> , 2018, 29, i3-i9. | 0.6 | 229 |
| 996 | Case sharing of a patient reâ€“challenged with afatinib for EGFRâ€“mutated advanced nonâ€“small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 4-6. | 0.7 | 2 |
| 997 | Management of acquired resistance to EGFR TKIâ€“targeted therapy in advanced non-small cell lung cancer. <i>Molecular Cancer</i> , 2018, 17, 38. | 7.9 | 489 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 998 | A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations. <i>Medical Oncology</i> , 2018, 35, 34. | 1.2 | 10 |
| 999 | Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1123-1132. | 1.9 | 19 |
| 1000 | Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples. <i>Cancer Science</i> , 2018, 109, 1177-1184. | 1.7 | 10 |
| 1001 | Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 821-830. | 0.5 | 53 |
| 1002 | Clinicopathologic Features and Immune Microenvironment of Non-Small-cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Clinical Lung Cancer</i> , 2018, 19, 352-359.e1. | 1.1 | 15 |
| 1003 | Identification of subsets of actionable genetic alterations in KRAS-mutant lung cancers using association rule mining. <i>Cellular Oncology (Dordrecht)</i> , 2018, 41, 395-408. | 2.1 | 7 |
| 1004 | Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?. <i>ESMO Open</i> , 2018, 3, e000344. | 2.0 | 105 |
| 1005 | MicroRNA-197 induces epithelial-mesenchymal transition and invasion through the downregulation of HIPK2 in lung adenocarcinoma. <i>Journal of Genetics</i> , 2018, 97, 47-53. | 0.4 | 12 |
| 1006 | Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation. <i>Thoracic Cancer</i> , 2018, 9, 656-661. | 0.8 | 5 |
| 1007 | Synthesis and Biological Evaluation of Thieno[2,4-d]pyrimidine amides as Potential Anticancer Agents. <i>ChemistrySelect</i> , 2018, 3, 3101-3106. | 0.7 | 4 |
| 1008 | NSCLC: State of the Art Diagnosis, Treatment, and Outcomes. <i>Current Pulmonology Reports</i> , 2018, 7, 29-41. | 0.5 | 2 |
| 1009 | Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer. <i>Bladder Cancer</i> , 2018, 4, 77-90. | 0.2 | 19 |
| 1010 | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2018, 23, 1199-1209. | 1.9 | 42 |
| 1011 | Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer. <i>Oncologist</i> , 2018, 23, 891-899. | 1.9 | 36 |
| 1013 | Mechanisms of the CDK4/6 inhibitor palbociclib (PD 0332991) and its future application in cancer treatment (Review). <i>Oncology Reports</i> , 2018, 39, 901-911. | 1.2 | 60 |
| 1014 | Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 123, 149-161. | 2.0 | 50 |
| 1015 | Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. <i>Annals of Oncology</i> , 2018, 29, i10-i19. | 0.6 | 449 |
| 1016 | Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. <i>Annals of Oncology</i> , 2018, 29, i20-i27. | 0.6 | 159 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1017 | Cell death-based treatment of lung adenocarcinoma. <i>Cell Death and Disease</i> , 2018, 9, 117. | 2.7 | 434 |
| 1018 | Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion. <i>ESMO Open</i> , 2018, 3, e000262. | 2.0 | 69 |
| 1019 | The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1156-1169. | 1.1 | 47 |
| 1020 | Turning <i>EGFR</i> mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401775333. | 1.4 | 41 |
| 1021 | SOX10/keratin dual-color immunohistochemistry: An effective first-line test for the workup of epithelioid malignant neoplasms in FNA and small biopsy specimens. <i>Cancer Cytopathology</i> , 2018, 126, 179-189. | 1.4 | 9 |
| 1022 | Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies. <i>Future Oncology</i> , 2018, 14, 1477-1486. | 1.1 | 14 |
| 1023 | Optimizing outcomes in <i>EGFR</i> mutation-positive NSCLC: which tyrosine kinase inhibitor and when?. <i>Future Oncology</i> , 2018, 14, 1117-1132. | 1.1 | 89 |
| 1024 | Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2. <i>British Journal of Cancer</i> , 2018, 118, 344-352. | 2.9 | 7 |
| 1025 | Established, emerging and elusive molecular targets in the treatment of lung cancer. <i>Journal of Pathology</i> , 2018, 244, 565-577. | 2.1 | 15 |
| 1026 | Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer. <i>Targeted Oncology</i> , 2018, 13, 141-156. | 1.7 | 17 |
| 1027 | ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors) <i>Tj ETQq0 0 0z8T /Overlock 10 Tf</i> | | |
| 1028 | Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort. <i>Lung Cancer</i> , 2018, 117, 14-19. | 0.9 | 63 |
| 1029 | Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 267-276. | 1.1 | 14 |
| 1030 | Survival analysis of patients with advanced non-small cell lung cancer receiving tyrosine kinase inhibitor (TKI) treatment: A multi-center retrospective study. <i>Thoracic Cancer</i> , 2018, 9, 278-283. | 0.8 | 5 |
| 1031 | Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) - Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy. <i>Pathology and Oncology Research</i> , 2018, 24, 723-731. | 0.9 | 21 |
| 1032 | Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 211-220. | 1.5 | 24 |
| 1033 | Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population. <i>Archivos De Bronconeumologia</i> , 2018, 54, 10-17. | 0.4 | 0 |
| 1034 | Clinical impact of minocycline on afatinib-related rash in patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations. <i>Respiratory Investigation</i> , 2018, 56, 179-183. | 0.9 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1035 | EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: A case report. Lung Cancer, 2018, 115, 131-134. | 0.9 | 22 |
| 1036 | Immune Checkpoint Inhibition in Lung Cancer. , 2018, , 333-344. | | 0 |
| 1037 | Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR -Mutant Metastatic Nonâ€”Small-Cell Lung Cancer (RELAY): Phase Ib Results. Clinical Lung Cancer, 2018, 19, 213-220.e4. | 1.1 | 13 |
| 1038 | Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI. Clinical Drug Investigation, 2018, 38, 319-331. | 1.1 | 14 |
| 1039 | Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. Chemical Reviews, 2018, 118, 1599-1663. | 23.0 | 64 |
| 1040 | Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). Therapeutic Advances in Medical Oncology, 2018, 10, 175883401774501. | 1.4 | 101 |
| 1041 | Multiple single cell screening and DNA MDA amplification chip for oncogenic mutation profiling. Lab on A Chip, 2018, 18, 723-734. | 3.1 | 6 |
| 1042 | First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?. Cancer Chemotherapy and Pharmacology, 2018, 81, 443-453. | 1.1 | 10 |
| 1043 | Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payerâ€™s perspective. BMC Cancer, 2018, 18, 352. | 1.1 | 16 |
| 1044 | Molecular profiling of lung cancer specimens and liquid biopsies using MALDI-TOF mass spectrometry. Diagnostic Pathology, 2018, 13, 4. | 0.9 | 16 |
| 1045 | Histologic transformation from adenocarcinoma to both small cell lung cancer and squamous cell carcinoma after treatment with gefitinib. Medicine (United States), 2018, 97, e0650. | 0.4 | 13 |
| 1046 | Therapeutic strategies for afatinibâ€™resistant lung cancer harboring <i>HER2</i> alterations. Cancer Science, 2018, 109, 1493-1502. | 1.7 | 23 |
| 1047 | Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease. Targeted Oncology, 2018, 13, 269-285. | 1.7 | 46 |
| 1048 | Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. Clinical Cancer Research, 2018, 24, 3108-3118. | 3.2 | 200 |
| 1049 | The Introduction and Clinical Application of Cell-Free Tumor DNA. Methods in Molecular Biology, 2018, 1754, 45-65. | 0.4 | 2 |
| 1050 | Translation of Knowledge to Practiceâ€”Improving Awareness in NSCLC Molecular Testing. Journal of Thoracic Oncology, 2018, 13, 1004-1011. | 0.5 | 8 |
| 1051 | Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea. Lung Cancer, 2018, 119, 36-41. | 0.9 | 7 |
| 1052 | Target identification reveals protein arginine methyltransferase 1 is a potential target of phenyl vinyl sulfone and its derivatives. Bioscience Reports, 2018, 38, . | 1.1 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1053 | Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations. <i>ESMO Open</i> , 2018, 3, e000313. | 2.0 | 33 |
| 1054 | Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP). <i>Cancer</i> , 2018, 124, 2407-2414. | 2.0 | 17 |
| 1055 | Acquired Resistance to Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers: The Role of Next-Generation Sequencing on Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 465-473. | 1.2 | 4 |
| 1056 | A Decade of Never-smokers Among Lung Cancer Patients: Increasing Trend and Improved Survival. <i>Clinical Lung Cancer</i> , 2018, 19, e539-e550. | 1.1 | 21 |
| 1057 | In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition. <i>Computational Biology and Chemistry</i> , 2018, 74, 167-189. | 1.1 | 19 |
| 1058 | The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 792-800. | 0.5 | 17 |
| 1059 | The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics. <i>Journal of Clinical Pathology</i> , 2018, 71, 767-773. | 1.0 | 14 |
| 1060 | A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 3583-3592. | 3.2 | 151 |
| 1061 | Afatinib in advanced NSCLC: a profile of its use. <i>Drugs and Therapy Perspectives</i> , 2018, 34, 89-98. | 0.3 | 14 |
| 1062 | Successful treatment with an EGFR tyrosine kinase inhibitor Afatinib in a patient with combined small-cell lung Cancer with EGFR mutation. <i>Investigational New Drugs</i> , 2018, 36, 715-717. | 1.2 | 7 |
| 1063 | Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. <i>Clinical Lung Cancer</i> , 2018, 19, e465-e479. | 1.1 | 56 |
| 1064 | Genomic Testing in Lung Cancer: Past, Present, and Future. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 323-334. | 2.3 | 20 |
| 1065 | Circulating tumor DNA testing in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 119, 42-47. | 0.9 | 31 |
| 1066 | Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?. <i>Clinical and Experimental Medicine</i> , 2018, 18, 15-20. | 1.9 | 43 |
| 1067 | Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 23-31. | 0.7 | 43 |
| 1068 | Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 379-388. | 0.5 | 46 |
| 1069 | An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach. <i>Clinical Lung Cancer</i> , 2018, 19, 42-50. | 1.1 | 6 |
| 1070 | Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic non-small cell lung carcinoma. <i>Internal Medicine Journal</i> , 2018, 48, 37-44. | 0.5 | 12 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1071 | Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 326-331. | 0.8 | 10 |
| 1072 | Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors. <i>Clinical and Translational Oncology</i> , 2018, 20, 140-149. | 1.2 | 3 |
| 1073 | Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC). <i>Clinical Lung Cancer</i> , 2018, 19, e19-e28. | 1.1 | 17 |
| 1074 | Association between clinical characteristics and the diagnostic accuracy of circulating single-molecule amplification and resequencing technology on detection epidermal growth factor receptor mutation status in plasma of lung adenocarcinoma. <i>Journal of Clinical Laboratory Analysis</i> , 2018, 32, . | 0.9 | 4 |
| 1075 | Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study. <i>Journal of Medical Economics</i> , 2018, 21, 192-200. | 1.0 | 31 |
| 1076 | Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors. <i>Neurosurgery</i> , 2018, 82, E6-E14. | 0.6 | 2 |
| 1077 | Squamous Cell Carcinoma Transformation from EGFR-mutated Lung Adenocarcinoma: A Case Report and Literature Review. <i>Clinical Lung Cancer</i> , 2018, 19, e63-e66. | 1.1 | 50 |
| 1078 | Erlotinib Plus Bevacizumab Phase II Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results. <i>Drug Safety</i> , 2018, 41, 229-237. | 1.4 | 48 |
| 1079 | Adverse Prognostic CT Findings for Patients With Advanced Lung Adenocarcinoma Receiving First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy. <i>American Journal of Roentgenology</i> , 2018, 210, 43-51. | 1.0 | 3 |
| 1080 | Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population. <i>Archivos De Bronconeumologia</i> , 2018, 54, 10-17. | 0.4 | 17 |
| 1081 | Genomic Characterization of Lung Cancer and Its Impact on the Use and Timing of PET in Therapeutic Response Assessment. <i>PET Clinics</i> , 2018, 13, 33-42. | 1.5 | 2 |
| 1082 | Are exon 19 deletions and L858R different in early stage lung adenocarcinoma?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 165-171. | 1.2 | 6 |
| 1083 | Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases. <i>Cancer</i> , 2018, 124, 105-109. | 2.0 | 25 |
| 1084 | Clinical Presentation and Prognostic Factors in Lung Cancer. , 2018, , 186-198.e6. | | 0 |
| 1085 | Frontline Systemic Therapy Options in Nonsmall Cell Lung Cancer. , 2018, , 418-433.e6. | | 0 |
| 1086 | Systemic Options for Second-Line Therapy and Beyond. , 2018, , 434-447.e5. | | 0 |
| 1087 | Maintenance Chemotherapy for Nonsmall Cell Lung Cancer. , 2018, , 448-465.e4. | | 0 |
| 1088 | New Targets for Therapy in Lung Cancer. , 2018, , 479-489.e6. | | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 1089 | Management of Toxicities of Targeted Therapies. , 2018, , 490-500.e3. | | 2 |
| 1090 | Synthesis and evaluation of novel ¹⁸ F-labeled quinazoline derivatives with low lipophilicity for tumor PET imaging. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 42-53. | 0.5 | 2 |
| 1091 | Lung cancer epigenetics: From knowledge to applications. Seminars in Cancer Biology, 2018, 51, 116-128. | 4.3 | 202 |
| 1092 | Biomarker-Stratified Phase III Clinical Trials: Enhancement with a Subgroup-Focused Sequential Design. Clinical Cancer Research, 2018, 24, 994-1001. | 3.2 | 10 |
| 1093 | Molecular Testing in Lung Cancer. , 2018, , 164-177.e5. | | 0 |
| 1094 | Neurological Complications of Targeted Therapies. , 2018, , 311-333. | | 2 |
| 1095 | Molecular Adequacy of Image-Guided Rebiopsies for Molecular Retesting in Advanced Non-Small Cell Lung Cancer: A Single-Center Experience. Journal of Thoracic Oncology, 2018, 13, 63-72. | 0.5 | 21 |
| 1096 | Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nature Reviews Clinical Oncology, 2018, 15, 151-167. | 12.5 | 247 |
| 1097 | Molecular Diagnosis and Targeting for Lung Cancer. Current Human Cell Research and Applications, 2018, , 1-32. | 0.1 | 0 |
| 1098 | Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6). Patient, 2018, 11, 131-141. | 1.1 | 20 |
| 1099 | Identifying EGFR-Expressed Cells and Detecting EGFR Multi-Mutations at Single-Cell Level by Microfluidic Chip. Nano-Micro Letters, 2018, 10, 16. | 14.4 | 6 |
| 1100 | Pharmacogenomic Biomarkers for Improved Drug Therapy—Recent Progress and Future Developments. AAPS Journal, 2018, 20, 4. | 2.2 | 106 |
| 1101 | Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases. Expert Review of Anticancer Therapy, 2018, 18, 81-89. | 1.1 | 29 |
| 1103 | Navigating the “No Man’s Land” of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A Review. Neoplasia, 2018, 20, 92-98. | 2.3 | 24 |
| 1104 | Pharmacokinetics of Osimertinib in Chinese Patients With Advanced NSCLC: A Phase 1 Study. Journal of Clinical Pharmacology, 2018, 58, 504-513. | 1.0 | 20 |
| 1105 | NSCLC Patients Harboring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy. Respiration, 2018, 95, 169-176. | 1.2 | 14 |
| 1106 | A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404. Lung Cancer, 2018, 115, 103-108. | 0.9 | 25 |
| 1107 | Drug development in the era of precision medicine. Nature Reviews Drug Discovery, 2018, 17, 183-196. | 21.5 | 294 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 1108 | Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations. <i>Biochemical and Biophysical Research Communications</i> , 2018, 495, 360-367. | 1.0 | 15 |
| 1109 | Utility of Liquid Biopsy by Improved PNA-LNA PCR Clamp Method for Detecting EGFR Mutation at Initial Diagnosis of Non-Small-Cell Lung Cancer: Observational Study of 190 Consecutive Cases in Clinical Practice. <i>Clinical Lung Cancer</i> , 2018, 19, 181-190. | 1.1 | 16 |
| 1110 | Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 113-125. | 13.9 | 3,530 |
| 1111 | Oligoprogressive Oncogene-addicted Lung Tumours: Does Stereotactic Body Radiotherapy Have a Role? Introducing the HALT Trial. <i>Clinical Oncology</i> , 2018, 30, 1-4. | 0.6 | 18 |
| 1112 | Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions. <i>Lung Cancer</i> , 2018, 115, 12-20. | 0.9 | 131 |
| 1113 | Cost-effectiveness analysis of the addition of bevacizumab to chemotherapy as induction and maintenance therapy for metastatic non-squamous non-small-cell lung cancer. <i>Clinical and Translational Oncology</i> , 2018, 20, 286-293. | 1.2 | 25 |
| 1114 | Design and synthesis of novel 2,4-disubstituted aminopyrimidines: reversible non-covalent T790M EGFR inhibitors. <i>Journal of Receptor and Signal Transduction Research</i> , 2018, 38, 393-412. | 1.3 | 21 |
| 1115 | Eukaryotic translation initiation factor 3 subunit C is associated with acquired resistance to erlotinib in non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 37520-37533. | 0.8 | 7 |
| 1116 | Use of Low-Frequency Driver Mutations Detected by Cell-Free Circulating Tumor DNA to Guide Targeted Therapy in Non-Small-Cell Lung Cancer: A Multicenter Case Series. <i>JCO Precision Oncology</i> , 2018, 2, 1-10. | 1.5 | 7 |
| 1117 | Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations. <i>Oncotarget</i> , 2018, 9, 24237-24247. | 0.8 | 32 |
| 1118 | Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 726-739. | 1.8 | 13 |
| 1119 | Systemic Therapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancers. <i>Journal of Clinical Oncology</i> , 2018, 36, 2571-2574. | 0.8 | 6 |
| 1120 | CNS Metastases in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: Impact on Health Resource Utilization. <i>Journal of Oncology Practice</i> , 2018, 14, e612-e620. | 2.5 | 8 |
| 1121 | Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 841-849. | 0.8 | 423 |
| 1122 | Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1853-1860. | 0.8 | 32 |
| 1123 | Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-13. | 1.5 | 17 |
| 1124 | Selective gene amplification to detect the T790M mutation in plasma from patients with advanced non-small cell lung cancer (NSCLC) who have developed epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance. <i>Journal of Thoracic Disease</i> , 2018, 10, 1431-1439. | 0.6 | 9 |
| 1125 | Squamous cell carcinoma transformation from adenocarcinoma as an acquired resistance after the EGFR TKI therapy in (EGFR-mutated) non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, E526-E531. | 0.6 | 16 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1126 | Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken option. Translational Lung Cancer Research, 2018, 7, S100-S102. | 1.3 | 7 |
| 1127 | BRAF inhibitors in metastatic non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, 589-592. | 0.6 | 27 |
| 1128 | Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an EGFR mutation. Journal of Thoracic Disease, 2018, 10, 2166-2178. | 0.6 | 14 |
| 1129 | Value of combining serum carcinoembryonic antigen and PET/CT in predicting EGFR mutation in non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, 723-731. | 0.6 | 20 |
| 1130 | Oncogene-addicted non-small cell lung cancer and immunotherapy. Journal of Thoracic Disease, 2018, 10, S1547-S1555. | 0.6 | 25 |
| 1131 | Early radiological response as predictor of overall survival in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor mutations. Journal of Thoracic Disease, 2018, 10, 1386-1393. | 0.6 | 4 |
| 1132 | A case of different EGFR mutations in surgically resected synchronous triple lung cancer. Journal of Thoracic Disease, 2018, 10, E255-E259. | 0.6 | 4 |
| 1133 | Moving osimertinib to first-line: the right "strategy" in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer?. Journal of Thoracic Disease, 2018, 10, S1076-S1080. | 0.6 | 5 |
| 1134 | Adjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine. Journal of Thoracic Disease, 2018, 10, 1364-1369. | 0.6 | 6 |
| 1135 | Targeting the metastatic niche through anti-angiogenic approaches in epidermal growth factor receptor mutant non-small cell lung cancer. Translational Lung Cancer Research, 2018, 7, S13-S18. | 1.3 | 1 |
| 1136 | Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer. Translational Lung Cancer Research, 2018, 7, S165-S170. | 1.3 | 14 |
| 1137 | Factors associated with the prognosis and long-term survival of patients with metastatic lung adenocarcinoma: a retrospective analysis. Journal of Thoracic Disease, 2018, 10, 2070-2078. | 0.6 | 18 |
| 1138 | Choosing the Best EGFR TKI in the Era of Precision Medicine. Journal of Oncology Translational Research, 2018, 04, . | 0.2 | 0 |
| 1139 | Management of Advanced Non-Small Cell Lung Cancer. , 2018, , 99-115. | | 1 |
| 1140 | Osimertinib therapy as first-line treatment before acquiring T790M mutation: from AURA1 trial. Journal of Thoracic Disease, 2018, 10, S3071-S3077. | 0.6 | 4 |
| 1141 | The clinical utility of tumor mutational burden in non-small cell lung cancer. Translational Lung Cancer Research, 2018, 7, 639-646. | 1.3 | 98 |
| 1142 | Phase 1 Studies of Pozitotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors. Cancer Research and Treatment, 2018, 50, 835-842. | 1.3 | 64 |
| 1143 | Circulating Cell-Free Tumor DNA in the Management of Double Primary Tumors. JCO Precision Oncology, 2018, 2, 1-6. | 1.5 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1144 | What is the best drug as a front-line treatment for EGFR activating mutation?. Precision Cancer Medicine, 2018, 1, 16-16. | 1.8 | 0 |
| 1148 | Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing. Cancer Science, 2018, 109, 3921-3933. | 1.7 | 27 |
| 1149 | Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy. Cells, 2018, 7, 212. | 1.8 | 190 |
| 1151 | Afatinib in Advanced Pretreated Non-Small-Cell Lung Cancer—A Canadian Experience. Current Oncology, 2018, 25, 385-390. | 0.9 | 4 |
| 1152 | Safety of osimertinib in EGFR-mutated non-small cell lung cancer. Expert Opinion on Drug Safety, 2018, 17, 1239-1248. | 1.0 | 25 |
| 1153 | Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors. Oncology Research and Treatment, 2018, 41, 755-761. | 0.8 | 17 |
| 1154 | Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases. BMC Cancer, 2018, 18, 1198. | 1.1 | 18 |
| 1155 | Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial. OncoTargets and Therapy, 2018, Volume 11, 8575-8587. | 1.0 | 21 |
| 1156 | Comparison between NOD/SCID mice and BALB/c mice for patient-derived tumor xenografts model of non-small-cell lung cancer. Cancer Management and Research, 2018, Volume 10, 6695-6703. | 0.9 | 8 |
| 1157 | Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors. BioScience Trends, 2018, 12, 537-552. | 1.1 | 20 |
| 1158 | Afatinib reverses ceritinib resistance (CR) in ALK/ROS1-positive non-small-cell lung cancer cell (NSCLC) via suppression of NRG1 pathway. OncoTargets and Therapy, 2018, Volume 11, 8201-8209. | 1.0 | 10 |
| 1159 | The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations. BMC Cancer, 2018, 18, 1241. | 1.1 | 1 |
| 1161 | Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study. BMC Cancer, 2018, 18, 1231. | 1.1 | 10 |
| 1162 | Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance. Oncotarget, 2018, 9, 15418-15434. | 0.8 | 21 |
| 1164 | Prise en charge thérapeutique des cancers bronchiques non À petites cellules de stades avancés mutés pour l'EGFR. Revue Des Maladies Respiratoires Actualites, 2018, 10, 425-439. | 0.0 | 1 |
| 1166 | Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer. Scientific Reports, 2018, 8, 14896. | 1.6 | 31 |
| 1167 | Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment. OncoTargets and Therapy, 2018, Volume 11, 6189-6196. | 1.0 | 47 |
| 1168 | Novel Systemic Treatments for Brain Metastases From Lung Cancer. Current Treatment Options in Neurology, 2018, 20, 48. | 0.7 | 6 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1169 | Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 58. | 1.3 | 41 |
| 1170 | Propranolol for the treatment of vascular sarcomas. <i>Journal of Experimental Pharmacology</i> , 2018, Volume 10, 51-58. | 1.5 | 31 |
| 1171 | First reported case of afatinib-associated toxic megacolon. <i>Respirology Case Reports</i> , 2018, 6, e00360. | 0.3 | 2 |
| 1172 | Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2457-2463. | 1.2 | 8 |
| 1173 | Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment. <i>Clinical Journal of Oncology Nursing</i> , 2018, 22, 542-548. | 0.3 | 15 |
| 1174 | A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2018, 104, 1-8. | 1.3 | 10 |
| 1175 | Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour. <i>BMJ Open</i> , 2018, 8, e017240. | 0.8 | 20 |
| 1176 | A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 1031-1038. | 1.1 | 18 |
| 1177 | Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv192-iv237. | 0.6 | 1,571 |
| 1178 | Budget Impact Analysis of Afatinib for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 Substitution Mutations in a U.S. Health Plan. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 544-553. | 0.5 | 7 |
| 1179 | Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies. <i>Lung Cancer</i> , 2018, 126, 1-8. | 0.9 | 40 |
| 1180 | Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation—Positive Advanced NSCLC: Findings From a Global Named Patient Use Program. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1897-1905. | 0.5 | 68 |
| 1181 | Generation and characterization of MEK and ERK inhibitors-resistant non-small-cells-lung-cancer (NSCLC) cells. <i>BMC Cancer</i> , 2018, 18, 1028. | 1.1 | 7 |
| 1182 | Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical Trials. <i>Cancers</i> , 2018, 10, 384. | 1.7 | 9 |
| 1183 | Significance of the epidermal growth factor receptor mutation status and differences among molecular subgroups in surgically resected lung microinvasive adenocarcinoma. <i>Oncology Letters</i> , 2018, 16, 7057-7067. | 0.8 | 3 |
| 1184 | Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions. <i>Annals of Oncology</i> , 2018, 29, 2092-2097. | 0.6 | 56 |
| 1185 | Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1625-1637. | 0.5 | 10 |
| 1186 | Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661880865. | 1.0 | 22 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1187 | A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation. <i>Medicine (United States)</i> , 2018, 97, e11569. | 0.4 | 20 |
| 1188 | An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer. <i>Medicine (United States)</i> , 2018, 97, e12660. | 0.4 | 0 |
| 1189 | Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 125, 282-290. | 0.9 | 48 |
| 1190 | A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations. <i>Lung Cancer</i> , 2018, 126, 41-47. | 0.9 | 39 |
| 1191 | Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study. <i>Future Oncology</i> , 2018, 14, 2861-2874. | 1.1 | 90 |
| 1192 | Treatment Patterns by EGFR Mutation Status in Non-Small Cell Lung Cancer Patients in the USA: A Retrospective Database Analysis. <i>Advances in Therapy</i> , 2018, 35, 1905-1919. | 1.3 | 9 |
| 1193 | Epidermal growth factor receptor T790M mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China. <i>Scientific Reports</i> , 2018, 8, 15426. | 1.6 | 12 |
| 1194 | Pan-HER-targeted approach for cancer therapy: Mechanisms, recent advances and clinical prospect. <i>Cancer Letters</i> , 2018, 439, 113-130. | 3.2 | 11 |
| 1195 | Do statins improve outcomes for patients with non-small cell lung cancer? A systematic review and meta-analysis protocol. <i>BMJ Open</i> , 2018, 8, e022161. | 0.8 | 4 |
| 1196 | Epidermal growth factor receptor gene mutations in non-small-cell lung cancer cells are associated with increased radiosensitivity in vitro. <i>Cancer Management and Research</i> , 2018, Volume 10, 3551-3560. | 0.9 | 4 |
| 1197 | Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada. <i>Lung Cancer</i> , 2018, 125, 1-7. | 0.9 | 30 |
| 1198 | The evolving first-line treatment of advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations. <i>Translational Lung Cancer Research</i> , 2018, 7, S134-S137. | 1.3 | 7 |
| 1199 | Impact of menopausal status and HER-2/neu protein on efficacy of EGFR-TKI in EGFR mutant patients with non-small cell lung cancer. <i>Journal of Cancer</i> , 2018, 9, 2987-2993. | 1.2 | 1 |
| 1200 | Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591879463. | 1.4 | 317 |
| 1201 | A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer. <i>Oncology Research</i> , 2018, 26, 1031-1036. | 0.6 | 21 |
| 1202 | New drugs in thoracic oncology: needs and knowledge – an online ERS Lung Cancer Assembly survey. <i>ERJ Open Research</i> , 2018, 4, 00040-2018. | 1.1 | 2 |
| 1203 | Treatment effectiveness and tolerability of afatinib at different doses in patients with EGFR-mutated lung adenocarcinoma: How low can we go?. <i>European Journal of Cancer</i> , 2018, 103, 32-40. | 1.3 | 19 |
| 1204 | The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2018, 8, 13379. | 1.6 | 66 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1205 | Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC. <i>Clinical Cancer Research</i> , 2018, 24, 6195-6203. | 3.2 | 292 |
| 1206 | Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis. <i>Oncotarget</i> , 2018, 9, 11805-11815. | 0.8 | 9 |
| 1207 | Osimertinib With Ramucirumab in EGFR-mutated, T790M-positive Patients With Progression During EGFR-TKI Therapy: Phase Ib Study. <i>Clinical Lung Cancer</i> , 2018, 19, e871-e874. | 1.1 | 10 |
| 1208 | Real Clinical Practice of Using Afatinib Therapy in NSCLC Patients with an Acquired EGFR T790M Mutation. <i>Anticancer Research</i> , 2018, 38, 5409-5415. | 0.5 | 8 |
| 1209 | Real-World EGFR T790M Testing in Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study in Japan. <i>Oncology and Therapy</i> , 2018, 6, 203-215. | 1.0 | 47 |
| 1210 | Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1560-1568. | 0.5 | 158 |
| 1211 | Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 124, 248-254. | 0.9 | 61 |
| 1212 | Impact of serum vascular endothelial growth factor and interleukin-6 on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer. <i>Lung Cancer</i> , 2018, 125, 22-28. | 0.9 | 16 |
| 1213 | Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors. <i>CNS Drugs</i> , 2018, 32, 527-542. | 2.7 | 10 |
| 1214 | Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors. <i>Investigational New Drugs</i> , 2018, 36, 1044-1059. | 1.2 | 0 |
| 1215 | Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877281. | 1.4 | 18 |
| 1216 | Black Phosphorus Quantum Dots Gated, Carbon-Coated Fe ₃ O ₄ Nanocapsules (BPQDs@Fe ₃ O ₄ @C) with Low Premature Release Could Enable Imaging-Guided Cancer Combination Therapy. <i>Chemistry - A European Journal</i> , 2018, 24, 12890-12901. | 1.7 | 47 |
| 1217 | Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program. <i>Oncology and Therapy</i> , 2018, 6, 45-58. | 1.0 | 5 |
| 1218 | Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer. <i>Targeted Oncology</i> , 2018, 13, 389-398. | 1.7 | 2 |
| 1219 | Gastrointestinal perforation during treatment with erlotinib plus bevacizumab in two patients with non-small cell lung cancer exhibiting epidermal growth factor receptor mutations: A case report. <i>Oncology Letters</i> , 2018, 16, 1046-1050. | 0.8 | 3 |
| 1220 | Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management. <i>BioMed Research International</i> , 2018, 2018, 1-8. | 0.9 | 24 |
| 1221 | Stereotactic Body Radiotherapy. <i>Progress in Tumor Research</i> , 2018, , 67-88. | 0.1 | 0 |
| 1222 | Chemotherapy of Brain Metastases. , 2018, , 527-543. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1223 | Can We Prevent Resistance to Osimertinib? Combination or Sequential. <i>Journal of Thoracic Oncology</i> , 2018, 13, 877-879. | 0.5 | 2 |
| 1224 | Acute-phase reaction induced by zoledronate and its effect on prognosis of patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 122, 200-205. | 0.9 | 10 |
| 1225 | Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer. <i>Cancer Treatment Reviews</i> , 2018, 69, 143-151. | 3.4 | 23 |
| 1226 | Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer. <i>Current Oncology</i> , 2018, 25, 73-82. | 0.9 | 24 |
| 1227 | Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients. <i>Lung Cancer</i> , 2018, 123, 60-69. | 0.9 | 58 |
| 1228 | Rapidly Changing Treatment Algorithms for Metastatic Nonsquamous Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2018, 25, 68-76. | 0.9 | 11 |
| 1229 | Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1248-1268. | 0.5 | 515 |
| 1230 | Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists. <i>Journal of Clinical Medicine</i> , 2018, 7, 192. | 1.0 | 27 |
| 1231 | Therapeutic approaches for T790M mutation positive non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1021-1030. | 1.1 | 21 |
| 1232 | A comparison of QuantStudio 3D Digital PCR and ARMS-PCR for measuring plasma EGFR T790M mutations of NSCLC patients. <i>Cancer Management and Research</i> , 2018, Volume 10, 115-121. | 0.9 | 16 |
| 1233 | Brain Metastases in Non-Small-Cell Lung Cancer: Are Tyrosine Kinase Inhibitors and Checkpoint Inhibitors Now Viable Options?. <i>Current Oncology</i> , 2018, 25, 103-114. | 0.9 | 42 |
| 1234 | Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, T790M, and Clinical Trials. <i>Current Oncology</i> , 2018, 25, 28-37. | 0.9 | 23 |
| 1235 | Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1363-1372. | 0.5 | 140 |
| 1236 | Afatinib. <i>Recent Results in Cancer Research</i> , 2018, 211, 199-215. | 1.8 | 40 |
| 1237 | Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs. <i>Anticancer Research</i> , 2018, 38, 4699-4704. | 0.5 | 6 |
| 1238 | Current views on molecularly targeted therapy for lung cancer – a review of literature from the last five years. <i>Kardiochirurgia I Torakochirurgia Polska</i> , 2018, 15, 119-124. | 0.1 | 6 |
| 1239 | Cost-effectiveness and budget impact of lung cancer immunotherapy in South America: strategies to improve access. <i>Immunotherapy</i> , 2018, 10, 887-897. | 1.0 | 13 |
| 1240 | First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?. <i>Frontiers in Oncology</i> , 2018, 8, 94. | 1.3 | 20 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1241 | Acquired resistance in oncogene-addicted non-small-cell lung cancer. <i>Future Oncology</i> , 2018, 14, 29-40. | 1.1 | 18 |
| 1242 | Oncogene addicted non-small-cell lung cancer: current standard and hot topics. <i>Future Oncology</i> , 2018, 14, 3-17. | 1.1 | 18 |
| 1243 | Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?. <i>Journal of Clinical Medicine</i> , 2018, 7, 144. | 1.0 | 54 |
| 1244 | EGFR: How Important Is EGFR Mutation Status in the Management of Lung Cancer?. <i>Respiratory Disease Series</i> , 2018, , 275-293. | 0.1 | 0 |
| 1245 | Common cancer-driver mutations and their association with abnormally methylated genes in lung adenocarcinoma from never-smokers. <i>Lung Cancer</i> , 2018, 123, 99-106. | 0.9 | 20 |
| 1246 | Non-“Small Cell Lung Cancer with Resistance to EGFR-TKI Therapy: CT Characteristics of T790M Mutation”-positive Cancer. <i>Radiology</i> , 2018, 289, 227-237. | 3.6 | 19 |
| 1247 | Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 208. | 1.3 | 62 |
| 1248 | A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC. <i>Cancers</i> , 2018, 10, 236. | 1.7 | 31 |
| 1249 | A systematic review of targeted agents for non-small cell lung cancer. <i>Acta OncolÃ³gica</i> , 2018, 57, 176-186. | 0.8 | 54 |
| 1250 | Irreversible Tyrosine Kinase Inhibition of Epidermal Growth Factor Receptor with Afatinib in Egfr Activating Mutation”-Positive Advanced Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2018, 25, 9-17. | 0.9 | 15 |
| 1251 | Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors. <i>Clinical Lung Cancer</i> , 2018, 19, e655-e665. | 1.1 | 7 |
| 1253 | TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1648-1658. | 1.9 | 64 |
| 1254 | Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma (Review). <i>Oncology Letters</i> , 2018, 15, 7497-7505. | 0.8 | 50 |
| 1255 | Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. <i>BMC Cancer</i> , 2018, 18, 106. | 1.1 | 9 |
| 1256 | Mechanisms of receptor tyrosine kinase activation in cancer. <i>Molecular Cancer</i> , 2018, 17, 58. | 7.9 | 580 |
| 1257 | Kinase-targeted cancer therapies: progress, challenges and future directions. <i>Molecular Cancer</i> , 2018, 17, 48. | 7.9 | 796 |
| 1258 | Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-“Small-cell Lung Cancer in Asia. <i>Clinical Lung Cancer</i> , 2018, 19, e601-e608. | 1.1 | 8 |
| 1259 | Xenograft tumors derived from malignant pleural effusion of the patients with non-“small-“cell lung cancer as models to explore drug resistance. <i>Cancer Communications</i> , 2018, 38, 1-12. | 3.7 | 14 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 1260 | Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 851-864. | 0.9 | 6 |
| 1261 | Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer. <i>BMC Cancer</i> , 2018, 18, 6. | 1.1 | 7 |
| 1262 | Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). <i>Annals of Translational Medicine</i> , 2018, 6, 144-144. | 0.7 | 19 |
| 1263 | Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor. <i>Clinical Lung Cancer</i> , 2018, 19, 518-530.e7. | 1.1 | 48 |
| 1264 | Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 3335-3343. | 1.0 | 20 |
| 1265 | No Therapeutic Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Retreatment Despite T790M Disappearance: Case Report of 3 Cases. <i>Chemotherapy</i> , 2018, 63, 198-202. | 0.8 | 0 |
| 1266 | Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 694-708. | 12.5 | 255 |
| 1267 | Characterization of Factors Affecting the Detection Limit of EGFR p.T790M in Circulating Tumor DNA. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381879365. | 0.8 | 3 |
| 1268 | The Role of Targeted Agents and Immunotherapy in Older Patients with Non-small Cell Lung Cancer. <i>Drugs and Aging</i> , 2018, 35, 819-834. | 1.3 | 16 |
| 1269 | Efficacy of icotinib in advanced lung squamous cell carcinoma. <i>Cancer Medicine</i> , 2018, 7, 4456-4466. | 1.3 | 13 |
| 1270 | Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 529-538. | 1.0 | 13 |
| 1271 | A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 757-766. | 1.1 | 3 |
| 1272 | Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy. <i>Thoracic Cancer</i> , 2018, 9, 1285-1290. | 0.8 | 26 |
| 1273 | Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments. <i>International Journal of Clinical Oncology</i> , 2018, 23, 1052-1059. | 1.0 | 27 |
| 1274 | Comparing first-line treatment patterns and clinical outcomes of patients with pan-negative advanced non-squamous non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 1005-1011. | 0.8 | 2 |
| 1275 | Targeting EGFR in Lung Cancer: Current Standards and Developments. <i>Drugs</i> , 2018, 78, 893-911. | 4.9 | 61 |
| 1276 | Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 1063-1069. | 3.2 | 257 |
| 1277 | Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinib. <i>Supportive Care in Cancer</i> , 2019, 27, 1029-1039. | 1.0 | 4 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1278 | Response to alectinib oil-based suspension in anaplastic lymphoma kinase-positive non-small cell lung cancer in a patient unable to swallow: A case report. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1722-1725. | 0.5 | 4 |
| 1279 | Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities. , 2019, 193, 20-30. | | 49 |
| 1280 | Clinical pharmacology of oncology agents in older adults: A comprehensive review of how chronologic and functional age can influence treatment-related effects. <i>Journal of Geriatric Oncology</i> , 2019, 10, 4-30. | 0.5 | 27 |
| 1281 | Newly characterized motile sperm domain-containing protein 2 promotes human breast cancer metastasis. <i>International Journal of Cancer</i> , 2019, 144, 125-135. | 2.3 | 6 |
| 1282 | Osimertinib for Japanese patients with T790M-positive advanced non-small cell lung cancer: A pooled subgroup analysis. <i>Cancer Science</i> , 2019, 110, 2884-2893. | 1.7 | 22 |
| 1283 | Imaging of Precision Therapy for Lung Cancer: Current State of the Art. <i>Radiology</i> , 2019, 293, 15-29. | 3.6 | 45 |
| 1284 | Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, 1448. | 3.4 | 94 |
| 1285 | Cost-effectiveness analysis of alectinib versus crizotinib in first-line treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer. <i>Global & Regional Health Technology Assessment</i> , 2019, 2019, 228424031985507. | 0.2 | 0 |
| 1286 | Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). <i>International Journal of Molecular Sciences</i> , 2019, 20, 3821. | 1.8 | 116 |
| 1287 | The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2019, 138, 131-138. | 0.9 | 6 |
| 1288 | Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity. <i>Science Immunology</i> , 2019, 4, . | 5.6 | 30 |
| 1289 | Relative value assessment: characterizing the benefit of oncology therapies through diverse survival metrics from a US perspective. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 199-219. | 0.7 | 1 |
| 1290 | Concomitant Genetic Alterations are Associated with Worse Clinical Outcome in EGFR Mutant NSCLC Patients Treated with Tyrosine Kinase Inhibitors. <i>Translational Oncology</i> , 2019, 12, 1425-1431. | 1.7 | 21 |
| 1291 | Rethink of EGFR in Cancer With Its Kinase Independent Function on Board. <i>Frontiers in Oncology</i> , 2019, 9, 800. | 1.3 | 123 |
| 1292 | Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib. <i>Cancer Research and Treatment</i> , 2019, 51, 502-509. | 1.3 | 74 |
| 1293 | Detection of Plasma EGFR Mutations in NSCLC Patients with a Validated ddPCR Lung cfDNA Assay. <i>Journal of Cancer</i> , 2019, 10, 4341-4349. | 1.2 | 24 |
| 1294 | Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR-mutated non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 1928-1935. | 0.8 | 10 |
| 1295 | Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer. <i>Theranostics</i> , 2019, 9, 5532-5541. | 4.6 | 80 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1296 | Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. <i>Nature Reviews Cancer</i> , 2019, 19, 495-509. | 12.8 | 573 |
| 1297 | SRC and MEK Co-inhibition Synergistically Enhances the Anti-tumor Effect in Both Non-small-cell Lung Cancer (NSCLC) and Erlotinib-Resistant NSCLC. <i>Frontiers in Oncology</i> , 2019, 9, 586. | 1.3 | 15 |
| 1298 | Afatinib use in recurrent epithelial ovarian carcinoma. <i>Gynecologic Oncology Reports</i> , 2019, 29, 70-72. | 0.3 | 5 |
| 1299 | Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. <i>Translational Lung Cancer Research</i> , 2019, 8, 302-316. | 1.3 | 91 |
| 1300 | The clinical impact of family history of cancer in female never-smoker lung adenocarcinoma. <i>Lung Cancer</i> , 2019, 136, 15-22. | 0.9 | 6 |
| 1301 | Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey. <i>Translational Lung Cancer Research</i> , 2019, 8, 286-301. | 1.3 | 69 |
| 1302 | ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 3003-3014. | 1.1 | 42 |
| 1303 | Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 831-840. | 1.3 | 4 |
| 1304 | Systematic review and network meta-analysis of first-line therapy for advanced EGFR-positive non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 2857-2871. | 1.1 | 17 |
| 1305 | Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society. <i>Lung Cancer</i> , 2019, 136, 65-73. | 0.9 | 8 |
| 1306 | Compliance to regional recommendations for molecular analyses and management of advanced lung cancer patients. <i>Future Oncology</i> , 2019, 15, 2139-2149. | 1.1 | 2 |
| 1307 | Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1623-1640. | 1.4 | 1,153 |
| 1308 | Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers. <i>Journal of Clinical Medicine</i> , 2019, 8, 998. | 1.0 | 28 |
| 1309 | Opportunities of circulating tumor DNA in lung cancer. <i>Cancer Treatment Reviews</i> , 2019, 78, 31-41. | 3.4 | 16 |
| 1310 | Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade. <i>Journal of Clinical Medicine</i> , 2019, 8, 1014. | 1.0 | 41 |
| 1311 | Treatment of Non-small Cell Lung Cancer with EGFR-mutations. <i>Journal of UOEH</i> , 2019, 41, 153-163. | 0.3 | 65 |
| 1312 | Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners. , 2019, , . | | 0 |
| 1313 | Cardiac Toxicity From Afatinib in EGFR-Mutated NSCLC: A Rare But Possible Side Effect. <i>Journal of Thoracic Oncology</i> , 2019, 14, e145-e146. | 0.5 | 12 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1314 | Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial. <i>Lung Cancer</i> , 2019, 135, 66-72. | 0.9 | 22 |
| 1315 | Efficacy of Platinum-Based Adjuvant Chemotherapy on Prognosis of Pathological Stage II/III Lung Adenocarcinoma based on EGFR Mutation Status: A Propensity Score Matching Analysis. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 657-665. | 1.6 | 7 |
| 1316 | <p>Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 5665-5675. | 0.9 | 48 |
| 1317 | <p>Comparative review of drug–drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5467-5484. | 1.0 | 36 |
| 1318 | Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1593-1601. | 1.9 | 4 |
| 1319 | Effectiveness of Treatments for Advanced Non–Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations. <i>Clinical Lung Cancer</i> , 2019, 20, e620-e630. | 1.1 | 39 |
| 1320 | Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM). <i>Tumori</i> , 2019, 105, 3-14. | 0.6 | 9 |
| 1321 | Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors. <i>Molecules</i> , 2019, 24, 2407. | 1.7 | 30 |
| 1322 | Reliable Gene Expression Profiling from Small and Hematoxylin and Eosin–Stained Clinical Formalin-Fixed, Paraffin-Embedded Specimens Using the HTG EdgeSeq Platform. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 796-807. | 1.2 | 19 |
| 1323 | Chronological Trends in Progression-Free, Overall, and Post-Progression Survival in First-Line Therapy for Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1619-1627. | 0.5 | 11 |
| 1324 | Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients. <i>European Journal of Cancer</i> , 2019, 117, 107-115. | 1.3 | 31 |
| 1325 | EGFR Targeted Therapy. <i>Current Cancer Research</i> , 2019, , 1-30. | 0.2 | 2 |
| 1326 | Green Synthesis of Substituted Anilines and Quinazolines from Isatoic Anhydride-8-amide. <i>Scientific Reports</i> , 2019, 9, 14258. | 1.6 | 5 |
| 1327 | First-line EGFR TKI therapy in non-small-cell lung cancer: looking back before leaping forward. <i>Annals of Oncology</i> , 2019, 30, 1852-1855. | 0.6 | 13 |
| 1328 | Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis. <i>BMJ: British Medical Journal</i> , 2019, 367, I5460. | 2.4 | 108 |
| 1329 | Platycodon grandiflorus enhances the effect of DDP against lung cancer by down regulating PI3K/Akt signaling pathway. <i>Biomedicine and Pharmacotherapy</i> , 2019, 120, 109496. | 2.5 | 14 |
| 1330 | Relationship between performance status or younger age and osimertinib therapy in T790M-positive NSCLC: are the available data convincing?. <i>Journal of Thoracic Disease</i> , 2019, 11, S1837-S1840. | 0.6 | 2 |
| 1332 | Sequential EGFR mutation and ALK rearrangement in adenocarcinoma lung, with rare metastasis to bilateral breast, ovary and endometrium. <i>Respiratory Medicine Case Reports</i> , 2019, 28, 100954. | 0.2 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1333 | Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine. <i>Frontiers in Medicine</i> , 2019, 6, 233. | 1.2 | 8 |
| 1334 | Patient preferences for attributes of tyrosine kinase inhibitor treatments for EGFR mutation-positive non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 3895-3907. | 1.1 | 10 |
| 1335 | Predicting EGFR mutation status in lung adenocarcinoma on computed tomography image using deep learning. <i>European Respiratory Journal</i> , 2019, 53, 1800986. | 3.1 | 298 |
| 1336 | Systemic Therapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 764. | 3.8 | 720 |
| 1337 | Optimizing outcomes and treatment sequences in EGFR mutation-positive non-small-cell lung cancer: recent updates. <i>Future Oncology</i> , 2019, 15, 2983-2997. | 1.1 | 27 |
| 1338 | Health-Related Quality of Life in Advanced Non-small Cell Lung Cancer: A Methodological Appraisal Based on a Systematic Literature Review. <i>Frontiers in Oncology</i> , 2019, 9, 715. | 1.3 | 13 |
| 1339 | Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors. <i>European Journal of Cancer</i> , 2019, 119, 77-86. | 1.3 | 23 |
| 1340 | Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study. <i>PLoS ONE</i> , 2019, 14, e0221575. | 1.1 | 11 |
| 1341 | Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 1259. | 1.7 | 18 |
| 1342 | Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 6535-6548. | 1.0 | 26 |
| 1343 | A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1065-1071. | 1.1 | 1 |
| 1344 | Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2613-2624. | 1.2 | 14 |
| 1345 | EGFR-TKI acquired resistance in lung cancers harboring EGFR mutations in immunocompetent C57BL/6J mice. <i>Lung Cancer</i> , 2019, 136, 86-93. | 0.9 | 7 |
| 1346 | Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study. <i>BMC Cancer</i> , 2019, 19, 896. | 1.1 | 33 |
| 1347 | Molecular mechanisms of Cisplatin-induced placental toxicity and teratogenicity in rats and the ameliorating role of N-acetyl-cysteine. <i>International Journal of Biochemistry and Cell Biology</i> , 2019, 115, 105579. | 1.2 | 4 |
| 1348 | Dacomitinib in non-small-cell lung cancer: a comprehensive review for clinical application. <i>Future Oncology</i> , 2019, 15, 2769-2777. | 1.1 | 8 |
| 1349 | Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer. <i>Cancers</i> , 2019, 11, 1360. | 1.7 | 20 |
| 1350 | Emerging 2D material-based nanocarrier for cancer therapy beyond graphene. <i>Coordination Chemistry Reviews</i> , 2019, 400, 213041. | 9.5 | 103 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1351 | Treatment modes for EGFR mutations in patients with brain metastases from non-small cell lung cancer: controversy, causes, and solutions. <i>Translational Lung Cancer Research</i> , 2019, 8, 524-531. | 1.3 | 9 |
| 1352 | Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib. <i>Seminars in Oncology</i> , 2019, 46, 271-283. | 0.8 | 61 |
| 1353 | <p>Great efficacy of afatinib on a patient with lung adenocarcinoma harboring uncommon EGFR delE709_T710insD mutations: a case report</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 7399-7404. | 1.0 | 12 |
| 1354 | Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. <i>Annals of Oncology</i> , 2019, 30, 1978-1984. | 0.6 | 75 |
| 1355 | <p>Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 3187-3198. | 2.0 | 39 |
| 1356 | Cancer Management by Tyrosine Kinase Inhibitors: Efficacy, Limitation, and Future Strategies. , 2019, , . | | 3 |
| 1357 | First-line treatments in EGFR-mutated advanced non-small cell lung cancer: A network meta-analysis. <i>PLoS ONE</i> , 2019, 14, e0223530. | 1.1 | 11 |
| 1358 | Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Pozotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. <i>Cancer Cell</i> , 2019, 36, 444-457.e7. | 7.7 | 145 |
| 1359 | Defining subpopulations of differential drug response to reveal novel target populations. <i>Npj Systems Biology and Applications</i> , 2019, 5, 36. | 1.4 | 18 |
| 1360 | Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2019, 137, 113-122. | 0.9 | 154 |
| 1362 | Current Approaches in the Development of Covalent Irreversible EGFR Inhibitors. , 2019, , 45-128. | | 0 |
| 1363 | Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib. <i>Internal Medicine</i> , 2019, 58, 101-104. | 0.3 | 3 |
| 1364 | Modeling Exposureâ€Driven Adverse Event Time Courses in Oncology Exemplified by Afatinib. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 230-239. | 1.3 | 5 |
| 1365 | Local Thermal Ablation with Continuous EGFR Tyrosine Kinase Inhibitors for EGFR-Mutant Non-small Cell Lung Cancers that Developed Extra-Central Nervous System (CNS) Oligoprogressive Disease. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 693-699. | 0.9 | 19 |
| 1366 | Diarrhea With HER2â€Targeted Agents in Cancer Patients: A Systematic Review and Metaâ€Analysis. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 935-946. | 1.0 | 6 |
| 1367 | YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Nonâ€Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 2575-2587. | 3.2 | 71 |
| 1368 | Comparative analysis of co-occurring mutations of specific tumor suppressor genes in lung adenocarcinoma between Asian and Caucasian populations. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 747-757. | 1.2 | 8 |
| 1369 | The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 5-15. | 1.1 | 48 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1370 | Molecular Profile of Advanced Non-Small Cell Lung Cancers in Octogenarians: The Door to Precision Medicine in Elderly Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 112. | 1.0 | 7 |
| 1371 | Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3 pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 31. | 3.5 | 63 |
| 1372 | Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 805-816. | 1.1 | 32 |
| 1373 | Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 134, 1-6. | 0.9 | 20 |
| 1374 | A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 211. | 3.5 | 10 |
| 1375 | Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. <i>Lung Cancer</i> , 2019, 133, 96-102. | 0.9 | 85 |
| 1376 | A safety, pharmacokinetic, pharmacogenomic and population pharmacokinetic analysis of the third-generation EGFR TKI, osimertinib (HM61713), after single oral administration in healthy volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019, 125, 370-381. | 1.2 | 9 |
| 1377 | Targeted Therapies in Non-small-Cell Lung Cancer. <i>Cancer Treatment and Research</i> , 2019, 178, 3-43. | 0.2 | 16 |
| 1378 | EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer. <i>BMC Cancer</i> , 2019, 19, 595. | 1.1 | 93 |
| 1379 | Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFR/III-cMet signaling in glioblastoma cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 266. | 3.5 | 81 |
| 1380 | Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study. <i>Cancer Management and Research</i> , 2019, Volume 11, 4883-4892. | 0.9 | 17 |
| 1381 | Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells. <i>Cancer Science</i> , 2019, 110, 2549-2557. | 1.7 | 26 |
| 1383 | Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1134-1155. | 0.5 | 61 |
| 1384 | Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein). <i>Pharmacological Research</i> , 2019, 146, 104297. | 3.1 | 29 |
| 1385 | The EGFR Exon 19 Mutant L747-A750&P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 6382-6391. | 3.2 | 39 |
| 1386 | Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib. <i>Targeted Oncology</i> , 2019, 14, 335-342. | 1.7 | 28 |
| 1387 | Cas clinique n° 5 : Adaptation thérapeutique chez un patient atteint de cancer du poumon EGFR-muté. <i>Revue Des Maladies Respiratoires Actualités</i> , 2019, 11, 34-37. | 0.0 | 0 |
| 1388 | Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor-Mutant Lung Cancer. <i>Oncologist</i> , 2019, 24, 1570-1576. | 1.9 | 14 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1389 | Outcomes comparison between neoadjuvant chemotherapy and adjuvant chemotherapy in stage IIIA non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2019, 11, 1443-1455. | 0.6 | 9 |
| 1390 | Clinical management of third-generation EGFR inhibitor-resistant patients with advanced non-small cell lung cancer: Current status and future perspectives. <i>Cancer Letters</i> , 2019, 459, 240-247. | 3.2 | 19 |
| 1391 | Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer. <i>Targeted Oncology</i> , 2019, 14, 307-314. | 1.7 | 7 |
| 1392 | Precision Medical Approaches to the Diagnoses and Management of Brain Metastases. <i>Current Treatment Options in Oncology</i> , 2019, 20, 49. | 1.3 | 6 |
| 1393 | Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer. <i>Drugs</i> , 2019, 79, 823-831. | 4.9 | 35 |
| 1394 | Osimertinib (TAGRISSO [®]) and the cobas [®] EGFR Mutation Test v2. , 2019, , 429-443. | | 2 |
| 1395 | Outcome Differences Between First- and Second-generation EGFR Inhibitors in Advanced EGFR Mutated NSCLC in a Large Population-based Cohort. <i>Clinical Lung Cancer</i> , 2019, 20, e576-e583. | 1.1 | 32 |
| 1396 | Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1366-1373. | 1.9 | 12 |
| 1397 | Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. <i>Cancer Discovery</i> , 2019, 9, 926-943. | 7.7 | 220 |
| 1398 | Toward automatic prediction of EGFR mutation status in pulmonary adenocarcinoma with 3D deep learning. <i>Cancer Medicine</i> , 2019, 8, 3532-3543. | 1.3 | 87 |
| 1399 | Determination of BPI15086 and its metabolite in human plasma by ultra-high performance liquid chromatography-MS/MS and its application to a pharmacokinetic study. <i>Bioanalysis</i> , 2019, 11, 773-784. | 0.6 | 0 |
| 1400 | Focus on Recommendations for the Management of Non-small Cell Lung Cancer. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 1230-1239. | 0.9 | 2 |
| 1401 | Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations. <i>Thoracic Cancer</i> , 2019, 10, 1461-1468. | 0.8 | 11 |
| 1402 | Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer. <i>Medical Oncology</i> , 2019, 36, 57. | 1.2 | 18 |
| 1403 | Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level. <i>BMC Cancer</i> , 2019, 19, 369. | 1.1 | 13 |
| 1404 | Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in mutated non-small cell lung cancer: new avenues and strategies to overcome resistance. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 128-135. | 0.3 | 1 |
| 1405 | Impact of single nucleotide polymorphisms on the efficacy and toxicity of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients. <i>Mutation Research - Reviews in Mutation Research</i> , 2019, 781, 63-70. | 2.4 | 10 |
| 1406 | Clinical analysis of EGFR-positive non-small cell lung cancer patients treated with first-line afatinib: A Nagano Lung Cancer Research Group. <i>Thoracic Cancer</i> , 2019, 10, 1078-1085. | 0.8 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1407 | Acute Respiratory Distress Syndrome Phenotypes. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2019, 40, 019-030. | 0.8 | 83 |
| 1408 | Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 10025-10030. | 3.3 | 41 |
| 1409 | The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. <i>International Journal of Clinical Oncology</i> , 2019, 24, 731-770. | 1.0 | 100 |
| 1410 | Brain metastases in resected non-small cell lung cancer: The impact of different tyrosine kinase inhibitors. <i>PLoS ONE</i> , 2019, 14, e0215923. | 1.1 | 2 |
| 1411 | Comparison of T790M Acquisition Between Patients Treated with Afatinib and Gefitinib as First-Line Therapy: Retrospective Propensity Score Matching Analysis. <i>Translational Oncology</i> , 2019, 12, 852-858. | 1.7 | 14 |
| 1412 | Molecular and Morphological Profiling of Lung Cancer: A Foundation for "Next-Generation" Pathologists and Oncologists. <i>Cancers</i> , 2019, 11, 599. | 1.7 | 41 |
| 1413 | Tyrosine Kinase Inhibitor Gold Nanoconjugates for the Treatment of Non-Small Cell Lung Cancer. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 16336-16346. | 4.0 | 31 |
| 1414 | First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the "real-world" clinical setting. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591983637. | 1.4 | 25 |
| 1415 | Emerging therapies for non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 45. | 6.9 | 111 |
| 1416 | Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4881-4887. | 3.2 | 10 |
| 1417 | Epidermal Growth Factor Receptor Mutation Status Confers Survival Benefit in Patients with Non-Small-Cell Lung Cancer Undergoing Surgical Resection of Brain Metastases: A Retrospective Cohort Study. <i>World Neurosurgery</i> , 2019, 125, e487-e496. | 0.7 | 5 |
| 1418 | Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis. <i>Future Oncology</i> , 2019, 15, 1481-1491. | 1.1 | 11 |
| 1419 | Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation. <i>Cancers</i> , 2019, 11, 365. | 1.7 | 8 |
| 1420 | Adjuvant and Neoadjuvant Therapy in Non-Small-Cell Lung Cancer. , 2019, , 35-55. | | 0 |
| 1421 | Pleural Effusion Aspirate for Use in 3D Lung Cancer Modeling and Chemotherapy Screening. <i>ACS Biomaterials Science and Engineering</i> , 2019, 5, 1937-1943. | 2.6 | 58 |
| 1422 | Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?. <i>Cancers</i> , 2019, 11, 366. | 1.7 | 50 |
| 1423 | Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA. <i>Future Oncology</i> , 2019, 15, 1493-1504. | 1.1 | 6 |
| 1424 | Epidermal Growth Factor Receptor "Mutant Non-Small-Cell Lung Cancer. , 2019, , 115-131. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1425 | Tackling Lung Cancer Drug Resistance Using Integrated Drug-Repurposing Strategy. , 2019, , 549-575. | | 0 |
| 1426 | Macrophage Origin, Metabolic Reprogramming and IL-1 Signaling: Promises and Pitfalls in Lung Cancer. <i>Cancers</i> , 2019, 11, 298. | 1.7 | 10 |
| 1427 | Adjunctive Traditional Chinese Medicine Improves Survival in Patients With Advanced Lung Adenocarcinoma Treated With First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs): A Nationwide, Population-Based Cohort Study. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541982707. | 0.8 | 13 |
| 1428 | Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: A prospective observational study. <i>Thoracic Cancer</i> , 2019, 10, 880-889. | 0.8 | 14 |
| 1429 | Transformation of epidermal growth factor receptor T790M mutation-positive adenosquamous carcinoma of the lung to small cell carcinoma and large cell neuroendocrine carcinoma following osimertinib therapy: an autopsy case report. <i>Respirology Case Reports</i> , 2019, 7, e00402. | 0.3 | 8 |
| 1430 | Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1431. | 1.8 | 77 |
| 1431 | Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019, 24, e1070-e1081. | 1.9 | 76 |
| 1432 | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 547-559. | 1.1 | 22 |
| 1433 | A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402). <i>Lung Cancer</i> , 2019, 135, 175-180. | 0.9 | 24 |
| 1434 | Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 5. | 7.1 | 231 |
| 1435 | Prophylactic Dermatologic Treatment of Afatinib-Induced Skin Toxicities in Patients with Metastatic Lung Cancer: A Pilot Study. <i>Scientifica</i> , 2019, 2019, 1-6. | 0.6 | 5 |
| 1436 | Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2019, 26, 81-93. | 0.9 | 38 |
| 1438 | Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2019, 21, 1287-1301. | 1.2 | 73 |
| 1439 | The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 129. | 1.3 | 61 |
| 1440 | The Impact of Afatinib on Survival in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Cancer</i> , 2019, 10, 885-892. | 1.2 | 2 |
| 1441 | Data from real world to evaluate the efficacy of osimertinib in non-small cell lung cancer patients with central nervous system metastasis. <i>Clinical and Translational Oncology</i> , 2019, 21, 1424-1431. | 1.2 | 19 |
| 1442 | <p>Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1521-1538. | 1.0 | 3 |
| 1443 | <p><p>First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1413-1421. | 1.0 | 51 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1444 | Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer. <i>Anticancer Research</i> , 2019, 39, 1317-1328. | 0.5 | 2 |
| 1445 | TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 920-928. | 1.9 | 11 |
| 1446 | Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1099-1109. | 1.0 | 6 |
| 1447 | Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-14. | 1.5 | 17 |
| 1448 | Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib. <i>International Journal of Clinical Oncology</i> , 2019, 24, 917-926. | 1.0 | 19 |
| 1449 | Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 625-635. | 5.1 | 470 |
| 1450 | LAPTM4B is a novel diagnostic and prognostic marker for lung adenocarcinoma and associated with mutant EGFR. <i>BMC Cancer</i> , 2019, 19, 293. | 1.1 | 10 |
| 1451 | First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. <i>Lung Cancer</i> , 2019, 133, 10-19. | 0.9 | 25 |
| 1452 | Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 132, 126-131. | 0.9 | 26 |
| 1453 | Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review. <i>Oncologist</i> , 2019, 24, 1270-1284. | 1.9 | 21 |
| 1454 | Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations. <i>PLoS ONE</i> , 2019, 14, e0215292. | 1.1 | 12 |
| 1455 | Clinical development of targeted and immune based anti-cancer therapies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 156. | 3.5 | 170 |
| 1456 | Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 671-675. | 0.6 | 17 |
| 1457 | Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. <i>Lancet Respiratory Medicine</i> , the, 2019, 7, 387-401. | 5.2 | 704 |
| 1458 | Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study). <i>Lung Cancer</i> , 2019, 131, 128-133. | 0.9 | 18 |
| 1459 | Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer. <i>Cancer Medicine</i> , 2019, 8, 1521-1529. | 1.3 | 82 |
| 1460 | Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation. <i>Scientific Reports</i> , 2019, 9, 2516. | 1.6 | 41 |
| 1461 | Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations. <i>Investigational New Drugs</i> , 2019, 37, 1207-1217. | 1.2 | 6 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1462 | Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer. <i>Annals of Oncology</i> , 2019, 30, 830-838. | 0.6 | 88 |
| 1463 | On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation. <i>Clinical Cancer Research</i> , 2019, 25, 3341-3351. | 3.2 | 80 |
| 1464 | First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease. <i>Journal of Cancer</i> , 2019, 10, 522-529. | 1.2 | 43 |
| 1465 | Central Nervous System Metastases in HER2-Positive Breast Cancer. , 2019, , 75-93. | | 0 |
| 1466 | Afatinib-loaded immunoliposomes functionalized with cetuximab: A novel strategy targeting the epidermal growth factor receptor for treatment of non-small-cell lung cancer. <i>International Journal of Pharmaceutics</i> , 2019, 560, 126-135. | 2.6 | 39 |
| 1467 | Histologic transformation to small-cell lung cancer following gefitinib and radiotherapy in a patient with pulmonary adenocarcinoma. <i>Tumori</i> , 2019, 105, NP12-NP16. | 0.6 | 9 |
| 1468 | Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice. <i>Translational Oncology</i> , 2019, 12, 640-645. | 1.7 | 10 |
| 1470 | Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study. <i>Lung Cancer</i> , 2019, 130, 149-155. | 0.9 | 36 |
| 1471 | EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: Implications for combination therapies. <i>International Journal of Cancer</i> , 2019, 145, 1432-1444. | 2.3 | 112 |
| 1472 | First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1569-1579. | 1.2 | 31 |
| 1473 | Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 817-825. | 1.1 | 13 |
| 1474 | Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?. <i>Oncologist</i> , 2019, 24, 1469-1478. | 1.9 | 25 |
| 1475 | The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era. <i>Translational Lung Cancer Research</i> , 2019, 8, 1134-1151. | 1.3 | 3 |
| 1476 | Adverse Event Management in Patients with <i>BRAF</i> V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib. <i>Oncologist</i> , 2019, 24, 963-972. | 1.9 | 16 |
| 1477 | Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpoints. <i>Translational Lung Cancer Research</i> , 2019, 8, S334-S338. | 1.3 | 1 |
| 1478 | Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 989-999. | 1.3 | 28 |
| 1479 | EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. <i>Molecular Cancer</i> , 2019, 18, 165. | 7.9 | 160 |
| 1480 | Current Approaches in NSCLC Targeting K-RAS and EGFR. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5701. | 1.8 | 47 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1481 | Genetic testing for prevention of severe drug-induced skin rash. The Cochrane Library, 2019, 7, CD010891. | 1.5 | 7 |
| 1482 | Identifying Resistance Mechanisms to Osimertinib via Blood Biopsy. Clinical Lung Cancer, 2019, 20, e597-e600. | 1.1 | 1 |
| 1483 | Excellent platinum dependent response to chemotherapy after relapse under TKI treatment in NSCLC with sensitizing EGFR mutations and no detectable resistance mutations: three case studies. AME Case Reports, 2019, 3, 36-36. | 0.2 | 1 |
| 1484 | Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer. Future Oncology, 2019, 15, 3775-3782. | 1.1 | 10 |
| 1485 | <p><p>Distribution Of Brain Metastasis From Lung Cancer</p>. Cancer Management and Research, 2019, Volume 11, 9331-9338. | 0.9 | 24 |
| 1486 | FGA isoform as an indicator of targeted therapy for EGFR mutated lung adenocarcinoma. Journal of Molecular Medicine, 2019, 97, 1657-1668. | 1.7 | 7 |
| 1487 | Second-line treatment of <i>EGFR</i> T790M-negative non-small cell lung cancer patients. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591989028. | 1.4 | 28 |
| 1488 | <p>Clinicopathological Characteristics And EGFR-TKIs Efficacies In Lung Squamous Cell Carcinoma Patients Harboring An EGFR Sensitizing Mutation</p>. OncoTargets and Therapy, 2019, Volume 12, 8863-8871. | 1.0 | 6 |
| 1489 | Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Nonâ€“Small Cell Lung Cancer (NSCLC). American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 440-445. | 0.6 | 25 |
| 1490 | A Repeated Biopsy by EBUS-TBNA Contributed to the Selection of an Appropriate Therapeutic Regimen for a Lung Cancer Patient. Journal of Bronchology and Interventional Pulmonology, 2019, 26, 129-131. | 0.8 | 2 |
| 1491 | Treatment of oncogene-driven non-small cell lung cancer. Current Opinion in Pulmonary Medicine, 2019, 25, 300-307. | 1.2 | 7 |
| 1492 | Clinical characteristics and prognosis of nonsurgically treated patients with pneumonic-type adenocarcinoma. Medicine (United States), 2019, 98, e15420. | 0.4 | 6 |
| 1493 | Epidermal growth factor receptor tyrosine kinase inhibitors combined with thoracic radiotherapy or chemoradiotherapy for advanced or metastatic non-small cell lung cancer: A systematic review and meta-analysis of single-arm trials. Medicine (United States), 2019, 98, e16427. | 0.4 | 2 |
| 1494 | Afatinib, an irreversible ErbB family blocker for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer. European Journal of Oncology Pharmacy, 2019, 2, e18. | 0.5 | 1 |
| 1495 | Role of liquid biopsy in oncogene-addicted non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, S265-S279. | 1.3 | 17 |
| 1496 | Educational Case: Non-Small Cell Lung Cancer: Pathologic Diagnosis and Molecular Understanding. Academic Pathology, 2019, 6, 237428951988195. | 0.7 | 1 |
| 1498 | Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detection and quantification of circulating tumor DNA from lung cancer patients. PLoS ONE, 2019, 14, e0226193. | 1.1 | 18 |
| 1499 | <p>A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer</p>. Cancer Management and Research, 2019, Volume 11, 9469-9481. | 0.9 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1500 | Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study. <i>Lung Cancer Management</i> , 2019, 8, LMT15. | 1.5 | 4 |
| 1501 | Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, S247-S264. | 1.3 | 59 |
| 1502 | <p>Real-World Data Of Osimertinib In Patients With Pretreated Non-Small Cell Lung Cancer: A Retrospective Study</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 9243-9251. | 0.9 | 16 |
| 1503 | Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer. <i>Scientific Reports</i> , 2019, 9, 18202. | 1.6 | 23 |
| 1504 | Highly sensitive and specific screening of EGFR mutation using a PNA microarray-based fluorometric assay based on rolling circle amplification and graphene oxide. <i>RSC Advances</i> , 2019, 9, 38298-38308. | 1.7 | 8 |
| 1505 | Familienanamnese bei der Diagnosestellung, Therapiesteckbriefe und Weiterbildungsabschnitte. <i>Karger Kompass Pneumologie</i> , 2019, , III-VI. | 0.0 | 0 |
| 1506 | Concurrent Small-Cell Transformation and Emergence of <i>Trans</i>-C797S and T790M Mutations Under Sequential Treatment With EGFR Inhibitors in Lung Adenocarcinoma. <i>JCO Precision Oncology</i> , 2019, 3, 1-5. | 1.5 | 4 |
| 1507 | Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) <i>EGFR</i> Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study. <i>Oncologist</i> , 2019, 24, 157-e64. | 1.9 | 79 |
| 1508 | Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma. <i>Journal of Bronchology and Interventional Pulmonology</i> , 2019, 26, 96-101. | 0.8 | 18 |
| 1509 | Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-“small cell lung cancer negative for EGFR mutation and ALK fusion. <i>Lung Cancer</i> , 2019, 127, 59-65. | 0.9 | 36 |
| 1510 | Adequacy of EBUS-“TBNA specimen for mutation analysis of lung cancer. <i>Clinical Respiratory Journal</i> , 2019, 13, 92-97. | 0.6 | 20 |
| 1511 | Approaches to Capturing Value in Oncology. <i>Recent Results in Cancer Research</i> , 2019, 213, 85-108. | 1.8 | 5 |
| 1512 | Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M. <i>Lung Cancer</i> , 2019, 128, 33-39. | 0.9 | 34 |
| 1513 | Multicenter experience with large panel next-generation sequencing in patients with advanced solid cancers in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 174-182. | 0.6 | 4 |
| 1514 | Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-“ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. <i>Annals of Oncology</i> , 2019, 30, 171-210. | 0.6 | 214 |
| 1515 | Early Noninvasive Detection of Response to Targeted Therapy in Non-“Small Cell Lung Cancer. <i>Cancer Research</i> , 2019, 79, 1204-1213. | 0.4 | 75 |
| 1516 | Prevalence of ROS1 fusion in Chinese patients with non-“small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 47-53. | 0.8 | 29 |
| 1517 | Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation. <i>Lung Cancer</i> , 2019, 127, 96-102. | 0.9 | 31 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1518 | Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing. <i>Future Oncology</i> , 2019, 15, 637-652. | 1.1 | 80 |
| 1519 | EGFR Mutations. , 2019, , 477-486. | | 2 |
| 1520 | Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol. <i>Clinical Lung Cancer</i> , 2019, 20, 134-138. | 1.1 | 19 |
| 1521 | High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment-naïve advanced EGFR-mutant lung adenocarcinoma patients. <i>Lung Cancer</i> , 2019, 127, 37-43. | 0.9 | 60 |
| 1522 | Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies. <i>Modern Pathology</i> , 2019, 32, 627-638. | 2.9 | 22 |
| 1523 | Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program. <i>BMC Cancer</i> , 2019, 19, 55. | 1.1 | 24 |
| 1524 | Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, e338-e345. | 1.1 | 14 |
| 1525 | Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA. <i>PLoS ONE</i> , 2019, 14, e0209709. | 1.1 | 41 |
| 1526 | First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 146. | 1.8 | 118 |
| 1527 | Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis. <i>International Journal of Cancer</i> , 2019, 145, 284-294. | 2.3 | 52 |
| 1528 | AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. <i>Nature Communications</i> , 2019, 10, 259. | 5.8 | 223 |
| 1529 | Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in Europe. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 697-706. | 0.8 | 3 |
| 1530 | Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations. <i>Lung Cancer</i> , 2019, 127, 146-152. | 0.9 | 42 |
| 1531 | Elucidating synergistic dependencies in lung adenocarcinoma by proteome-wide signaling-network analysis. <i>PLoS ONE</i> , 2019, 14, e0208646. | 1.1 | 6 |
| 1532 | Necitumumab for the treatment of advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 705-716. | 1.1 | 28 |
| 1533 | Cold atmospheric plasma and iron oxide-based magnetic nanoparticles for synergetic lung cancer therapy. <i>Free Radical Biology and Medicine</i> , 2019, 130, 71-81. | 1.3 | 83 |
| 1534 | Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo). <i>Lung Cancer</i> , 2019, 127, 103-111. | 0.9 | 57 |
| 1535 | Clinicopathologic characteristics and outcome of patients with different EGFR mutations. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 166-171. | 0.7 | 7 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1536 | <i>KRAS</i> and <i>EGFR</i> Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in <i>EGFR</i>. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 112-126. | 1.9 | 39 |
| 1537 | Academic Discovery of Anticancer Drugs: Historic and Future Perspectives. <i>Annual Review of Cancer Biology</i> , 2019, 3, 385-408. | 2.3 | 17 |
| 1539 | Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations. <i>Clinical Lung Cancer</i> , 2019, 20, e186-e194. | 1.1 | 40 |
| 1540 | Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. <i>International Journal of Cancer</i> , 2019, 144, 2887-2896. | 2.3 | 56 |
| 1541 | Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case. <i>Lung Cancer</i> , 2019, 127, 12-18. | 0.9 | 40 |
| 1542 | Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. <i>Cancer</i> , 2019, 125, 892-901. | 2.0 | 117 |
| 1543 | The role of cytology in molecular testing and personalized medicine in lung cancer: A clinical perspective. <i>Cancer Cytopathology</i> , 2019, 127, 72-78. | 1.4 | 10 |
| 1544 | Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. <i>Lung Cancer</i> , 2019, 127, 84-89. | 0.9 | 49 |
| 1545 | Resistance to molecularly targeted therapy in non-small-cell lung cancer. <i>Respiratory Investigation</i> , 2019, 57, 20-26. | 0.9 | 46 |
| 1546 | Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition. <i>Oncogene</i> , 2019, 38, 1477-1488. | 2.6 | 11 |
| 1547 | Development of a competitive enzyme-linked immunosorbent assay for therapeutic drug monitoring of afatinib. <i>Journal of Pharmaceutical Analysis</i> , 2019, 9, 49-54. | 2.4 | 15 |
| 1548 | Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications. <i>Seminars in Cancer Biology</i> , 2019, 54, 14-28. | 4.3 | 51 |
| 1549 | Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis. <i>Pathology and Oncology Research</i> , 2019, 25, 513-520. | 0.9 | 5 |
| 1550 | Absolute Bioavailability of Osimertinib in Healthy Adults. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 198-207. | 0.8 | 22 |
| 1551 | The effects of switching EGFR-TKI treatments for non-small cell lung cancer because of adverse events. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, e113-e117. | 0.7 | 10 |
| 1552 | Pharmacist-led patient education and adverse event management in patients with non-small cell lung cancer receiving afatinib in a community-based, real-world clinical setting. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 13-22. | 0.5 | 17 |
| 1553 | Real-World Data of the Correlation between EGFR Determination by Liquid Biopsy in Non-squamous Non-small Cell Lung Cancer (NSCLC) and the EGFR Profile in Tumor Biopsy. <i>Pathology and Oncology Research</i> , 2020, 26, 845-851. | 0.9 | 18 |
| 1554 | Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1731-1741. | 0.8 | 60 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 1555 | Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations. <i>European Journal of Health Economics</i> , 2020, 21, 153-164. | 1.4 | 30 |
| 1556 | A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis. <i>Journal of Thoracic Oncology</i> , 2020, 15, 91-100. | 0.5 | 31 |
| 1557 | Differences Between the East and the West in Managing Advanced-Stage Non-small Cell Lung Cancer. <i>Clinical Oncology</i> , 2020, 32, e1-e9. | 0.6 | 6 |
| 1558 | Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. <i>Clinical Lung Cancer</i> , 2020, 21, 1-14.e3. | 1.1 | 19 |
| 1559 | Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 124-136. | 0.8 | 295 |
| 1560 | Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy. <i>Asian Journal of Pharmaceutical Sciences</i> , 2020, 15, 26-41. | 4.3 | 35 |
| 1561 | Cancer of the Lung. , 2020, , 1108-1158.e16. | | 11 |
| 1562 | A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities. <i>Oncologist</i> , 2020, 25, e186-e193. | 1.9 | 10 |
| 1563 | Current development in integrative therapy of traditional Chinese medicine for cancer treatment: A mini-review. <i>Journal of Traditional and Complementary Medicine</i> , 2020, 10, 429-433. | 1.5 | 4 |
| 1564 | Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2020, 139, 80-88. | 0.9 | 9 |
| 1565 | Factors correlating with shorter survival after treatment: aiding oncologists to choose who (not) to receive palliative systemic therapy. <i>Annals of Palliative Medicine</i> , 2020, 9, 4430-4445. | 0.5 | 0 |
| 1566 | Additional bevacizumab in EGFR-mutant lung adenocarcinoma patients who had oligo-progression after the failure of EGFR-TKI: A single-institute retrospective study. <i>Cancer Treatment and Research Communications</i> , 2020, 22, 100163. | 0.7 | 5 |
| 1567 | Tumor angiogenesis: causes, consequences, challenges and opportunities. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 1745-1770. | 2.4 | 927 |
| 1568 | Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 115-123. | 0.8 | 327 |
| 1569 | Synthetic lethality as an engine for cancer drug target discovery. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 23-38. | 21.5 | 295 |
| 1570 | Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy. <i>Journal of Cellular Physiology</i> , 2020, 235, 3142-3156. | 2.0 | 65 |
| 1571 | Therapies after first-line afatinib in patients with EGFR ^m NSCLC in Japan: retrospective analysis of LUX-Lung 3. <i>Future Oncology</i> , 2020, 16, 49-60. | 1.1 | 4 |
| 1572 | Cryobiopsy increases the EGFR detection rate in non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 141, 56-63. | 0.9 | 20 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1573 | Systems biology analysis identifies molecular determinants of chemotherapy-induced diarrhoea. <i>Journal of Molecular Medicine</i> , 2020, 98, 149-159. | 1.7 | 2 |
| 1574 | Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical) Tj ETQq1 1 0.784314 rgBT/Overlo | 2.0 | 39 |
| 1575 | Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small cell lung cancer: A retrospective cohort study in Taiwan. <i>International Journal of Cancer</i> , 2020, 147, 1107-1116. | 2.3 | 13 |
| 1576 | Oral Complications. , 2020, , 607-620.e6. | | 0 |
| 1577 | Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 141, 37-43. | 0.9 | 24 |
| 1578 | Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations. <i>Clinical Lung Cancer</i> , 2020, 21, e216-e228. | 1.1 | 89 |
| 1579 | Î²-Adrenergic Signaling in Lung Cancer: A Potential Role for Beta-Blockers. <i>Journal of NeuroImmune Pharmacology</i> , 2020, 15, 27-36. | 2.1 | 35 |
| 1580 | Targeting innate sensing in the tumor microenvironment to improve immunotherapy. <i>Cellular and Molecular Immunology</i> , 2020, 17, 13-26. | 4.8 | 76 |
| 1581 | Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 125-136. | 1.0 | 51 |
| 1582 | Blood mRNA expression of REV3L and TYMS as potential predictive biomarkers from platinum-based chemotherapy plus pemetrexed in non-small cell lung cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 525-535. | 1.1 | 15 |
| 1583 | Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). <i>Journal of Clinical Oncology</i> , 2020, 38, 488-495. | 0.8 | 233 |
| 1584 | Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC. <i>Lung Cancer</i> , 2020, 139, 133-139. | 0.9 | 16 |
| 1585 | Successful treatment of an elderly patient with an uncommon L861Q epidermal growth factor receptor mutation with low-dose afatinib: A case report. <i>Thoracic Cancer</i> , 2020, 11, 447-450. | 0.8 | 6 |
| 1586 | Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e191-e204. | 1.1 | 26 |
| 1587 | Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation. <i>Thoracic Cancer</i> , 2020, 11, 140-149. | 0.8 | 34 |
| 1588 | What's Old Is New Again: Revisiting Up-Front Chemotherapy in EGFR-Mutated Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 107-110. | 0.8 | 5 |
| 1589 | Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L). <i>Journal of Clinical Oncology</i> , 2020, 38, 793-803. | 0.8 | 28 |
| 1590 | Efficacy of EGFR-TKIs with or without angiogenesis inhibitors in advanced non-small-cell lung cancer: A systematic review and meta-analysis. <i>Journal of Cancer</i> , 2020, 11, 686-695. | 1.2 | 9 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1591 | Characteristics of surgically resected non-small cell lung cancer patients with post-recurrence cure. <i>Thoracic Cancer</i> , 2020, 11, 3280-3288. | 0.8 | 15 |
| 1592 | Immunotherapy in advanced non-small-cell lung cancer with EGFR mutations. <i>Immunotherapy</i> , 2020, 12, 1195-1207. | 1.0 | 2 |
| 1593 | A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) Patients. <i>Diagnostics</i> , 2020, 10, 765. | 1.3 | 7 |
| 1594 | Understanding EGFR heterogeneity in lung cancer. <i>ESMO Open</i> , 2020, 5, e000919. | 2.0 | 32 |
| 1595 | Fatal toxic effects related to EGFR tyrosine kinase inhibitors based on 53 cohorts with 9,569 participants. <i>Journal of Thoracic Disease</i> , 2020, 12, 4057-4069. | 0.6 | 9 |
| 1596 | Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review. <i>Cancers</i> , 2020, 12, 2658. | 1.7 | 10 |
| 1597 | Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. <i>Annals of Oncology</i> , 2020, 31, 1536-1544. | 0.6 | 149 |
| 1598 | Discovery of 4-methyl-N-(4-((4-methylpiperazin-1-yl)ethoxy)-1-piperidin-1-yl)-3-(trifluoromethyl)benzamide as a potent inhibitor of RET and its gatekeeper mutant. <i>European Journal of Medicinal Chemistry</i> , 2020, 207, 112755. | 2.6 | 8 |
| 1599 | Futibatinib Is a Novel Irreversible FGFR 4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors. <i>Cancer Research</i> , 2020, 80, 4986-4997. | 0.4 | 102 |
| 1600 | Afatinib for the first-line treatment of EGFR mutation-positive NSCLC in China: a review of clinical data. <i>Future Oncology</i> , 2020, 16, 2569-2586. | 1.1 | 2 |
| 1601 | Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis. <i>Lung Cancer</i> , 2020, 150, 83-89. | 0.9 | 9 |
| 1602 | Overview of current targeted therapy in gallbladder cancer. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 230. | 7.1 | 84 |
| 1603 | Chemotherapy should be performed in epidermal growth factor receptor mutation-positive lung adenocarcinoma patients who had progressive disease to the first epidermal growth factor receptor-tyrosine kinase inhibitor. <i>Anti-Cancer Drugs</i> , 2020, 31, 959-965. | 0.7 | 0 |
| 1604 | Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 27, 107815522096489. | 0.5 | 0 |
| 1605 | Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?. <i>Biology</i> , 2020, 9, 326. | 1.3 | 6 |
| 1606 | Spectrum of uncommon and compound epidermal growth factor receptor mutations in non-small-cell lung carcinomas with treatment response and outcome analysis: A study from India. <i>Lung Cancer</i> , 2020, 149, 53-60. | 0.9 | 8 |
| 1607 | Emerging and investigational targeted chemotherapy and immunotherapy agents for metastatic brain tumors. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1389-1406. | 1.9 | 4 |
| 1608 | Traitement des cancers bronchiques non À petites cellules de stades avancés mutés EGFR : quels inhibiteurs ? Quelles séquences thérapeutiques ?. <i>Revue Des Maladies Respiratoires Actualites</i> , 2020, 12, 2S195-2S211. | 0.0 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1609 | EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins. <i>Cancer Treatment Reviews</i> , 2020, 90, 102105. | 3.4 | 80 |
| 1610 | Value of interim 18F-FDG PET/CT for predicting progression-free survival in stage â€¦B/IV EGFR-mutant nonâ€¦small-cell lung cancer patients with EGFR-TKI therapy. <i>Lung Cancer</i> , 2020, 149, 137-143. | 0.9 | 6 |
| 1611 | Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI. <i>Targeted Oncology</i> , 2020, 15, 503-512. | 1.7 | 12 |
| 1612 | LncRNA SNHG15 regulates EGFR-TKI acquired resistance in lung adenocarcinoma through sponging miR-451 to upregulate MDR-1. <i>Cell Death and Disease</i> , 2020, 11, 525. | 2.7 | 38 |
| 1613 | Application of Zizao Yangrong Granules for Treating Targeted Drugsâ€¦Related Skin Xerosis: A Randomized Double-Blinded Controlled Study. <i>Integrative Cancer Therapies</i> , 2020, 19, 153473542092483. | 0.8 | 0 |
| 1614 | 18F-fluorodeoxyglucose positron emission tomography/computed tomography-based radiomic features for prediction of epidermal growth factor receptor mutation status and prognosis in patients with lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2020, 9, 563-574. | 1.3 | 18 |
| 1615 | Mechanisms of osimertinib resistance and emerging treatment options. <i>Lung Cancer</i> , 2020, 147, 123-129. | 0.9 | 95 |
| 1616 | Erlotinib for Nonâ€¦Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101) Tj ETQq1,1 0.784314 rgB7 (k | 1.9 | 10 |
| 1617 | Tyrosine Kinase Receptors in Oncology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8529. | 1.8 | 46 |
| 1618 | Hypothesis generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with EGFR mutations (Heat on Beat study). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096725. | 1.4 | 6 |
| 1619 | Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib. <i>Scientific Reports</i> , 2020, 10, 20243. | 1.6 | 21 |
| 1620 | Osimertinib Resistance With a Novel EGFR L858R/A859S/Y891D Triple Mutation in a Patient With Non-Small Cell Lung Cancer: A Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 542277. | 1.3 | 8 |
| 1621 | CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer. <i>Nature Communications</i> , 2020, 11, 6119. | 5.8 | 53 |
| 1622 | Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients. <i>ESMO Open</i> , 2020, 5, e001011. | 2.0 | 15 |
| 1623 | Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way. <i>Annals of Translational Medicine</i> , 2020, 8, 1111-1111. | 0.7 | 2 |
| 1624 | EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells. <i>BMC Cancer</i> , 2020, 20, 1189. | 1.1 | 26 |
| 1625 | Myositis â€¦ A common but underreported adverse effect of osimertinib: Case series and review of the literature. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100254. | 0.7 | 7 |
| 1626 | Itâ€¦s Got Too Greedy. New Therapeutic Options for Metabolic[ally] Addicted NSCLC?. <i>Cancers</i> , 2020, 12, 3223. | 1.7 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1627 | First line Immunotherapy for Non-Small Cell Lung Cancer. <i>Pharmaceuticals</i> , 2020, 13, 373. | 1.7 | 49 |
| 1628 | EEF1A2 and ERN2 could potentially discriminate metastatic status of mediastinal lymph node in lung adenocarcinomas harboring EGFR 19Del / L858R mutations. <i>Thoracic Cancer</i> , 2020, 11, 2755-2766. | 0.8 | 4 |
| 1629 | Making the case for EGFR TKI sequencing in EGFR mutation-positive NSCLC: a GioTag study US patient analysis. <i>Future Oncology</i> , 2020, 16, 1585-1595. | 1.1 | 5 |
| 1630 | Emerging Therapies in Thoracic Malignancies—Immunotherapy, Targeted Therapy, and T-Cell Therapy in Non-Small Cell Lung Cancer. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 555-569. | 0.6 | 6 |
| 1631 | Repurposing of Kinase Inhibitors for Treatment of COVID-19. <i>Pharmaceutical Research</i> , 2020, 37, 167. | 1.7 | 102 |
| 1632 | The Effect of Advances in Lung-Cancer Treatment on Population Mortality. <i>New England Journal of Medicine</i> , 2020, 383, 640-649. | 13.9 | 893 |
| 1633 | Comparative analysis of first-line treatment regimens for advanced EGFR-mutant non-small cell lung cancer patients with stable brain metastases. <i>Annals of Palliative Medicine</i> , 2020, 9, 2062-2071. | 0.5 | 10 |
| 1634 | Lymphocyte percentage and platelet count correlate with the treatment outcome to tyrosine kinase inhibitors in epidermal growth factor receptor-mutated lung adenocarcinoma. <i>Medicine (United States)</i> 2020;99(14):e20414. | 0.7 | 14 |
| 1635 | KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting. <i>Journal of Thoracic Disease</i> , 2020, 12, 3836-3843. | 0.6 | 47 |
| 1636 | Role of YES1 amplification in EGFR mutation-positive non-small cell lung cancer: Primary resistance to afatinib in a patient. <i>Thoracic Cancer</i> , 2020, 11, 2736-2739. | 0.8 | 4 |
| 1637 | Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trophic Activity. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2044-2056. | 1.9 | 87 |
| 1638 | Propensity score analysis of overall survival between first- and second-generation EGFR-TKIs using real-world data. <i>Cancer Science</i> , 2020, 111, 3705-3713. | 1.7 | 10 |
| 1639 | A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity. <i>Lung Cancer: Targets and Therapy</i> , 2020, Volume 11, 73-103. | 1.3 | 4 |
| 1640 | Association of Genetic Polymorphisms With Afatinib-induced Diarrhoea. <i>In Vivo</i> , 2020, 34, 1415-1419. | 0.6 | 5 |
| 1641 | PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 1258-1267. | 1.3 | 47 |
| 1642 | Management of brain metastases according to molecular subtypes. <i>Nature Reviews Neurology</i> , 2020, 16, 557-574. | 4.9 | 104 |
| 1643 | Optimal sequencing strategies in the treatment of EGFR mutation-positive non-small cell lung cancer: Clinical benefits and cost-effectiveness. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, 1466-1476. | 0.5 | 10 |
| 1644 | EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa064. | 1.4 | 4 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1645 | Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 1711-1723. | 13.9 | 1,042 |
| 1646 | High PD-L1 Expression is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 8273-8285. | 1.0 | 19 |
| 1647 | The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer. <i>Scientific Reports</i> , 2020, 10, 14965. | 1.6 | 21 |
| 1648 | CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2288-2297. | 1.9 | 89 |
| 1649 | Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative. <i>BMC Pulmonary Medicine</i> , 2020, 20, 240. | 0.8 | 16 |
| 1650 | Diagnostic and Predictive Values of ¹⁸ F-FDG PET/CT Metabolic Parameters in EGFR-Mutated Advanced Lung Adenocarcinoma. <i>Cancer Management and Research</i> , 2020, Volume 12, 6453-6465. | 0.9 | 12 |
| 1652 | Cross-talk between SOX2 and TGF β 2 Signaling Regulates EGFR-TKI Tolerance and Lung Cancer Dissemination. <i>Cancer Research</i> , 2020, 80, 4426-4438. | 0.4 | 29 |
| 1653 | erbB in NSCLC as a molecular target: current evidences and future directions. <i>ESMO Open</i> , 2020, 5, e000724. | 2.0 | 22 |
| 1654 | The Clinical Significance of RAS, PIK3CA, and PTEN Mutations in Non-Small Cell Lung Cancer Using Cell-Free DNA. <i>Journal of Clinical Medicine</i> , 2020, 9, 2642. | 1.0 | 3 |
| 1655 | Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial Program. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 12539-12547. | 1.0 | 3 |
| 1656 | Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and Pitfalls. <i>Cancers</i> , 2020, 12, 3804. | 1.7 | 26 |
| 1657 | Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review. <i>Frontiers in Oncology</i> , 2020, 10, 610923. | 1.3 | 61 |
| 1658 | Assessment of a Highly Curated Somatic Oncology Database to Aid in the Interpretation of Clinically Important Variants in Next-Generation Sequencing Results. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1356-1366. | 1.2 | 3 |
| 1659 | A randomized, multi-center, open-label study to compare the safety and efficacy between afatinib monotherapy and combination therapy of afatinib and HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutations. <i>Medicine (United States)</i> , 2020, 99, e23455. | 0.4 | 1 |
| 1660 | Abnormally activated OPN/integrin α 3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2020, 13, 169. | 6.9 | 50 |
| 1661 | Preclinical Metrics Correlate With Drug Activity in Phase II Trials of Targeted Therapies for Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 587377. | 1.3 | 1 |
| 1662 | The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study. <i>Pharmaceuticals</i> , 2020, 13, 331. | 1.7 | 14 |
| 1663 | Bilirubin Can Be Used as a Prognostic Factor for Lung Adenocarcinoma Patients with EGFR Mutations. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 11089-11095. | 1.0 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1664 | EGFR tyrosine kinase inhibitors in non-small cell lung cancer: treatment paradigm, current evidence, and challenges. <i>Tumori</i> , 2020, 107, 030089162096813. | 0.6 | 2 |
| 1665 | Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC. <i>Lung Cancer Management</i> , 2020, 9, LMT29. | 1.5 | 5 |
| 1666 | A validated ultra-performance LC-MS/MS method for quantifying a novel oral EGFR inhibitor FCN-411 in human plasma. <i>Bioanalysis</i> , 2020, 12, 295-304. | 0.6 | 0 |
| 1667 | Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations. <i>Targeted Oncology</i> , 2020, 15, 357-364. | 1.7 | 9 |
| 1668 | Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial. <i>Investigational New Drugs</i> , 2020, 38, 1854-1861. | 1.2 | 18 |
| 1669 | A noteworthy treatment of metastatic small-cell lung cancer with afatinib, followed by subsequent development of rare metastatic lesions in the ascending and sigmoid colon. <i>Cancer Reports</i> , 2020, 3, e1243. | 0.6 | 2 |
| 1670 | Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2427-2433. | 1.2 | 41 |
| 1671 | Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 510. | 1.3 | 3 |
| 1672 | Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives. <i>Cancers</i> , 2020, 12, 1196. | 1.7 | 65 |
| 1673 | Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, e201250. | 3.4 | 36 |
| 1674 | EML4-ALK Fusion as a Resistance Mechanism to Osimertinib and Its Successful Management With Osimertinib and Alectinib: Case Report and Review of the Literature. <i>Clinical Lung Cancer</i> , 2020, 21, e597-e600. | 1.1 | 15 |
| 1675 | QT interval prolongation related to afatinib treatment in a patient with metastatic non-small-cell lung cancer. <i>Current Problems in Cancer</i> , 2020, 44, 100594. | 1.0 | 6 |
| 1676 | Current Landscape of Personalized Therapy. <i>Thoracic Surgery Clinics</i> , 2020, 30, 121-125. | 0.4 | 2 |
| 1677 | Genomics-guided pre-clinical development of cancer therapies. <i>Nature Cancer</i> , 2020, 1, 482-492. | 5.7 | 23 |
| 1678 | Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers. <i>JAMA Oncology</i> , 2020, 6, 1048. | 3.4 | 96 |
| 1679 | AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation. <i>Lung Cancer</i> , 2020, 146, 70-77. | 0.9 | 12 |
| 1680 | Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 531-542. | 1.1 | 6 |
| 1681 | Comparison between single-agent and combination chemotherapy as second-line treatment for advanced non-small cell lung cancer: a multi-institutional retrospective analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 65-74. | 1.1 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1682 | Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment. <i>Journal of Clinical Medicine</i> , 2020, 9, 1762. | 1.0 | 10 |
| 1683 | Successful immune checkpoint inhibition in an EGFR-mutant lung cancer patient refractory to epidermal growth factor receptor tyrosine kinase inhibitor treatment. <i>Anti-Cancer Drugs</i> , 2020, 31, 310-313. | 0.7 | 2 |
| 1684 | Imaging-Based Prediction of Molecular Therapy Targets in NSCLC by Radiogenomics and AI Approaches: A Systematic Review. <i>Diagnostics</i> , 2020, 10, 359. | 1.3 | 51 |
| 1685 | Canadian Consensus: A New Systemic Treatment Algorithm for Advanced EGFR-Mutated Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2020, 27, 146-155. | 0.9 | 14 |
| 1686 | Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment. <i>Thoracic Cancer</i> , 2020, 11, 2188-2195. | 0.8 | 11 |
| 1687 | Targeted Therapy for Non-Small Cell Lung Cancer. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 409-434. | 0.8 | 11 |
| 1688 | Successful treatment of a patient with NSCLC carrying uncommon compound EGFR G719X and S768I mutations using osimertinib: A case report. <i>Journal of International Medical Research</i> , 2020, 48, 030006052092879. | 0.4 | 6 |
| 1689 | Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review. <i>Journal of Clinical Oncology</i> , 2020, 38, 2926-2936. | 0.8 | 107 |
| 1690 | Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment. <i>Cancers</i> , 2020, 12, 1587. | 1.7 | 24 |
| 1691 | Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. <i>Journal of Clinical Medicine</i> , 2020, 9, 1870. | 1.0 | 16 |
| 1692 | Phase II Study of Low-Dose Afatinib Maintenance Treatment Among Patients with EGFR-Mutated Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCG1601). <i>Oncologist</i> , 2020, 25, e1451-e1456. | 1.9 | 5 |
| 1693 | Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1461-1474. | 0.5 | 61 |
| 1694 | Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors. <i>Journal of Thoracic Disease</i> , 2020, 12, 2859-2876. | 0.6 | 11 |
| 1695 | Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System. <i>Scientific Reports</i> , 2020, 10, 4803. | 1.6 | 48 |
| 1696 | Isoliquiritigenin Suppressed Esophageal Squamous Carcinoma Growth by Blocking EGFR Activation and Inducing Cell Cycle Arrest. <i>BioMed Research International</i> , 2020, 2020, 1-11. | 0.9 | 6 |
| 1697 | EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study. <i>Lung Cancer</i> , 2020, 145, 186-194. | 0.9 | 68 |
| 1698 | Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer. <i>Cancer</i> , 2020, 126, 2704-2712. | 2.0 | 26 |
| 1699 | Successful treatment of advanced lung adenocarcinoma complicated with Lambert-Eaton myasthenic syndrome: A case report and literature review. <i>Thoracic Cancer</i> , 2020, 11, 1334-1338. | 0.8 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1700 | Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial. <i>Clinical Cancer Research</i> , 2020, 26, 3162-3171. | 3.2 | 16 |
| 1701 | Tyrosine Kinase Inhibitors Could Be Effective Against Non-small Cell Lung Cancer Brain Metastases Harboring Uncommon EGFR Mutations. <i>Frontiers in Oncology</i> , 2020, 10, 224. | 1.3 | 17 |
| 1702 | Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study). <i>Lung Cancer</i> , 2020, 143, 27-35. | 0.9 | 42 |
| 1703 | EGFR blockade in GBM brain tumor stem cells synergizes with JAK2/STAT3 pathway inhibition to abrogate compensatory mechanisms in vitro and in vivo. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa020. | 0.4 | 14 |
| 1704 | Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy. <i>Cancers</i> , 2020, 12, 731. | 1.7 | 280 |
| 1705 | Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 565-576. | 1.0 | 9 |
| 1706 | Next-Generation Cancer-Specific Hybrid Theranostic Nanomaterials: MAGE-A3 NIR Persistent Luminescence Nanoparticles Conjugated to Afatinib for In Situ Suppression of Lung Adenocarcinoma Growth and Metastasis. <i>Advanced Science</i> , 2020, 7, 1903741. | 5.6 | 34 |
| 1707 | Synthesis of 1 H-Indazoles and Quinazolines Using Additive Intermediates of Grignard Reagents to 2-Amino Benzonitriles. <i>ChemistrySelect</i> , 2020, 5, 3007-3010. | 0.7 | 4 |
| 1708 | Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma. <i>Thoracic Cancer</i> , 2020, 11, 935-942. | 0.8 | 24 |
| 1709 | Observed versus modelled lifetime overall survival of targeted therapies and immunotherapies for advanced non-small cell lung cancer patients – A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103035. | 2.0 | 5 |
| 1710 | Non-small cell lung cancer patients with ex19del or exon 21 L858R mutation: distinct mechanisms, different efficacies to treatments. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2329-2338. | 1.2 | 33 |
| 1711 | <p>Icotinib as Adjuvant Treatment for Stage II-IIIa Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial<p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 4633-4643. | 0.9 | 8 |
| 1712 | Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting – Role of Academic and Hybrid Modeling. <i>Journal of Clinical Medicine</i> , 2020, 9, 1884. | 1.0 | 5 |
| 1713 | Pyrotinib in <i>HER2</i>-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 2753-2761. | 0.8 | 123 |
| 1714 | Treatment Rationale and Design of a Phase III Study of Afatinib or Chemotherapy in Patients with Non-small-cell Lung Cancer Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations (ACHILLES/TORG1834). <i>Clinical Lung Cancer</i> , 2020, 21, e592-e596. | 1.1 | 5 |
| 1715 | Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 211-219. | 1.1 | 14 |
| 1716 | Influence of Biopsy Technique on Molecular Genetic Tumor Characterization in Non-Small Cell Lung Cancer – The Prospective, Randomized, Single-Blinded, Multicenter PROFILER Study Protocol. <i>Diagnostics</i> , 2020, 10, 459. | 1.3 | 3 |
| 1717 | Nationwide Real-world Cohort Study of First-line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e647-e653. | 1.1 | 12 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1718 | Molecular therapeutic targets in non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 647-661. | 1.1 | 46 |
| 1719 | Disease-related cellular protein networks differentially affected under different EGFR mutations in lung adenocarcinoma. <i>Scientific Reports</i> , 2020, 10, 10881. | 1.6 | 9 |
| 1720 | Development of a quality measures tool for the utilization of tyrosine kinase inhibitors in non-small cell lung cancer: An integrated specialty pharmacy initiative. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1441-1451. | 0.5 | 0 |
| 1721 | Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy. <i>BMC Cancer</i> , 2020, 20, 103. | 1.1 | 14 |
| 1722 | Association of Divergent Carcinoembryonic Antigen Patterns and Lung Cancer Progression. <i>Scientific Reports</i> , 2020, 10, 2066. | 1.6 | 21 |
| 1723 | Tumour content ratio matters for detecting epidermal growth factor receptor mutation by cobas test in small biopsies; a retrospective study. <i>BMC Cancer</i> , 2020, 20, 104. | 1.1 | 1 |
| 1724 | Synergistic effect of metformin and EGFR-TKI in the treatment of non-small cell lung cancer. <i>Translational Cancer Research</i> , 2020, 9, 372-381. | 0.4 | 4 |
| 1725 | Multi-Type Interdependent Feature Analysis Based on Hybrid Neural Networks for Computer-Aided Diagnosis of Epidermal Growth Factor Receptor Mutations. <i>IEEE Access</i> , 2020, 8, 38517-38527. | 2.6 | 11 |
| 1726 | The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: State of the art. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 148, 102894. | 2.0 | 27 |
| 1727 | Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population. <i>Scientific Reports</i> , 2020, 10, 2707. | 1.6 | 29 |
| 1728 | BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors. <i>BMC Cancer</i> , 2020, 20, 129. | 1.1 | 9 |
| 1729 | Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. <i>Lancet Respiratory Medicine</i> , 2020, 8, 561-572. | 5.2 | 47 |
| 1730 | The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal. <i>Cancer Treatment Reviews</i> , 2020, 85, 101994. | 3.4 | 89 |
| 1731 | Number of metastatic organs negatively affects the treatment sequence in patients with EGFR-TKI failure. <i>Thoracic Cancer</i> , 2020, 11, 1038-1044. | 0.8 | 0 |
| 1732 | Feasibility Analysis of Cell-Free DNA Derived from Plasma of Lung Cancer Patients for Next-Generation Sequencing. <i>Biopreservation and Biobanking</i> , 2020, 18, 117-121. | 0.5 | 1 |
| 1733 | Use of a plasma test for verifying epidermal growth factor receptor gene (EGFR) mutations in fluid samples from non-small cell lung cancer patients. <i>Respiratory Medicine Case Reports</i> , 2020, 29, 101007. | 0.2 | 0 |
| 1734 | Radiomics Signature as a Predictive Factor for EGFR Mutations in Advanced Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 28. | 1.3 | 54 |
| 1735 | Precision medicine and actionable alterations in lung cancer: A single institution experience. <i>PLoS ONE</i> , 2020, 15, e0228188. | 1.1 | 7 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1736 | Treatment of Patients With Nonâ€“Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations. <i>Clinical Lung Cancer</i> , 2020, 21, 395-406. | 1.1 | 2 |
| 1737 | Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study. <i>PLoS ONE</i> , 2020, 15, e0228925. | 1.1 | 31 |
| 1738 | Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. <i>Journal of Thoracic Oncology</i> , 2020, 15, 803-815. | 0.5 | 178 |
| 1739 | Successful lung cancer EGFR sequencing from DNA extracted from TTF-1 immunohistochemistry slides: a new means to extend insufficient tissue. <i>Human Pathology</i> , 2020, 97, 52-59. | 1.1 | 3 |
| 1740 | Front-line Therapy in Advanced Nonâ€“Small Cell Lung Cancer With Sensitive Epidermal Growth Factor Receptor Mutations: A Network Meta-analysis. <i>Clinical Therapeutics</i> , 2020, 42, 338-350.e4. | 1.1 | 13 |
| 1741 | Abivertinib in patients with T790Mâ€“positive advanced NSCLC and its subsequentâ€“treatment with osimertinib. <i>Thoracic Cancer</i> , 2020, 11, 594-602. | 0.8 | 14 |
| 1742 | ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in<i>EGFR</i>-Mutated Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2244-2256. | 3.2 | 75 |
| 1743 | Precision Management of Advanced Nonâ€“Small Cell Lung Cancer. <i>Annual Review of Medicine</i> , 2020, 71, 117-136. | 5.0 | 101 |
| 1744 | IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 549-559. | 1.5 | 34 |
| 1745 | Patterns of care for older patients with stage IV nonâ€“small cell lung cancer in the immunotherapy era. <i>Cancer Medicine</i> , 2020, 9, 2019-2029. | 1.3 | 17 |
| 1746 | Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib. <i>Scientific Reports</i> , 2020, 10, 691. | 1.6 | 8 |
| 1747 | Does progress achieved in the treatment of patients with metastatic nonâ€“smallâ€“cell lung cancer reach the elderly population? A cohort study from a cancer centre from Eastern Switzerland. <i>European Journal of Cancer Care</i> , 2020, 29, e13206. | 0.7 | 3 |
| 1748 | Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma. <i>Medicine (United States)</i> , 2020, 99, e18726. | 0.4 | 23 |
| 1749 | Brain Metastases from Biliary Tract Cancers: A Case Series and Review of the Literature in the Genomic Era. <i>Oncologist</i> , 2020, 25, 447-453. | 1.9 | 4 |
| 1750 | Plasma screening for the T790M mutation of <i>EGFR</i> and phase 2 study of osimertinib efficacy in plasma T790Mâ€“positive nonâ€“small cell lung cancer: West Japan Oncology Group 8815L/LPS study. <i>Cancer</i> , 2020, 126, 1940-1948. | 2.0 | 18 |
| 1751 | Pharmacological cancer treatment and venous thromboembolism risk. <i>European Heart Journal Supplements</i> , 2020, 22, C2-C14. | 0.0 | 11 |
| 1752 | EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors. <i>BMC Cancer</i> , 2020, 20, 356. | 1.1 | 33 |
| 1753 | Clinical Activity of Afatinib in Patients With Nonâ€“Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study. <i>Clinical Lung Cancer</i> , 2020, 21, 428-436.e2. | 1.1 | 14 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1754 | Epidermal Growth Factor Receptor Mutations. <i>Thoracic Surgery Clinics</i> , 2020, 30, 127-136. | 0.4 | 14 |
| 1755 | Intratumor Heterogeneity in Early Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 349. | 1.3 | 41 |
| 1756 | Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study. <i>Clinical Lung Cancer</i> , 2020, 21, e464-e473. | 1.1 | 24 |
| 1757 | Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients. <i>Lung Cancer</i> , 2020, 143, 67-72. | 0.9 | 17 |
| 1758 | Immediate Adaptation Analysis Implicates BCL6 as an EGFR-TKI Combination Therapy Target in NSCLC. <i>Molecular and Cellular Proteomics</i> , 2020, 19, 928-943. | 2.5 | 9 |
| 1759 | Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 589-599. | 1.0 | 13 |
| 1760 | Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung Cancer. <i>Frontiers in Genetics</i> , 2020, 11, 281. | 1.1 | 50 |
| 1761 | Biopsy on Progression in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer—A Canadian Experience. <i>Current Oncology</i> , 2020, 27, 27-33. | 0.9 | 6 |
| 1762 | Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations. <i>European Journal of Health Economics</i> , 2020, 21, 931-943. | 1.4 | 7 |
| 1763 | Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer. <i>Cancer Science</i> , 2020, 111, 1724-1738. | 1.7 | 20 |
| 1764 | Complexity in Clinical Trials: Blind Spots, Misleading Criteria, Winners and Losers. <i>Clinical Cancer Drugs</i> , 2020, 7, 3-15. | 0.3 | 2 |
| 1765 | YIPF2 promotes chemotherapeutic agent-mediated apoptosis via enhancing TNFRSF10B recycling to plasma membrane in non-small cell lung cancer cells. <i>Cell Death and Disease</i> , 2020, 11, 242. | 2.7 | 17 |
| 1766 | EGFR mutation-positive NSCLC: factors to consider when deciding first-line therapy. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 365-372. | 1.1 | 6 |
| 1767 | Long-term safety of icotinib in patients with non-small cell lung cancer: a retrospective, real-world study. <i>Journal of Thoracic Disease</i> , 2020, 12, 639-650. | 0.6 | 6 |
| 1768 | Impact of pulmonary interstitial lesions on efficacy and prognosis of EGFR-TKI-treated advanced non-small cell lung cancers. <i>Journal of Thoracic Disease</i> , 2020, 12, 839-848. | 0.6 | 0 |
| 1769 | The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma—Letter. <i>Clinical Cancer Research</i> , 2020, 26, 518-519. | 3.2 | 18 |
| 1770 | Therapeutic Landscape of Metastatic Non-Small-Cell Lung Cancer in Canada in 2020. <i>Current Oncology</i> , 2020, 27, 52-60. | 0.9 | 13 |
| 1771 | The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 27-37. | 3.0 | 17 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1772 | BREED based de novo hybridization approach: generating novel T790M/C797S-EGFR tyrosine kinase inhibitors to overcome the problem of mutation and resistance in non small cell lung cancer (NSCLC). <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 2838-2856. | 2.0 | 24 |
| 1773 | Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumab. <i>Investigational New Drugs</i> , 2021, 39, 232-236. | 1.2 | 5 |
| 1774 | Development, internal validation and calibration of a risk score to predict survival in patients with EGFR-mutant non-small cell lung cancer. <i>Journal of Clinical Pathology</i> , 2021, 74, 116-122. | 1.0 | 5 |
| 1775 | Radiogenomic Models Using Machine Learning Techniques to Predict EGFR Mutations in Non-Small Cell Lung Cancer. <i>Canadian Association of Radiologists Journal</i> , 2021, 72, 109-119. | 1.1 | 51 |
| 1776 | The impact of smoking status on the progression-free survival of non-small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 256-266. | 0.7 | 15 |
| 1777 | Hepatotoxicity with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer patients: A network meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 310-318. | 0.7 | 6 |
| 1778 | Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 205-215. | 0.5 | 149 |
| 1779 | A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801). <i>Clinical Lung Cancer</i> , 2021, 22, 147-151. | 1.1 | 16 |
| 1780 | A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer. <i>Investigational New Drugs</i> , 2021, 39, 477-487. | 1.2 | 41 |
| 1781 | Allele-Specific Role of ERBB2 in the Oncogenic Function of EGFR L861Q in EGFR-Mutant Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2021, 16, 113-126. | 0.5 | 13 |
| 1782 | Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 992-1002. | 3.2 | 36 |
| 1783 | Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in a Japanese population. <i>Future Oncology</i> , 2021, 17, 103-115. | 1.1 | 1 |
| 1784 | AZD9291 Resistance Reversal Activity of a pH-Sensitive Nanocarrier Dual-Loaded with Chloroquine and FGFR1 Inhibitor in NSCLC. <i>Advanced Science</i> , 2021, 8, 2002922. | 5.6 | 23 |
| 1785 | Phase II open-label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid Lung. <i>Thoracic Cancer</i> , 2021, 12, 444-452. | 0.8 | 2 |
| 1786 | Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer. <i>Trends in Cancer</i> , 2021, 7, 410-429. | 3.8 | 13 |
| 1787 | Click-ExM enables expansion microscopy for all biomolecules. <i>Nature Methods</i> , 2021, 18, 107-113. | 9.0 | 91 |
| 1788 | Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression $\geq 50\%$ on first-line pembrolizumab. <i>Thoracic Cancer</i> , 2021, 12, 304-313. | 0.8 | 17 |
| 1789 | Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation. <i>Thoracic Cancer</i> , 2021, 12, 329-338. | 0.8 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1790 | Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer. <i>Future Oncology</i> , 2021, 17, 965-977. | 1.1 | 40 |
| 1791 | 2020 Innovation-Based Optimism for Lung Cancer Outcomes. <i>Oncologist</i> , 2021, 26, e454-e472. | 1.9 | 17 |
| 1792 | Suppression of tumor immune microenvironment via microRNA-141 after epidermal growth factor receptor tyrosine kinase inhibitor resistance acquisition in lung adenocarcinoma. <i>Cancer Medicine</i> , 2021, 10, 718-727. | 1.3 | 11 |
| 1793 | Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. <i>Journal of Thoracic Oncology</i> , 2021, 16, 764-773. | 0.5 | 128 |
| 1794 | Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis. <i>Lung Cancer Management</i> , 2021, 10, LMT43. | 1.5 | 19 |
| 1795 | Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 564-576. | 1.9 | 4 |
| 1796 | Long term follow-up of EGFR mutated NSCLC cases. <i>Translational Oncology</i> , 2021, 14, 100934. | 1.7 | 6 |
| 1797 | SHOC2 Is a Critical Modulator of Sensitivity to EGFR-TKIs in Non-Small Cell Lung Cancer Cells. <i>Molecular Cancer Research</i> , 2021, 19, 317-328. | 1.5 | 12 |
| 1798 | Results of the non-small cell lung cancer part of a phase III, open-label, randomized trial evaluating topical corticosteroid therapy for facial acneiform dermatitis induced by EGFR inhibitors: stepwise rank down from potent corticosteroid (FAEISS study, NCCH-1512). <i>Supportive Care in Cancer</i> , 2021, 29, 2327-2334. | 1.0 | 2 |
| 1799 | Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma. <i>Investigational New Drugs</i> , 2021, 39, 571-577. | 1.2 | 20 |
| 1800 | Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations. <i>Oncologist</i> , 2021, 26, 281-287. | 1.9 | 15 |
| 1801 | Mechanisms of drug resistance mediated by long non-coding RNAs in non-small-cell lung cancer. <i>Cancer Gene Therapy</i> , 2021, 28, 175-187. | 2.2 | 14 |
| 1802 | Outcomes of gefitinib therapy for disease recurrence in medically inoperable stage I lung adenocarcinoma patients with active EGFR mutations receiving stereotactic body radiotherapy: a single-institute retrospective study. <i>International Journal of Surgery Oncology</i> , 2021, 4, 72. | 0.2 | 0 |
| 1803 | New Approved First-line Combining Therapy of NSCLC in 2020. <i>E3S Web of Conferences</i> , 2021, 245, 03057. | 0.2 | 0 |
| 1804 | The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110180. | 1.4 | 3 |
| 1805 | First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110357. | 1.4 | 12 |
| 1806 | Deciphering the T790M/L858R-Selective Inhibition Mechanism of an Allosteric Inhibitor of EGFR: Insights from Molecular Simulations. <i>ACS Chemical Neuroscience</i> , 2021, 12, 462-472. | 1.7 | 7 |
| 1807 | Real-world analysis of the effect of gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer with EGFR mutations. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199297. | 1.4 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1808 | Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations. JTO Clinical and Research Reports, 2021, 2, 100107. | 0.6 | 15 |
| 1809 | Artificial intelligence-assisted decision making for prognosis and drug efficacy prediction in lung cancer patients: a narrative review. Journal of Thoracic Disease, 2021, 13, 7021-7033. | 0.6 | 19 |
| 1810 | Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. Journal of Biological Chemistry, 2021, 296, 100641. | 1.6 | 80 |
| 1811 | Molecular Therapeutics of Non-Small Cell Lung Cancer (NSCLC) and Challenges in Repeat Tissue Biopsy. Advances in Lung Cancer (Irvine), 2021, 10, 21-39. | 0.2 | 2 |
| 1812 | Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor. JCO Precision Oncology, 2021, 5, 55-64. | 1.5 | 10 |
| 1813 | The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy. OncoTargets and Therapy, 2020, Volume 13, 13425-13435. | 1.0 | 5 |
| 1814 | Efficacy of tyrosine kinase inhibitors against lung cancer with EGFR exon 18 deletion: Case report and pooled analysis. Cancer Treatment and Research Communications, 2021, 28, 100407. | 0.7 | 3 |
| 1815 | Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors. Frontiers in Oncology, 2020, 10, 607840. | 1.3 | 10 |
| 1816 | Association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage III/IV non-small-cell lung cancer: A retrospective study. Clinics, 2021, 76, e2251. | 0.6 | 2 |
| 1817 | Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer. , 2021, 4, 740-744. | | 1 |
| 1818 | Almonertinib-induced interstitial lung disease. Medicine (United States), 2021, 100, e24393. | 0.4 | 10 |
| 1819 | A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy. Cancer Treatment and Research Communications, 2021, 28, 100416. | 0.7 | 0 |
| 1820 | Management of Brain Metastases. Current Cancer Research, 2021, , 115-137. | 0.2 | 0 |
| 1821 | Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110123. | 1.4 | 8 |
| 1822 | Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types. BMC Cancer, 2021, 21, 52. | 1.1 | 9 |
| 1823 | Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors. Frontiers in Pharmacology, 2021, 12, 636324. | 1.6 | 2 |
| 1824 | Efficacy of afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report. World Journal of Clinical Cases, 2021, 9, 1329-1335. | 0.3 | 4 |
| 1825 | A narrative review: depth of response as a predictor of the long-term outcomes for solid tumors. Translational Cancer Research, 2021, 10, 1119-1130. | 0.4 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1826 | Precision treatment for metastatic non-small cell lung cancer: A conceptual overview. <i>Cleveland Clinic Journal of Medicine</i> , 2021, 88, 117-127. | 0.6 | 3 |
| 1827 | Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100114. | 0.6 | 11 |
| 1828 | Drug-induced Hypersensitivity Syndrome by EGFR-TKI in a Patient with Lung Cancer. <i>Internal Medicine</i> , 2021, 60, 441-444. | 0.3 | 2 |
| 1829 | Molecular mechanism and pharmacokinetics of flavonoids in the treatment of resistant EGFR-mutated non-small cell lung cancer: A narrative review. <i>British Journal of Pharmacology</i> , 2021, 178, 1388-1406. | 2.7 | 10 |
| 1830 | Factors affecting treatment selection and overall survival for first-line EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 193-206. | 0.6 | 5 |
| 1831 | Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2021, 11, 1672-1687. | 7.7 | 112 |
| 1832 | Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial. <i>Cancer Discovery</i> , 2021, 11, 1688-1699. | 7.7 | 154 |
| 1833 | Combination therapy with afatinib and bevacizumab in an EGFR-mutated non-small cell lung cancer patient with acquired ERBB2 amplification. <i>Medicine (United States)</i> , 2021, 100, e24380. | 0.4 | 2 |
| 1834 | Targeted drug delivery strategies for precision medicines. <i>Nature Reviews Materials</i> , 2021, 6, 351-370. | 23.3 | 388 |
| 1835 | Docetaxel maintenance therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study). <i>TJ ETQq1 1 0.784314 rgrBT /Overlock 10 TF 338-338</i> . | 0.7 | 3 |
| 1836 | Efficacy of Afatinib in the Treatment of Patients with Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 688. | 1.7 | 7 |
| 1837 | Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy. <i>Frontiers in Oncology</i> , 2021, 11, 621992. | 1.3 | 13 |
| 1838 | Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer patients: A meta-analysis. <i>Thoracic Cancer</i> , 2021, 12, 1096-1105. | 0.8 | 11 |
| 1839 | Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. <i>Cancers</i> , 2021, 13, 804. | 1.7 | 76 |
| 1840 | Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the "burden of therapy" method. <i>European Journal of Cancer</i> , 2021, 146, 95-106. | 1.3 | 21 |
| 1841 | Adjuvant Therapy With EGFR Tyrosine Kinase Inhibitors: Tempering Great Expectations With Realism. <i>Journal of Clinical Oncology</i> , 2021, 39, 697-700. | 0.8 | 3 |
| 1842 | Hematological parameters in EGFR-mutated advanced NSCLC patients treated with TKIs: predicting survival and toxicity. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 673-679. | 1.1 | 6 |
| 1843 | Afatinib Exerts Immunomodulatory Effects by Targeting the Pyrimidine Biosynthesis Enzyme CAD. <i>Cancer Research</i> , 2021, 81, 3270-3282. | 0.4 | 16 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1844 | High serum C-reactive protein levels predict survival in patients with treated advanced lung adenocarcinoma. <i>Journal of Thoracic Disease</i> , 2021, 13, 1476-1484. | 0.6 | 4 |
| 1845 | N-glycosylated GPNMB ligand independently activates mutated EGFR signaling and promotes metastasis in NSCLC. <i>Cancer Science</i> , 2021, 112, 1911-1923. | 1.7 | 10 |
| 1846 | EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong – A cost-effectiveness analysis. <i>PLoS ONE</i> , 2021, 16, e0247860. | 1.1 | 7 |
| 1847 | Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2139-2148. | 1.0 | 7 |
| 1848 | Standard-Dose Osimertinib in EGFR-Mutated Non-Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease. <i>JCO Precision Oncology</i> , 2021, 5, 561-568. | 1.5 | 1 |
| 1849 | Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada. <i>Pharmacoeconomics</i> , 2021, 39, 537-548. | 1.7 | 6 |
| 1850 | Comparing survival and subsequent treatment of first-line tyrosine kinase inhibitors in patients of advanced lung adenocarcinoma with epidermal growth factor receptor mutation. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 170-180. | 0.8 | 7 |
| 1851 | Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence. <i>Advances in Therapy</i> , 2021, 38, 2038-2053. | 1.3 | 8 |
| 1852 | Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL Study. <i>Drugs - Real World Outcomes</i> , 2021, 8, 141-152. | 0.7 | 6 |
| 1853 | Efficacy and safety of anti-angiogenic drugs combined with erlotinib in the treatment of advanced non-small cell lung cancer: a meta-analysis of randomized clinical trials. <i>Annals of Palliative Medicine</i> , 2021, 10, 2687-2698. | 0.5 | 6 |
| 1854 | The role of EGFR-TKIs as adjuvant therapy in EGFR mutation-positive early-stage NSCLC: A meta-analysis. <i>Thoracic Cancer</i> , 2021, 12, 1084-1095. | 0.8 | 12 |
| 1855 | A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027. <i>BMC Cancer</i> , 2021, 21, 208. | 1.1 | 13 |
| 1856 | Dacomitinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 325-335. | 0.6 | 4 |
| 1857 | Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspective. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 159, 103225. | 2.0 | 10 |
| 1858 | Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. <i>JAMA Oncology</i> , 2021, 7, 386. | 3.4 | 108 |
| 1859 | First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. <i>The Cochrane Library</i> , 2021, 2021, CD010383. | 1.5 | 28 |
| 1860 | Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 161-171. | 0.4 | 5 |
| 1861 | Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 652560. | 1.3 | 8 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1862 | Long-Term Survival of Over 6 Years with Afatinib Sequential Treatment in a Patient with EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Case Report. <i>Clinical Drug Investigation</i> , 2021, 41, 483-488. | 1.1 | 0 |
| 1863 | Oncogenic driver mutations in non-small cell lung cancer: Past, present and future. <i>World Journal of Clinical Oncology</i> , 2021, 12, 217-237. | 0.9 | 88 |
| 1864 | Overcoming therapy resistance in EGFR-mutant lung cancer. <i>Nature Cancer</i> , 2021, 2, 377-391. | 5.7 | 198 |
| 1865 | Lung Adenocarcinoma Patient Harboring EGFR-KDD Achieve Durable Response to Afatinib: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2021, 11, 605853. | 1.3 | 3 |
| 1866 | Personalized and targeted therapies. <i>ChemistrySelect</i> , 2023, 8, 2103-2126. | 0.7 | 0 |
| 1867 | Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103305. | 2.0 | 25 |
| 1868 | Systemic Therapy for Mutation-Driven NSCLC. <i>Seminars in Radiation Oncology</i> , 2021, 31, 140-148. | 1.0 | 4 |
| 1869 | Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4005. | 1.8 | 24 |
| 1870 | Efficacy and dose of afatinib in patients with non-small cell lung cancer after failure of prior gefitinib or erlotinib treatment. <i>Thoracic Cancer</i> , 2021, 12, 1598-1604. | 0.8 | 2 |
| 1871 | Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103300. | 2.0 | 6 |
| 1872 | An Liquid Chromatography-Tandem Mass Spectrometry Method for the Simultaneous Determination of Afatinib, Alectinib, Ceritinib, Crizotinib, Dacomitinib, Erlotinib, Gefitinib, and Osimertinib in Human Serum. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 772-779. | 1.0 | 9 |
| 1873 | Clinical efficacy and safety of nazartinib for epidermal growth factor receptor mutated non-small cell lung cancer. <i>Medicine (United States)</i> , 2021, 100, e25992. | 0.4 | 5 |
| 1874 | Exploration of the Tumor-Suppressive Immune Microenvironment by Integrated Analysis in EGFR-Mutant Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 591922. | 1.3 | 8 |
| 1875 | Liquid biopsy in non-small cell lung cancer—current status and future outlook—a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 2237-2251. | 1.3 | 8 |
| 1876 | Radiotherapy in brain metastases from EGFR-mutated non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2021, 13, 3230-3234. | 0.6 | 5 |
| 1877 | Management of brain metastases in elderly patients with lung cancer. <i>Journal of Thoracic Disease</i> , 2021, 13, 3295-3307. | 0.6 | 1 |
| 1878 | VATS right upper lobectomy after alectinib administration for ALK-positive lung adenocarcinoma. <i>The Journal of the Japanese Association for Chest Surgery</i> , 2021, 35, 297-302. | 0.0 | 0 |
| 1879 | Cost-effectiveness analysis of dacomitinib versus gefitinib for the first-line therapy of patients with EGFR mutation-positive non-small-cell lung cancer in the United States and China. <i>Annals of Translational Medicine</i> , 2021, 9, 760-760. | 0.7 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1880 | Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2021, 148, 202-210. | 1.3 | 9 |
| 1881 | Untangling Dual-Targeting Therapeutic Mechanism of Epidermal Growth Factor Receptor (EGFR) Based on Reversed Allosteric Communication. <i>Pharmaceutics</i> , 2021, 13, 747. | 2.0 | 42 |
| 1882 | The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC. <i>Scientific Reports</i> , 2021, 11, 9629. | 1.6 | 3 |
| 1883 | Resistance Profile of Osimertinib in Pre-treated Patients With EGFR T790M-Mutated Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 602924. | 1.3 | 4 |
| 1884 | Testing EGFR with Idylla on Cytological Specimens of Lung Cancer: A Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4852. | 1.8 | 17 |
| 1885 | Successful treatment of triple <sc>EGFR</sc> mutation <sc>T785A</sc>/<sc>L861Q</sc>/H297_E298 with afatinib. <i>Thoracic Cancer</i> , 2021, 12, 2031-2034. | 0.8 | 1 |
| 1886 | Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review. <i>Cells</i> , 2021, 10, 1206. | 1.8 | 17 |
| 1888 | Limited effect of afatinib in a non-small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report. <i>Thoracic Cancer</i> , 2021, 12, 1770-1774. | 0.8 | 1 |
| 1889 | Sarcopenia as a predictor of initial administration dose of afatinib in patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 1824-1830. | 0.8 | 10 |
| 1890 | First-Line Afatinib plus Cetuximab for <i>EGFR</i>-Mutant Non-small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study. <i>Clinical Cancer Research</i> , 2021, 27, 4168-4176. | 3.2 | 9 |
| 1891 | Efficacy and Safety of EGFR Inhibitors in the Treatment of EGFRPositive NSCLC Patients: A Meta-Analysis. <i>Reviews on Recent Clinical Trials</i> , 2021, 16, 193-201. | 0.4 | 3 |
| 1892 | Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations. <i>BMC Cancer</i> , 2021, 21, 495. | 1.1 | 8 |
| 1893 | Epidermal growth factor receptor inhibitor-induced diarrhea: clinical incidence, toxicological mechanism, and management. <i>Toxicology Research</i> , 2021, 10, 476-486. | 0.9 | 16 |
| 1894 | Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 1581-1590. | 0.5 | 4 |
| 1895 | Challenges in the Treatment of Oligometastatic Non-small Cell Lung Cancer. , 0, , . | | 0 |
| 1896 | Non-small cell lung cancer molecular characterization of advanced disease with focus on sex differences: a narrative review. <i>Precision Cancer Medicine</i> , 0, 4, 14-14. | 1.8 | 3 |
| 1897 | An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor. <i>Cell Chemical Biology</i> , 2021, 28, 1795-1806.e5. | 2.5 | 50 |
| 1898 | The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 1091-1103. | 2.5 | 6 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1899 | Immunotherapy in oncogene addicted non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2736-2751. | 1.3 | 7 |
| 1900 | A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903. <i>ESMO Open</i> , 2021, 6, 100115. | 2.0 | 30 |
| 1901 | NOX4 Signaling Mediates Cancer Development and Therapeutic Resistance through HER3 in Ovarian Cancer Cells. <i>Cells</i> , 2021, 10, 1647. | 1.8 | 16 |
| 1902 | Value of radiomics model based on multi-parametric magnetic resonance imaging in predicting epidermal growth factor receptor mutation status in patients with lung adenocarcinoma. <i>Journal of Thoracic Disease</i> , 2021, 13, 3497-3508. | 0.6 | 7 |
| 1903 | Comparative Efficacy and Safety of TKIs Alone or in Combination With Antiangiogenic Agents in Advanced EGFR-Mutated NSCLC as the First-Line Treatment: A Systematic Review and Meta-Analysis. <i>Clinical Lung Cancer</i> , 2022, 23, 159-169. | 1.1 | 3 |
| 1904 | Vorinostat combined with brigatinib overcomes acquired resistance in EGFR-C797S-mutated lung cancer. <i>Cancer Letters</i> , 2021, 508, 76-91. | 3.2 | 18 |
| 1905 | The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M. <i>Scientific Reports</i> , 2021, 11, 12084. | 1.6 | 7 |
| 1906 | Surgical Intervention for Paronychia Induced by Targeted Anticancer Therapies. <i>Dermatologic Surgery</i> , 2021, 47, 775-779. | 0.4 | 1 |
| 1907 | Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status. <i>Annals of Translational Medicine</i> , 2021, 9, 937-937. | 0.7 | 9 |
| 1908 | Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies. <i>Cancers</i> , 2021, 13, 3164. | 1.7 | 35 |
| 1909 | EGFR tyrosine kinase inhibitors for <i>EGFR</i> mutation-positive non-small-cell lung cancer: outcomes in Asian populations. <i>Future Oncology</i> , 2021, 17, 2395-2408. | 1.1 | 17 |
| 1910 | Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma. <i>Journal of Molecular Pathology</i> , 2021, 2, 173-196. | 0.5 | 14 |
| 1911 | Survival Outcomes of Nonsmall Cell Lung Cancer Patients Treated with Afatinib Who Are Affected by Early Adverse Events. <i>Journal of Oncology</i> , 2021, 2021, 1-6. | 0.6 | 0 |
| 1912 | Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR-Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report. <i>Frontiers in Medicine</i> , 2021, 8, 570921. | 1.2 | 2 |
| 1913 | Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer. <i>Pharmaceuticals</i> , 2021, 14, 589. | 1.7 | 32 |
| 1914 | Survival of chemo-naïve patients with <i>EGFR</i> mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1269-1276. | 0.6 | 7 |
| 1915 | An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations. <i>BMC Cancer</i> , 2021, 21, 802. | 1.1 | 5 |
| 1916 | High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction. <i>Cancers</i> , 2021, 13, 3425. | 1.7 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1917 | RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5258-5271. | 3.2 | 23 |
| 1919 | Comparative assessment of NOIR-SS and ddPCR for ctDNA detection of EGFR L858R mutations in advanced L858R-positive lung adenocarcinomas. <i>Scientific Reports</i> , 2021, 11, 14999. | 1.6 | 5 |
| 1920 | Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2021, 30, 200294. | 3.0 | 7 |
| 1921 | Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies. <i>Frontiers in Oncology</i> , 2021, 11, 709877. | 1.3 | 6 |
| 1922 | Survival Trends of Metastatic Lung Cancer in California by Age at Diagnosis, Gender, Race/Ethnicity, and Histology, 1990-2014. <i>Clinical Lung Cancer</i> , 2021, 22, e602-e611. | 1.1 | 5 |
| 1923 | Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines. <i>Future Oncology</i> , 2021, 17, 2513-2527. | 1.1 | 7 |
| 1924 | Targeting EGFR Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates. <i>Cancer Discovery</i> , 2021, 11, 2145-2157. | 7.7 | 54 |
| 1925 | Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2021, 23, 2560-2567. | 1.2 | 7 |
| 1926 | Computational Probing the Methylation Sites Related to EGFR Inhibitor-Responsive Genes. <i>Biomolecules</i> , 2021, 11, 1042. | 1.8 | 2 |
| 1927 | Cytologic Investigations for the Diagnosis of Malignant Pleural Effusion in Non-small Cell Lung Cancer. <i>Journal of Bronchology and Interventional Pulmonology</i> , 2021, 28, 310-321. | 0.8 | 6 |
| 1928 | Hypoxia-related lncRNAs to build prognostic classifier and reveal the immune characteristics of EGFR wild type and low expression of PD-L1 squamous and adenocarcinoma NSCLC. <i>Cancer Medicine</i> , 2021, 10, 6099-6113. | 1.3 | 4 |
| 1929 | Bruton's tyrosine kinase (BTK) mediates resistance to EGFR inhibition in non-small-cell lung carcinoma. <i>Oncogenesis</i> , 2021, 10, 56. | 2.1 | 5 |
| 1930 | Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study. <i>BMC Cancer</i> , 2021, 21, 859. | 1.1 | 15 |
| 1931 | PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors. <i>Clinical Lung Cancer</i> , 2021, 22, 351-360. | 1.1 | 7 |
| 1932 | Update on recent key publications in lung oncology: picking up speed. <i>European Respiratory Review</i> , 2021, 30, 200300. | 3.0 | 1 |
| 1933 | Prediction of EGFR Mutation Status Based on 18F-FDG PET/CT Imaging Using Deep Learning-Based Model in Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 709137. | 1.3 | 14 |
| 1934 | Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non-small cell lung cancer harboring EGFR mutations: Results from a real-world study in South Korea. <i>Cancer Medicine</i> , 2021, 10, 5809-5822. | 1.3 | 13 |
| 1935 | Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation. <i>Frontiers in Pharmacology</i> , 2021, 12, 720687. | 1.6 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1936 | EGFR-mutated stage IV non-small cell lung cancer: What is the role of radiotherapy combined with TKI?. <i>Cancer Medicine</i> , 2021, 10, 6167-6188. | 1.3 | 8 |
| 1937 | Lung cancer. <i>Lancet, The</i> , 2021, 398, 535-554. | 6.3 | 896 |
| 1938 | Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4579-4597. | 1.0 | 21 |
| 1939 | How specific molecular-targeted agents can make obsolete a "one size fits all" approach in EGFR-mutated NSCLC treatment (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1150. | 0.8 | 3 |
| 1940 | Growth Suppression in Lung Cancer Cells Harboring EGFR-C797S Mutation by Quercetin. <i>Biomolecules</i> , 2021, 11, 1271. | 1.8 | 23 |
| 1941 | The Combiome Hypothesis: Selecting Optimal Treatment for Cancer Patients. <i>Clinical Lung Cancer</i> , 2021, , . | 1.1 | 4 |
| 1942 | Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 829-839. | 5.2 | 66 |
| 1943 | Liquid biopsy uncovers distinct patterns of DNA methylation and copy number changes in NSCLC patients with different EGFR-TKI resistant mutations. <i>Scientific Reports</i> , 2021, 11, 16436. | 1.6 | 15 |
| 1944 | Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. <i>JCO Precision Oncology</i> , 2021, 5, 1241-1249. | 1.5 | 11 |
| 1945 | Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer. <i>Pharmacoeconomics</i> , 2021, 39, 1429-1442. | 1.7 | 10 |
| 1946 | Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with EGFR exon 19 deletions or exon 21 mutations. <i>Future Oncology</i> , 2021, 17, 2867-2881. | 1.1 | 5 |
| 1947 | Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous subgroup of NSCLC. <i>Current Problems in Cancer</i> , 2022, 46, 100787. | 1.0 | 5 |
| 1949 | The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon EGFR Mutations: The Mutation Patterns, Use of Different Generations of EGFR-TKIs, and Concurrent Genetic Alterations. <i>Frontiers in Oncology</i> , 2021, 11, 646577. | 1.3 | 12 |
| 1950 | Black Disparities in Targeted Therapy Clinical Trials: A Call for Future Reset. <i>Journal of Education and Teaching in Emergency Medicine</i> , 2021, 7, 8-28. | 0.0 | 1 |
| 1951 | What management for epidermal growth factor receptor-mutated non-small-cell lung cancer, with squamous cell transformation and T790M-acquired resistance mechanisms? A Case report and review of literature. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, . | 0.7 | 3 |
| 1952 | Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study. <i>Translational Lung Cancer Research</i> , 2021, 10, 3582-3593. | 1.3 | 12 |
| 1953 | Clinicopathological and Prognostic Significance of Inhibitor of Apoptosis Protein (IAP) Family Members in Lung Cancer: A Meta-Analysis. <i>Cancers</i> , 2021, 13, 4098. | 1.7 | 4 |
| 1954 | The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1071-1080. | 1.1 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1955 | Development and validation of an HPLC-MS/MS method to simultaneously quantify alectinib, crizotinib, erlotinib, gefitinib and osimertinib in human plasma samples, using one assay run. <i>Biomedical Chromatography</i> , 2021, 35, e5224. | 0.8 | 9 |
| 1956 | Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1267-1288. | 0.5 | 77 |
| 1957 | Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer. <i>Science Translational Medicine</i> , 2021, 13, eabb3738. | 5.8 | 10 |
| 1958 | Structure-based classification predicts drug response in EGFR-mutant NSCLC. <i>Nature</i> , 2021, 597, 732-737. | 13.7 | 185 |
| 1959 | Outcomes of salvage lung resections in advanced EGFR-mutant lung adenocarcinomas under EGFR TKIs. <i>Thoracic Cancer</i> , 2021, 12, 2655-2665. | 0.8 | 10 |
| 1960 | Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC. <i>Biomarker Research</i> , 2021, 9, 69. | 2.8 | 4 |
| 1961 | Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations. <i>Medicina (Lithuania)</i> , 2021, 57, 929. | 0.8 | 3 |
| 1962 | Pozotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 702-709. | 0.8 | 53 |
| 1963 | Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions. <i>Scientific Reports</i> , 2021, 11, 18762. | 1.6 | 13 |
| 1964 | Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective. <i>Pharmaceutics</i> , 2021, 13, 1500. | 2.0 | 10 |
| 1965 | Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100206. | 0.6 | 3 |
| 1966 | Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation. <i>International Journal of Cancer</i> , 2022, 150, 626-635. | 2.3 | 16 |
| 1967 | LC-MS/MS Estimation of Rociletinib Levels in Human Liver Microsomes: Application to Metabolic Stability Estimation. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 3915-3925. | 2.0 | 2 |
| 1968 | First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study. <i>Oncologist</i> , 2022, 27, 87-e115. | 1.9 | 25 |
| 1969 | Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG). <i>Lung Cancer</i> , 2021, 162, 9-15. | 0.9 | 18 |
| 1970 | Management of Oligometastasis and Oligoprogression in Patients with Epidermal Growth Factor Receptor Mutation-Positive NSCLC in the Era of Third-Generation Tyrosine Kinase Inhibitors. <i>Clinical Lung Cancer</i> , 2021, 22, e786-e792. | 1.1 | 9 |
| 1971 | EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 1729-1739. | 0.8 | 9 |
| 1972 | Patient-Reported and End-of-Life Outcomes Among Adults With Lung Cancer Receiving Targeted Therapy in a Clinical Trial of Early Integrated Palliative Care: A Secondary Analysis. <i>Journal of Pain and Symptom Management</i> , 2021, 62, e65-e74. | 0.6 | 8 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1973 | Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities. <i>Genes and Diseases</i> , 2022, 9, 1181-1193. | 1.5 | 8 |
| 1974 | XHL11, a novel selective EGFR inhibitor, overcomes EGFR790M-mediated resistance in non-small cell lung cancer. <i>European Journal of Pharmacology</i> , 2021, 907, 174297. | 1.7 | 1 |
| 1975 | Entrectinib: A new Selective Tyrosine Kinase Inhibitor Approved for the Treatment of Pediatric and Adult Patients with NTRK Fusion-positive, Recurrent or Advanced Solid Tumors. <i>Current Medicinal Chemistry</i> , 2021, 28, . | 1.2 | 2 |
| 1976 | Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3823-3839. | 1.3 | 13 |
| 1977 | GPCR-mediated EGFR transactivation ameliorates skin toxicities induced by afatinib. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 1534-1543. | 2.8 | 1 |
| 1978 | Access to Tyrosine Kinase Inhibitors and Survival in Patients with Advanced EGFR+ and ALK+ Positive Non-small-cell Lung Cancer Treated in the Real-World. <i>Clinical Lung Cancer</i> , 2021, 22, e723-e733. | 1.1 | 7 |
| 1979 | European and US Real-World Treatment Patterns in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Medical Record Review. <i>Drugs - Real World Outcomes</i> , 2021, 8, 537-545. | 0.7 | 10 |
| 1981 | Hypotension from afatinib in epidermal growth factor receptor-mutated non-small cell lung cancer: a case report and literature review. <i>Anti-Cancer Drugs</i> , 2022, 33, e840-e841. | 0.7 | 2 |
| 1982 | Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring. <i>Cancers</i> , 2021, 13, 4926. | 1.7 | 52 |
| 1983 | Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 166, 103454. | 2.0 | 15 |
| 1984 | Hypoalbuminaemia as a Prognostic Biomarker of First-Line Treatment Resistance in Metastatic Non-small Cell Lung Cancer. <i>Frontiers in Nutrition</i> , 2021, 8, 734735. | 1.6 | 16 |
| 1985 | Presentación radiológica infrecuente del adenocarcinoma de pulmón: a propósito de un caso clínico. <i>Open Respiratory Archives</i> , 2021, 3, 100129. | 0.0 | 0 |
| 1986 | The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC. <i>Lung Cancer</i> , 2021, 160, 118-126. | 0.9 | 5 |
| 1987 | Nuclear Pore Glycoprotein 62 Genetic Variant rs9523 is Associated with Clinical Outcomes of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Adenocarcinoma Patients. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 1291-1302. | 0.4 | 0 |
| 1988 | A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance. <i>Frontiers in Oncology</i> , 2021, 11, 722039. | 1.3 | 12 |
| 1989 | Optimising fusion detection through sequential DNA and RNA molecular profiling of non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 161, 55-59. | 0.9 | 8 |
| 1990 | A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632. <i>Lung Cancer</i> , 2021, 161, 49-54. | 0.9 | 9 |
| 1991 | Does large NGS panel analysed using exome tumour sequencing improve the management of advanced non-small-cell lung cancers?. <i>Lung Cancer</i> , 2021, 161, 98-107. | 0.9 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 1992 | Molecular Targetable Pathways of EGFR. , 2022, , 844-852. | | 0 |
| 1993 | Breakthrough in targeted therapy for non-small cell lung cancer. Biomedicine and Pharmacotherapy, 2021, 133, 111079. | 2.5 | 59 |
| 1994 | Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma. International Journal of Molecular Sciences, 2021, 22, 593. | 1.8 | 35 |
| 1995 | Biomarkers: Is Tumor Mutational Burden the New Prognostic Grail?. Current Cancer Research, 2021, , 27-54. | 0.2 | 0 |
| 1996 | Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort. Frontiers in Oncology, 2020, 10, 590356. | 1.3 | 4 |
| 1997 | A prospective phase II study of multimodal prophylactic treatment for afatinib-induced adverse events in advanced non-small cell lung cancer (Niigata Lung Cancer Treatment Group 1401). Translational Lung Cancer Research, 2021, 10, 252-260. | 1.3 | 5 |
| 1998 | Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations. Translational Lung Cancer Research, 2021, 10, 183-192. | 1.3 | 7 |
| 1999 | Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M-Positive NSCLC. JTO Clinical and Research Reports, 2021, 2, 100099. | 0.6 | 0 |
| 2000 | Cholesterol synthesis disruption combined with a molecule-targeted drug is a promising metabolic therapy for EGFR mutant non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 128-142. | 1.3 | 13 |
| 2001 | Tyrosine Kinase Inhibitors (TKIs) in Lung Cancer Treatment: A Comprehensive Analysis. Current Cancer Drug Targets, 2021, 21, 55-69. | 0.8 | 8 |
| 2003 | Stratifying Cancer Therapies by Molecular Interactions and Imaging. , 2017, , 315-358. | | 1 |
| 2004 | Neue Arzneimittel 2013. , 2014, , 47-145. | | 2 |
| 2005 | Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology. Recent Results in Cancer Research, 2016, 198, 45-87. | 1.8 | 4 |
| 2006 | Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nature Reviews Clinical Oncology, 2019, 16, 341-355. | 12.5 | 347 |
| 2009 | Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer. Cancer Science, 2020, 111, 561-570. | 1.7 | 31 |
| 2010 | Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non-small cell lung cancer. Cancer Science, 2020, 111, 2736-2746. | 1.7 | 12 |
| 2011 | Statins use and its impact in EGFR-TKIs resistance to prolong the survival of lung cancer patients: A Cancer registry cohort study in Taiwan. Cancer Science, 2020, 111, 2965-2973. | 1.7 | 17 |
| 2012 | Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion. Therapeutic Advances in Medical Oncology, 2020, 12, 175883591989575. | 1.4 | 39 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2013 | Afatinib approval for NSCLC brings EGFR TKI story full circle. <i>Journal of Community and Supportive Oncology</i> , 2014, 12, 2-3. | 0.1 | 4 |
| 2014 | Development of a Highly Sensitive and Specific Method for Detection of Circulating Tumor Cells Harboring Somatic Mutations in Non-Small-Cell Lung Cancer Patients. <i>PLoS ONE</i> , 2014, 9, e85350. | 1.1 | 51 |
| 2015 | Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>PLoS ONE</i> , 2015, 10, e0123587. | 1.1 | 30 |
| 2016 | The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study. <i>PLoS ONE</i> , 2015, 10, e0142500. | 1.1 | 14 |
| 2017 | Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIET). <i>PLoS ONE</i> , 2016, 11, e0147599. | 1.1 | 17 |
| 2018 | The percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinoma. <i>PLoS ONE</i> , 2017, 12, e0177822. | 1.1 | 5 |
| 2019 | In- and ex-vivo molecular imaging of apoptosis to assess sensitivity of non-small cell lung cancer to EGFR inhibitors using probe-based confocal laser endomicroscopy. <i>PLoS ONE</i> , 2017, 12, e0180576. | 1.1 | 8 |
| 2020 | Lung Cancer Staging and Associated Genetic and Epigenetic Events. <i>Molecules and Cells</i> , 2020, 43, 1-9. | 1.0 | 23 |
| 2021 | Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Use for Subclassification and Genotyping of Lung Non-Small-Cell Carcinoma. <i>Southern Medical Journal</i> , 2018, 111, 484-488. | 0.3 | 5 |
| 2022 | TW37 enhances the pro-apoptosis and anti-migration ability of gefitinib in Non-Small Cell Lung Cancer. <i>Cellular and Molecular Biology</i> , 2018, 64, 6-10. | 0.3 | 7 |
| 2023 | Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come. <i>Critical Reviews in Oncogenesis</i> , 2015, 20, 339-347. | 0.2 | 6 |
| 2024 | From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study). <i>Oncologist</i> , 2019, 24, e318-e326. | 1.9 | 5 |
| 2025 | Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada. <i>Oncologist</i> , 2020, 25, e130-e137. | 1.9 | 19 |
| 2026 | Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses. <i>Aging</i> , 2020, 12, 14244-14270. | 1.4 | 23 |
| 2027 | Phase I/II study of erlotinib, carboplatin, pemetrexed, and bevacizumab in chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer harboring epidermal growth factor receptor mutation. <i>Genes and Cancer</i> , 2017, 8, 559-565. | 0.6 | 7 |
| 2028 | Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung. <i>Oncoscience</i> , 2014, 1, 522-528. | 0.9 | 24 |
| 2029 | Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations. <i>Oncotarget</i> , 2016, 7, 47998-48010. | 0.8 | 21 |
| 2030 | Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients. <i>Oncotarget</i> , 2016, 7, 53299-53308. | 0.8 | 9 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2031 | EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models. <i>Oncotarget</i> , 2016, 7, 54137-54156. | 0.8 | 27 |
| 2032 | Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 81906-81917. | 0.8 | 20 |
| 2033 | Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations. <i>Oncotarget</i> , 2016, 7, 68442-68448. | 0.8 | 13 |
| 2034 | BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations. <i>Oncotarget</i> , 2016, 7, 68933-68942. | 0.8 | 26 |
| 2035 | PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors. <i>Oncotarget</i> , 2016, 7, 84951-84964. | 0.8 | 41 |
| 2036 | Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 85917-85928. | 0.8 | 6 |
| 2037 | Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts. <i>Oncotarget</i> , 2017, 8, 9134-9143. | 0.8 | 8 |
| 2038 | Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring leu858Arg or exon 19 deletions. <i>Oncotarget</i> , 2017, 8, 1343-1353. | 0.8 | 36 |
| 2039 | A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 27286-27299. | 0.8 | 13 |
| 2040 | Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations. <i>Oncotarget</i> , 2017, 8, 32626-32638. | 0.8 | 14 |
| 2041 | Epidermal growth factor receptor-mutant lung cancer in Down syndrome: a case presentation and review of the literature. <i>Oncotarget</i> , 2017, 8, 55760-55765. | 0.8 | 1 |
| 2042 | Molecular dissection of effector mechanisms of <i>RAS</i> -mediated resistance to anti-EGFR antibody therapy. <i>Oncotarget</i> , 2017, 8, 45898-45917. | 0.8 | 12 |
| 2043 | Strategies targeting angiogenesis in advanced non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 53854-53872. | 0.8 | 57 |
| 2044 | Clinical mutational profiling of 1006 lung cancers by next generation sequencing. <i>Oncotarget</i> , 2017, 8, 96684-96696. | 0.8 | 32 |
| 2045 | FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor. <i>Oncotarget</i> , 2014, 5, 5908-5919. | 0.8 | 92 |
| 2046 | Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study. <i>Oncotarget</i> , 2014, 5, 2293-2304. | 0.8 | 32 |
| 2047 | Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer. <i>Oncotarget</i> , 2014, 5, 10434-10445. | 0.8 | 30 |
| 2048 | Effect of postoperative systemic therapy on pulmonary adenocarcinoma with unexpected pleural spread detected during thoracotomy or thoracoscopy. <i>Oncotarget</i> , 2018, 9, 5435-5444. | 0.8 | 6 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2049 | Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study). <i>Oncotarget</i> , 2018, 9, 8253-8262. | 0.8 | 25 |
| 2050 | Antibody-assisted target identification reveals afatinib, an EGFR covalent inhibitor, down-regulating ribonucleotide reductase. <i>Oncotarget</i> , 2018, 9, 21512-21529. | 0.8 | 10 |
| 2051 | Prognostic factors of afatinib as a first-line therapy for advanced <i>EGFR</i> mutation-positive lung adenocarcinoma: a real-world, large cohort study. <i>Oncotarget</i> , 2018, 9, 23749-23760. | 0.8 | 18 |
| 2052 | Anticancer activity of 2â€™-hydroxyflavanone towards lung cancer. <i>Oncotarget</i> , 2018, 9, 36202-36219. | 0.8 | 22 |
| 2053 | Targeted therapies for advanced non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 37589-37607. | 0.8 | 52 |
| 2054 | Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A. <i>Oncotarget</i> , 2015, 6, 2164-2179. | 0.8 | 43 |
| 2055 | <i>ROS1</i> rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability. <i>Oncotarget</i> , 2015, 6, 10577-10585. | 0.8 | 85 |
| 2056 | Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of <i>EGFR</i> mutant advanced lung adenocarcinoma. <i>Oncotarget</i> , 2015, 6, 12783-12795. | 0.8 | 58 |
| 2057 | Highly sensitive and quantitative evaluation of the EGFR T790M mutation by nanofluidic digital PCR. <i>Oncotarget</i> , 2015, 6, 20466-20473. | 0.8 | 32 |
| 2058 | Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors. <i>Oncotarget</i> , 2015, 6, 24904-24911. | 0.8 | 22 |
| 2059 | Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status. <i>Oncotarget</i> , 2015, 6, 26090-26103. | 0.8 | 37 |
| 2060 | Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 30929-30938. | 0.8 | 10 |
| 2061 | The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 33602-33611. | 0.8 | 53 |
| 2062 | Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: A case report. <i>Oncotarget</i> , 2015, 6, 34030-34037. | 0.8 | 17 |
| 2063 | <i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer. <i>Oncotarget</i> , 2015, 6, 38789-38803. | 0.8 | 137 |
| 2064 | Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. <i>Oncotarget</i> , 2015, 6, 39538-39549. | 0.8 | 27 |
| 2065 | Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis. <i>Oncotarget</i> , 2016, 7, 3635-3644. | 0.8 | 24 |
| 2066 | Contribution of <i>KRAS</i> mutations and c.2369C > T (p.T790M) <i>EGFR</i> to acquired resistance to EGFR-TKIs in <i>EGFR</i> mutant NSCLC: a study on circulating tumor DNA. <i>Oncotarget</i> , 2017, 8, 13611-13619. | 0.8 | 81 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2067 | The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. <i>Oncotarget</i> , 2016, 7, 12404-12413. | 0.8 | 209 |
| 2068 | Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network metaanalysis. <i>Oncotarget</i> , 2016, 7, 20093-20108. | 0.8 | 31 |
| 2069 | Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer?. <i>Annals of Translational Medicine</i> , 2016, 4, 225-225. | 0.7 | 7 |
| 2070 | The aftermath of LUX-Lung 7 study—what have we learnt from it?. <i>Annals of Translational Medicine</i> , 2016, 4, 294-294. | 0.7 | 1 |
| 2071 | Skin communicates what we deeply feel: antibiotic prophylactic treatment to reduce epidermal growth factor receptor inhibitors induced rash in lung cancer (the Pan Canadian rash trial). <i>Annals of Translational Medicine</i> , 2016, 4, 313-313. | 0.7 | 2 |
| 2072 | Prioritizing molecular markers to test for in the initial workup of advanced non-small cell lung cancer: wants versus needs. <i>Annals of Translational Medicine</i> , 2017, 5, 371-371. | 0.7 | 2 |
| 2073 | Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs). <i>Annals of Translational Medicine</i> , 2018, 6, 140-140. | 0.7 | 14 |
| 2074 | The emerging treatment landscape of advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2018, 6, 138-138. | 0.7 | 29 |
| 2075 | Evaluation bias in objective response rate and disease control rate between blinded independent central review and local assessment: a study-level pooled analysis of phase III randomized control trials in the past seven years. <i>Annals of Translational Medicine</i> , 2017, 5, 481-481. | 0.7 | 11 |
| 2076 | Osimertinib in first-line treatment—“is a comparison not proof?”. <i>Annals of Translational Medicine</i> , 2018, 6, 57-57. | 0.7 | 3 |
| 2077 | Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?. <i>Annals of Translational Medicine</i> , 2018, 6, 143-143. | 0.7 | 13 |
| 2078 | Emerging application of genomics-guided therapeutics in personalized lung cancer treatment. <i>Annals of Translational Medicine</i> , 2018, 6, 160-160. | 0.7 | 22 |
| 2079 | Systemic therapy of elderly patients with advanced non-small cell lung cancer—“individualized treatment is key. <i>Annals of Translational Medicine</i> , 2019, 7, S48-S48. | 0.7 | 3 |
| 2080 | EGFR first- and second-generation TKIs—“there is still place for them in EGFR-mutant NSCLC patients. <i>Translational Cancer Research</i> , 2018, 8, S23-S47. | 0.4 | 48 |
| 2081 | Akt/mTOR and AMPK signaling pathways are responsible for liver X receptor agonist GW3965-enhanced gefitinib sensitivity in non-small cell lung cancer cell lines. <i>Translational Cancer Research</i> , 2019, 8, 66-76. | 0.4 | 8 |
| 2082 | Adjuvant TKI treatment of EGFR-mutant lung cancer—“already ripe for decision?. <i>Translational Lung Cancer Research</i> , 2020, 9, 964-966. | 1.3 | 3 |
| 2083 | Comparing overall survival between first generation EGFR-TKIs and chemotherapy in lung cancer patients with Del19/L858R. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2016, 28, 339-347. | 0.7 | 9 |
| 2084 | Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer: A phase II open-label clinical study. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2019, 31, 339-348. | 0.7 | 6 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2085 | <p>Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib</p>. OncoTargets and Therapy, 2020, Volume 13, 9305-9321. | 1.0 | 16 |
| 2086 | Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy. Current Medicinal Chemistry, 2020, 27, 5274-5316. | 1.2 | 28 |
| 2087 | Efficacy and Safety of Addition of Anti-PD1 to Chemotherapy in Treatment of Non-Small Cell Lung Cancer. Combinatorial Chemistry and High Throughput Screening, 2019, 21, 711-717. | 0.6 | 5 |
| 2088 | Investigating the Impact of Different Acrylamide (Electrophilic Warhead) on Osimertinibâ€™s Pharmacological Spectrum by Molecular Mechanic and Quantum Mechanic Approach. Combinatorial Chemistry and High Throughput Screening, 2021, 25, 149-166. | 0.6 | 25 |
| 2089 | Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. Current Cancer Drug Targets, 2019, 19, 595-630. | 0.8 | 61 |
| 2090 | Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors. Current Topics in Medicinal Chemistry, 2020, 20, 815-834. | 1.0 | 229 |
| 2091 | Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Mutation: First Line Treatment and Beyond. Reviews on Recent Clinical Trials, 2019, 14, 120-128. | 0.4 | 11 |
| 2092 | From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2019, 18, 1235-1240. | 0.9 | 9 |
| 2093 | HB-EGF Is A Promising Therapeutic Target for Lung Cancer with Secondary Mutation of EGFR T790M. Anticancer Research, 2017, 37, 3825-3831. | 0.5 | 16 |
| 2094 | Utilization of Molecular Testing and Survival Outcomes of Treatment with First- or Second-line Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer in a Dutch Population. Anticancer Research, 2018, 38, 393-400. | 0.5 | 10 |
| 2095 | Neoadjuvant Tyrosine Kinase Inhibition in Locally-advanced Non-small Cell Lung Cancer: Two Cases and a Brief Literature Review. Anticancer Research, 2019, 39, 897-902. | 0.5 | 10 |
| 2096 | A Case-control Study Supporting the Use of Liquid Biopsy in the Targeted Therapy for Lung Cancer. Asian Pacific Journal of Cancer Prevention, 2018, 19, 1761-1766. | 0.5 | 5 |
| 2098 | Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Nonâ€™Small Cell Lung Cancer Treatment Setting. Journal of Clinical Pathways: the Foundation of Value-based Care, 2018, 4, 49-54. | 0.2 | 15 |
| 2099 | Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC). Pharmaceuticals, 2020, 13, 273. | 1.7 | 28 |
| 2103 | Local ablative radiotherapy for oligometastatic non-small cell lung cancer. Radiation Oncology Journal, 2019, 37, 149-155. | 0.7 | 12 |
| 2104 | Predictive value of tumor genetic alteration profiling for chemotherapy and EGFRâ€™TKI treatment in advanced NSCLC. Oncology Letters, 2020, 19, 3859-3870. | 0.8 | 1 |
| 2105 | Anti-Cancer Therapy of Advanced Lung Cancer in Elderly Patients. Korean Journal of Medicine, 2014, 87, 537. | 0.1 | 1 |
| 2106 | Targeted Therapy for Non-Small Cell Lung Cancer. Korean Journal of Medicine, 2020, 95, 78-88. | 0.1 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2107 | A meta-analysis of the comparing of the first-generation and next-generation TKIs in the treatment of NSCLC. <i>Mathematical Biosciences and Engineering</i> , 2019, 16, 5687-5696. | 1.0 | 1 |
| 2108 | Apatinib in the treatment of advanced non-small-cell lung cancer: A meta-analysis. <i>Mathematical Biosciences and Engineering</i> , 2019, 16, 7659-7670. | 1.0 | 11 |
| 2109 | Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials. <i>Journal of Thoracic Disease</i> , 2013, 5, 383-4. | 0.6 | 20 |
| 2110 | Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. <i>Journal of Thoracic Disease</i> , 2013, 5 Suppl 5, S579-92. | 0.6 | 37 |
| 2111 | China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version). <i>Journal of Thoracic Disease</i> , 2015, 7, E468-72. | 0.6 | 6 |
| 2112 | EGFR mutation heterogeneity and mixed response to EGFR tyrosine kinase inhibitors of non small cell lung cancer: a clue to overcoming resistance. <i>Translational Lung Cancer Research</i> , 2013, 2, 445-8. | 1.3 | 22 |
| 2113 | ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation. <i>Translational Lung Cancer Research</i> , 2014, 3, 122-30. | 1.3 | 25 |
| 2114 | Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. <i>Translational Lung Cancer Research</i> , 2015, 4, 36-54. | 1.3 | 499 |
| 2115 | Update on third-generation EGFR tyrosine kinase inhibitors. <i>Translational Lung Cancer Research</i> , 2014, 3, 360-2. | 1.3 | 8 |
| 2116 | Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. <i>Translational Lung Cancer Research</i> , 2015, 4, 67-81. | 1.3 | 241 |
| 2117 | Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 165-76. | 1.3 | 103 |
| 2118 | Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond. <i>Translational Lung Cancer Research</i> , 2015, 4, 126-41. | 1.3 | 59 |
| 2119 | Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer-the Holy Grail in cancer treatment?. <i>Translational Lung Cancer Research</i> , 2015, 4, 223-7. | 1.3 | 18 |
| 2120 | Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers. <i>Translational Lung Cancer Research</i> , 2015, 4, 639-41. | 1.3 | 16 |
| 2121 | PROFILE 1014: lessons for the new era of lung cancer clinical research. <i>Translational Lung Cancer Research</i> , 2015, 4, 642-8. | 1.3 | 9 |
| 2122 | Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M. <i>Translational Lung Cancer Research</i> , 2015, 4, 809-15. | 1.3 | 43 |
| 2123 | Lung cancer biomarkers, targeted therapies and clinical assays. <i>Translational Lung Cancer Research</i> , 2015, 4, 503-14. | 1.3 | 23 |
| 2124 | New strategies in immunotherapy for non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 553-9. | 1.3 | 35 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2125 | Treatment of advanced squamous cell carcinoma of the lung: a review. <i>Translational Lung Cancer Research</i> , 2015, 4, 524-32. | 1.3 | 74 |
| 2126 | Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2015, 4, 515-23. | 1.3 | 85 |
| 2127 | Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis. <i>Translational Lung Cancer Research</i> , 2015, 4, 392-403. | 1.3 | 24 |
| 2128 | Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance. <i>Translational Lung Cancer Research</i> , 2015, 4, 576-83. | 1.3 | 26 |
| 2129 | Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies. <i>Translational Lung Cancer Research</i> , 2015, 4, 545-52. | 1.3 | 70 |
| 2130 | Chemotherapy for advanced cancers. <i>Annals of Palliative Medicine</i> , 2014, 3, 203-28. | 0.5 | 11 |
| 2131 | China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version). <i>Annals of Translational Medicine</i> , 2015, 3, 260. | 0.7 | 9 |
| 2132 | Targeted therapies in development for non-small cell lung cancer. <i>Journal of Carcinogenesis</i> , 2013, 12, 22. | 2.5 | 67 |
| 2133 | Saudi lung cancer management guidelines 2017. <i>Annals of Thoracic Medicine</i> , 2017, 12, 221. | 0.7 | 16 |
| 2134 | Indian consensus statement for treatment of advanced non small cell lung cancer: First line, maintenance, and second line. <i>Indian Journal of Cancer</i> , 2017, 54, 89. | 0.2 | 5 |
| 2135 | Targeted therapy in nonsmall cell lung cancer. <i>Indian Journal of Cancer</i> , 2017, 54, 83. | 0.2 | 6 |
| 2136 | T790M mutations identified by circulating tumor DNA test in lung adenocarcinoma patients who progressed on first-line epidermal growth factor receptor-tyrosine kinase inhibitors. <i>Lung India</i> , 2020, 37, 13. | 0.3 | 8 |
| 2137 | Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?. <i>Lung India</i> , 2018, 35, 27. | 0.3 | 3 |
| 2138 | Clinical profile of lung cancer in North India: A 10-year analysis of 1862 patients from a tertiary care center. <i>Lung India</i> , 2020, 37, 190. | 0.3 | 62 |
| 2139 | Frequency of T790M mutations after progression on epidermal growth factor receptor tyrosine kinase inhibitor in metastatic non-small cell lung cancer in Indian patients: real-time data from tertiary cancer hospital. <i>Lung India</i> , 2018, 35, 390. | 0.3 | 9 |
| 2140 | Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line “ Indian consensus statement update. <i>South Asian Journal of Cancer</i> , 2019, 08, 01-17. | 0.2 | 8 |
| 2141 | The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma. <i>Cancer Research and Treatment</i> , 2018, 50, 1294-1303. | 1.3 | 49 |
| 2142 | Impact of Pulmonary Tuberculosis on the EGFR Mutational Status and Clinical Outcome in Patients with Lung Adenocarcinoma. <i>Cancer Research and Treatment</i> , 2019, 51, 158-168. | 1.3 | 16 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2143 | A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13. <i>Cancer Research and Treatment</i> , 2019, 51, 718-726. | 1.3 | 10 |
| 2144 | Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea. <i>Cancer Research and Treatment</i> , 2020, 52, 292-300. | 1.3 | 17 |
| 2145 | Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. <i>Cancer Research and Treatment</i> , 2020, 52, 284-291. | 1.3 | 4 |
| 2146 | Current Algorithm for Treatment of Advanced NSCLC Patients: How to Include Active Immunotherapy?. <i>Journal of Cancer Therapy</i> , 2013, 04, 59-75. | 0.1 | 1 |
| 2147 | Carcinomatous meningitis and EGFR mutation. <i>Annals of Cancer Research and Therapy</i> , 2015, 23, 14-18. | 0.1 | 2 |
| 2148 | Treatment After First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small-Cell Lung Cancer. <i>Turkish Thoracic Journal</i> , 2017, 18, 66-71. | 0.2 | 7 |
| 2149 | Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation. <i>World Journal of Clinical Oncology</i> , 2014, 5, 560. | 0.9 | 16 |
| 2150 | UBE2S promotes the proliferation and survival of human lung adenocarcinoma cells. <i>BMB Reports</i> , 2018, 51, 642-647. | 1.1 | 25 |
| 2151 | Risk Factors of Afatinib Induced Diarrhea: A Retrospective Study. <i>Iryo Yakugaku (Japanese Journal of)</i> Tj ETQqO 0 0 rgBT /Overlock 10 Tf 5 0.0 2 | 0.0 | 2 |
| 2152 | Drug-Drug Interactions, Safety, and Pharmacokinetics of EGFR Tyrosine Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018, 9, . | 0.2 | 10 |
| 2153 | Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 36-43. | 2.3 | 21 |
| 2154 | Selection of Luteolin as a potential antagonist from molecular docking analysis of EGFR mutant. <i>Bioinformation</i> , 2018, 14, 241-247. | 0.2 | 12 |
| 2155 | Real-World T790M Mutation Frequency and Impact of Rebiopsy in Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer. <i>Cureus</i> , 2020, 12, e12128. | 0.2 | 14 |
| 2156 | A large-scale, multicentered trial evaluating the sensitivity and specificity of digital PCR versus ARMS-PCR for detecting ctDNA-based EGFR p.T790M in non-small-cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2021, 10, 3888-3901. | 1.3 | 7 |
| 2159 | An Anti-EGFR/anti-HER2 Bispecific Antibody with Enhanced Antitumor Activity Against Acquired Gefitinib-Resistant NSCLC Cells. <i>Protein and Peptide Letters</i> , 2021, 28, 1290-1297. | 0.4 | 2 |
| 2160 | Qing-Kai-Ling Injection Acts Better Than Shen-Fu Injection in Enhancing the Antitumor Effect of Gefitinib in Resistant Non-Small Cell Lung Cancer Models. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-14. | 0.5 | 4 |
| 2161 | Detailed Analysis and Radiomic Prediction of First Progression Sites of First-Line Targeted Therapy for EGFR-Mutant Lung Adenocarcinoma Patients With Systemic Metastasis. <i>Frontiers in Oncology</i> , 2021, 11, 757892. | 1.3 | 0 |
| 2162 | Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC. <i>Npj Precision Oncology</i> , 2021, 5, 91. | 2.3 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2163 | Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer. <i>World Journal of Clinical Oncology</i> , 2021, 12, 912-925. | 0.9 | 4 |
| 2164 | Systemic Therapy for Lung Cancer Brain Metastases. <i>Current Treatment Options in Oncology</i> , 2021, 22, 110. | 1.3 | 12 |
| 2165 | Prognostic Value of BIM Deletion in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs: A Meta-Analysis. <i>BioMed Research International</i> , 2021, 2021, 1-13. | 0.9 | 3 |
| 2166 | Highly sensitive detection of driver mutations from cytological samples and cfDNA in lung cancer. <i>Cancer Medicine</i> , 2021, 10, 8595-8603. | 1.3 | 3 |
| 2167 | A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes. <i>Targeted Oncology</i> , 2021, 16, 801-811. | 1.7 | 13 |
| 2168 | Relationship between Plasma Concentrations of Afatinib and the Onset of Diarrhea in Patients with Non-Small Cell Lung Cancer. <i>Biology</i> , 2021, 10, 1054. | 1.3 | 8 |
| 2169 | Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China. <i>Pharmacology</i> , 2021, 106, 658-666. | 0.9 | 4 |
| 2170 | Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations. <i>Clinical Lung Cancer</i> , 2022, 23, e69-e82. | 1.1 | 31 |
| 2171 | Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 637-646. | 0.7 | 3 |
| 2172 | Comparing survival and treatment response of patients with acquired T790M mutation second-line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real-world study. <i>Thoracic Cancer</i> , 2021, 12, 3263-3272. | 0.8 | 2 |
| 2173 | Therapeutic exploration of uncommon EGFR exon 20 insertion mutations in advanced non-small cell lung cancer: breaking through brambles and thorns. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 163-176. | 1.2 | 4 |
| 2174 | Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies. <i>ESMO Open</i> , 2021, 6, 100280. | 2.0 | 29 |
| 2175 | Evolving Management with Molecular-Targeted and Bone-Targeted Medicine in Patients with Advanced Non-Small Cell Lung Cancer. <i>General Medicine (Los Angeles, Calif)</i> , 2013, 01, . | 0.2 | 0 |
| 2177 | Current status and perspectives of molecular target therapy for advanced lung cancer. <i>Nihon Koku Geka Gakkai Zasshi</i> , 2014, 60, 328-334. | 0.0 | 0 |
| 2178 | EGFR-Targeted Therapies in Non-small Cell Lung Cancer. , 2014, , 31-66. | | 0 |
| 2179 | Pitfalls in Clinical Research. The Case of the New Antineoplastic Agents. <i>Global & Regional Health Technology Assessment</i> , 2014, 1, GRHTA.5000183. | 0.2 | 1 |
| 2181 | Rola systemowych metod leczenia u chorych na niedrobnokomórkowego raka płuca i żołądka: międzybaniaka opłucnej: uaktualnione zalecenia ekspertów. <i>Nowotwory</i> , 2014, 64, 61-75. | 0.1 | 0 |
| 2182 | Afatinib for advanced mutated NSCLC: New hope or new Coke?. <i>Journal of Community and Supportive Oncology</i> , 2014, 12, 115-117. | 0.1 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2184 | Strategy on Patients with EGFR Mutation. , 2015, , 133-145. | | 0 |
| 2185 | Advances in Radiotherapy for Locally Advanced NSCLC. , 2015, , 69-94. | | 0 |
| 2186 | Strategies in Patients with Other Molecular Alterations. , 2015, , 187-202. | | 0 |
| 2187 | Distribution of EGFR Mutations Commonly Observed in Primary Lung Adenocarcinomas in Pakistan as Predictors for Targeted Therapy. Asian Pacific Journal of Cancer Prevention, 2014, 15, 7125-7128. | 0.5 | 3 |
| 2188 | Development and Current Situation of Treatment for Patients with Acquired Resistance to EGFR-TKIs. Japanese Journal of Lung Cancer, 2015, 55, 932-935. | 0.0 | 0 |
| 2190 | Molecular targeted therapy of lung cancer. Tenri Medical Bulletin, 2015, 18, 75-79. | 0.1 | 0 |
| 2191 | Clinical Benefits Associated with First Line Treatment Using Afatinib. Japanese Journal of Lung Cancer, 2015, 55, 866-870. | 0.0 | 0 |
| 2192 | Lung Cancer: Diagnosis and Treatment Approach. , 2015, , 97-144. | | 2 |
| 2193 | Therapy options for advanced NSCLC. , 2015, , 5-25. | | 0 |
| 2194 | Targeted Therapies for Non-Small Cell Lung Cancer. Current Clinical Pathology, 2015, , 89-101. | 0.0 | 1 |
| 2195 | Non-small cell lung cancer and superior vena cava obstruction. , 2015, , 11-24. | | 0 |
| 2196 | Oncogenic drivers and immunotherapy: staying one step ahead of lung cancer. Journal of Community and Supportive Oncology, 2015, 13, 260-267. | 0.1 | 0 |
| 2197 | Resistance of Brain Tumours to Small-Molecule-Targeted Therapies: Lessons from Various Cancer Types. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 89-105. | 0.1 | 0 |
| 2198 | Treatment of Advanced and Metastatic Squamous Non-small Cell Lung Cancer. Korean Journal of Medicine, 2016, 90, 1-6. | 0.1 | 1 |
| 2200 | Current status and prospects of targeted therapies non-small cell lung cancer. Onkologie (Czech) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 | 0.0 | 0 |
| 2201 | Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non-Small Cell Lung Cancer. Journal of the Advanced Practitioner in Oncology, 2016, 7, 514-524. | 0.2 | 1 |
| 2202 | Afatinib plus chemotherapy versus chemotherapy alone after progression on afatinib: new insights on old question?. Annals of Translational Medicine, 2016, 4, S31-S31. | 0.7 | 1 |
| 2203 | Management Strategies for Adverse Events Associated With EGFR TKIs in Non-Small Cell Lung Cancer. Journal of the Advanced Practitioner in Oncology, 2016, 7, . | 0.2 | 6 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2204 | Effect of Coadministration of Gastric Acid-suppressing Drugs on the Safety and Efficacy of EGFR-TKIs in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer. Japanese Journal of Lung Cancer, 2017, 57, 190-195. | 0.0 | 0 |
| 2205 | Methods in Molecular Diagnosis. , 2017, , 63-77. | | 0 |
| 2206 | Companion Diagnostics. , 2017, , 117-136. | | 0 |
| 2207 | Prospective Analysis of Patients Treated with Chemotherapy in Metastatic Adenocarcinoma of Lung—Single Centre Experience. Journal of Cancer Therapy, 2017, 08, 838-844. | 0.1 | 0 |
| 2208 | Gene Signature. , 2017, , 279-292. | | 1 |
| 2209 | EGFR Mutant. , 2017, , 167-189. | | 0 |
| 2210 | The Heat Shock Protein Story—From Taking mTORC1,2 and Heat Shock Protein Inhibitors as Therapeutic Measures for Treating Cancers to Development of Cancer Vaccines. Journal of Cancer Therapy, 2017, 08, 962-1029. | 0.1 | 4 |
| 2211 | Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire disease. Translational Cancer Research, 2017, 6, S151-S157. | 0.4 | 2 |
| 2212 | Osimertinib: A Novel Therapeutic Option for Overcoming T790M Mutations in Non-Small Cell Lung Cancer. Journal of the Advanced Practitioner in Oncology, 2017, 8, 196-201. | 0.2 | 1 |
| 2213 | Upfront radiation versus EGFR-TKI: which is the best approach for EGFR-mutated NSCLC patients with brain metastasis?. Translational Cancer Research, 2017, 6, S533-S536. | 0.4 | 0 |
| 2214 | Nicht-kleinzelliges Lungenkarzinom. Pharma-Kritik (discontinued), 2017, 39, . | 0.0 | 0 |
| 2215 | 2. State of the Art of EGFR-TKI and Future Perspectives. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 1096-1100. | 0.0 | 0 |
| 2216 | The evaluation of the efficacy and toxicity of targeted treatment in non-small cell lung cancer patients—single centre experience. OnCOReview, 2017, 7, 92-97. | 0.1 | 0 |
| 2217 | Targeted Therapies for Lung Cancer. Molecular Pathology Library, 2018, , 239-255. | 0.1 | 0 |
| 2218 | Mutation Testing of Lung Cancer Biomarkers (Excluding IHC and NGS). Molecular Pathology Library, 2018, , 93-108. | 0.1 | 0 |
| 2219 | AFATINIB IN THE TREATMENT OF METASTATIC AND LOCALLY ADVANCED LUNG ADENOCARCINOMA WITH EGFR MUTATIONS: NEW SIDES STUDIED POSSIBILITIES. Meditsinskiy Sovet, 2017, , 46-55. | 0.1 | 0 |
| 2221 | Intratumor Heterogeneity of EGFR Activating Mutations in Advanced NSCLC Patients at Single-Cell Level. , 0, , . | | 0 |
| 2222 | Tyrosine kinase inhibitor versus physician choice chemotherapy in second-line epidermal growth factor receptor mutation non-small cell lung cancer: Post hoc analysis of randomized control trial. Indian Journal of Medical and Paediatric Oncology, 2018, 39, 493. | 0.1 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2223 | Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2018, 38, 2385-2390. | 0.5 | 1 |
| 2224 | Tyrosine Kinase Inhibition in HPV-related Squamous Cell Carcinoma Reveals Beneficial Expression of cKIT and Src. <i>Anticancer Research</i> , 2018, 38, 2723-2731. | 0.5 | 6 |
| 2225 | Tratamiento de c ncer de pulm n metast sico (estadio IV) de c lula no peque a : consenso de expertos, Asociaci n Colombiana de Hematolog a y Oncolog a (ACHO).. <i>Revista Colombiana De Hematolog a Y Oncolog a</i> , 2018, 5, 61-71. | 0.0 | 1 |
| 2226 | The evolution of views on the possibilities of drug therapy in overcoming acquired resistance not associated with T790M mutation to anti-EGFR drugs in non-small cell lung cancer. <i>Journal of Modern Oncology</i> , 2018, 20, 10-18. | 0.1 | 0 |
| 2227 | Traditional Korean Medicine for Skin Toxic Side Effects from Afatinib in a Non-Small Cell Lung Cancer Patient: A Case Report. <i>The Journal of Internal Korean Medicine</i> , 2018, 39, 973-983. | 0.0 | 1 |
| 2229 | Molecular Targeted Therapy of Lung Cancer. <i>Nihon Ika Daigaku Igakkai Zasshi</i> , 2018, 14, 177-179. | 0.0 | 0 |
| 2230 | The mechanisms of acquired resistance to anti-EGFR drugs in non-small cell lung cancer not associated with T790M mutation and their significance in clinical practice. <i>Uspehi Molekularnoj Onkologii</i> , 2018, 5, 17-24. | 0.1 | 0 |
| 2231 | Phenotypic transformation as a cause of secondary drug resistance to osimetinib clinical observation. <i>Meditsinskiy Sovet</i> , 2018, , 130-135. | 0.1 | 0 |
| 2232 | Non-small Cell Lung Cancer. , 2019, , 143-192. | | 0 |
| 2233 | Proteomics for Cancer: Approaches and Challenges. , 2019, , 343-368. | | 0 |
| 2234 | Non small cell lung cancer with targetable driver alterations: Imaging perspective. <i>Integrative Cancer Science and Therapeutics</i> , 2019, 6, . | 0.1 | 0 |
| 2235 | Targeted Agents and Immunotherapy. , 2019, , 381-388. | | 0 |
| 2237 | The efficacy and safety of erlotinib compared with chemotherapy in previously treated NSCLC: A meta-analysis. <i>Mathematical Biosciences and Engineering</i> , 2019, 16, 7921-7933. | 1.0 | 2 |
| 2238 | Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of a Phase III randomized trial to compare the benefit of gefitinib versus pemetrexed/carboplatin for epidermal growth factor receptor-mutated non-small cell lung cancer. <i>Cancer Research Statistics and Treatment</i> , 2019, 2, 21. | 0.1 | 0 |
| 2239 | Nursing Considerations with EGFR Inhibitors in NSCLC. , 2019, , 17-25. | | 0 |
| 2240 | Experiencia Con Erlotinib Y Gefitinib En Pacientes Con C ncer De Pulm n Avanzado Con Mutaci n Positiva En El Receptor De Factor De Crecimiento Epid rmico.. <i>Revista Medica De Panama</i> , 2019, 38, . | 0.0 | 0 |
| 2241 | Design, Synthesis and Antitumor Activity of Quinazoline Derivatives Bearing 2,3-Dihydro-indole or 1,2,3,4-Tetrahydroquinoline. <i>Letters in Drug Design and Discovery</i> , 2019, 16, 533-546. | 0.4 | 1 |
| 2242 | A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation. <i>Meditsinskiy Sovet</i> , 2019, , 110-114. | 0.1 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2243 | Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours. Asian Pacific Journal of Cancer Prevention, 2019, 20, 2415-2420. | 0.5 | 1 |
| 2244 | Osimertinib for the first-line treatment of EGFR-positive non-small cell lung cancer. Journal of Modern Oncology, 2019, 21, 17-20. | 0.1 | 1 |
| 2245 | Tratamiento de c ncer de pulm n metast sico (estadio IV) : segundo consenso de expertos, Asociaci n Colombiana de Hematolog a y Oncolog a (ACHO), 2019.. Revista Colombiana De Hematolog a Y Oncolog a, 2019, 6, 10-22. | 0.0 | 0 |
| 2246 | Traitement des cancers bronchiques non   petites cellules de stades avanc s mut s EGFR: quelle(s) s quence(s) ?. Revue Des Maladies Respiratoires Actualites, 2019, 11, 364-379. | 0.0 | 0 |
| 2247 | Neurological Complications of Targeted Therapies. , 2020, , 341-363. | | 0 |
| 2248 | Pathology of Brain Metastasis. , 2020, , 15-29. | | 1 |
| 2250 | Potential life years not saved due to lack of access to anti-EGFR tyrosine kinase inhibitors for lung cancer treatment in the Brazilian public healthcare system: Budget impact and strategies to improve access. A pharmaco-economic study. Sao Paulo Medical Journal, 2019, 137, 505-511. | 0.4 | 1 |
| 2251 | Cell Free Tumoral DNA Versus Paraffin Block Epidermal Growth Factor Receptor Mutation Detection in Patients with Non-Small Cell Lung Cancer. Asian Pacific Journal of Cancer Prevention, 2019, 20, 3591-3596. | 0.5 | 1 |
| 2252 | Systemic Therapy of Brain Metastases: Lung Cancer. , 2020, , 207-217. | | 0 |
| 2253 | Role of Precision Medicine in Patients with CNS Metastasis. , 2020, , 69-82. | | 0 |
| 2254 | Orthosteric and allosteric modulation of human kinases A mechanistic view. Frontiers in Bioscience - Landmark, 2020, 25, 1462-1487. | 3.0 | 4 |
| 2255 | Role of imaging biomarkers in mutation-driven non-small cell lung cancer. World Journal of Clinical Oncology, 2020, 11, 412-427. | 0.9 | 4 |
| 2256 | Progress in individualized treatment for <i>EGFR</i>-mutated advanced non-small cell lung cancer. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 2020, 96, 266-272. | 1.6 | 4 |
| 2258 | Changes in the concentration of EGFR-mutated plasma DNA in the first hours of anti-EGFR therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer. Voprosy Onkologii, 2021, 67, 665-674. | 0.1 | 0 |
| 2259 | EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1. Communications Biology, 2021, 4, 1237. | 2.0 | 20 |
| 2261 | Postoperative radiotherapy for patients with completely resected pathological stage IIIA-N2 non-small cell lung cancer: a preferential benefit for squamous cell carcinoma. Radiology and Oncology, 2020, 55, 66-76. | 0.6 | 4 |
| 2262 | OPTIMAL SEQUENCE OF APPLICATION OF EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS WITH ACTIVATING EGFR MUTATIONS. Siberian Journal of Oncology, 2020, 19, 119-125. | 0.1 | 0 |
| 2263 | Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma. PLoS ONE, 2020, 15, e0240736. | 1.1 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2265 | Transformation of advanced lung adenocarcinoma to acquired T790M resistance mutation adenosquamous carcinoma following tyrosine kinase inhibitor: a case report. <i>Tumori</i> , 2021, 107, 030089162097326. | 0.6 | 6 |
| 2266 | Endothelial growth factor receptor-mutant lung cancer and post-operative care management: one size does not fit all. <i>Annals of Translational Medicine</i> , 2020, 8, 1697-1697. | 0.7 | 0 |
| 2267 | Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?. <i>Translational Lung Cancer Research</i> , 2020, 9, 2599-2617. | 1.3 | 10 |
| 2268 | Tratamiento de cáncer de pulmón metastásico (estadio IV) : segundo consenso de expertos, Asociación Colombiana de Hematología y Oncología (ACHO), 2019.. <i>Revista Colombiana De Hematología Y Oncología</i> , 2019, 6, 10-22. | 0.0 | 0 |
| 2269 | Dermatological Toxicities of Targeted Therapy. , 2020, , 147-164. | | 1 |
| 2270 | Cyclooxygenase-2 contributes to mutant epidermal growth factor receptor lung tumorigenesis by promoting an immunosuppressive environment. <i>Cancer Translational Medicine</i> , 2020, 6, 40. | 0.2 | 0 |
| 2272 | Experience with Large Panel Next-generation Sequencing in Patients with Advanced Solid Cancers at Juntendo University Hospital. <i>Juntendo Medical Journal</i> , 2020, 66, 392-402. | 0.1 | 0 |
| 2273 | Pulmonary Toxicities of Targeted Therapy. , 2020, , 133-146. | | 0 |
| 2276 | Critical Review of EGFR-Mutated NSCLC: What We Do and Do Not Know. <i>Healthbook TIMES Oncology Hematology</i> , 2020, , 20-35. | 0.1 | 3 |
| 2277 | The prognostic analysis of lung cancer patients with occult malignant pleural disease at thoracotomy. <i>Translational Cancer Research</i> , 2020, 9, 1689-1697. | 0.4 | 0 |
| 2278 | Epidermal growth factor receptor variants in patients from Myanmar with lung adenocarcinoma. <i>Asian Biomedicine</i> , 2020, 14, 75-81. | 0.2 | 1 |
| 2279 | Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. <i>Lung Cancer</i> , 2021, 162, 154-161. | 0.9 | 24 |
| 2280 | Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutationâ€“positive nonâ€“small-cell lung cancer in a real-world setting (OSI-FACT). <i>European Journal of Cancer</i> , 2021, 159, 144-153. | 1.3 | 33 |
| 2281 | Molecular pathology. , 0, , 95-118. | | 2 |
| 2282 | Achievements in targeted therapies. , 0, , 215-233. | | 0 |
| 2283 | Tyrosine kinase inhibitors in the treatment of advanced lung cancer from example of preferential medicine provision in Moscow city. <i>Pulmonologiya</i> , 2020, 30, 463-472. | 0.2 | 1 |
| 2284 | Landmark Studies of Targeted Therapies for Advanced Non-Small Cell Lung Cancer: A Guide for Pulmonologists. <i>Current Respiratory Medicine Reviews</i> , 2020, 16, 5-10. | 0.1 | 0 |
| 2285 | Morphological and molecular genetic diagnosis of lung cancer: methods and problems. <i>Issledovaniya I Praktika V Medicine</i> , 2020, 7, 51-62. | 0.1 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2287 | Immunotherapy for Lung Cancer—Improving Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer With Immunotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 548-554. | 1.0 | 2 |
| 2289 | Clinical features and mutation status of EGFR, KRAS, BRAF, EML4-ALK and ROS1 between surgical resection samples and non surgical resection samples in lung cancer. <i>Journal of Thoracic Disease</i> , 2015, 7, 875-80. | 0.6 | 10 |
| 2290 | Predicting resistance by selection of signaling pathways. <i>Translational Lung Cancer Research</i> , 2014, 3, 107-15. | 1.3 | 21 |
| 2291 | Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents. <i>Annals of Translational Medicine</i> , 2015, 3, 81. | 0.7 | 9 |
| 2292 | EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. <i>American Journal of Cancer Research</i> , 2014, 4, 411-35. | 1.4 | 102 |
| 2293 | Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond. <i>Cancer Biology and Medicine</i> , 2014, 11, 173-81. | 1.4 | 20 |
| 2294 | Chinese expert consensus on molecularly targeted therapy for advanced non-small cell lung cancer (2013 edition). <i>Journal of Thoracic Disease</i> , 2014, 6, 1489-98. | 0.6 | 2 |
| 2295 | Writing in PROSE proteomic-based selection for second line treatment in non-small-cell lung cancer. <i>Annals of Translational Medicine</i> , 2015, 3, 32. | 0.7 | 0 |
| 2296 | Is the third generation EGFR TKIs the solution for making EGFR mutant NSCLC a curable disease?. <i>Translational Lung Cancer Research</i> , 2014, 3, 363-4. | 1.3 | 0 |
| 2297 | Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a decade of progress and hopeful future. <i>Journal of Thoracic Disease</i> , 2015, 7, 217-9. | 0.6 | 0 |
| 2298 | Clinical significance of coexpression of L-type amino acid transporter 1 (LAT1) and ASC amino acid transporter 2 (ASCT2) in lung adenocarcinoma. <i>American Journal of Translational Research (discontinued)</i> , 2015, 7, 1126-39. | 0.0 | 23 |
| 2299 | Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 10330-9. | 1.3 | 19 |
| 2300 | The continuing role of epidermal growth factor receptor tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung. <i>Translational Lung Cancer Research</i> , 2016, 5, 106-9. | 1.3 | 5 |
| 2301 | Afatinib in Non-Small Cell Lung Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2015, 6, 448-55. | 0.2 | 6 |
| 2303 | Role of epidermal growth factor receptor in lung cancer and targeted therapies. <i>American Journal of Cancer Research</i> , 2017, 7, 187-202. | 1.4 | 43 |
| 2304 | Beyond epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) testing in advanced non-small cell lung cancer: Is the picture as "ROS1" as it appears?. <i>Lung India</i> , 2017, 34, 405-408. | 0.3 | 1 |
| 2305 | Molecular Targets in Non-Small Cell Lung Cancer. <i>Ochsner Journal</i> , 2017, 17, 388-392. | 0.5 | 20 |
| 2307 | Management Strategies for Adverse Events Associated With EGFR TKIs in Non-Small Cell Lung Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, 723-735. | 0.2 | 4 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2322 | Diagnosis and Treatment of Adenocarcinomas and Squamous Cell Carcinomas of the Lung. <i>Journal of the Advanced Practitioner in Oncology</i> , 2017, 8, 267-272. | 0.2 | 0 |
| 2324 | Drug-Drug Interactions, Safety, and Pharmacokinetics of EGFR Tyrosine Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018, 9, 189-200. | 0.2 | 12 |
| 2325 | Effect of EGFR gene polymorphism on efficacy of chemotherapy combined with targeted therapy for non-small cell lung cancer in Chinese patients. <i>American Journal of Cancer Research</i> , 2019, 9, 619-627. | 1.4 | 7 |
| 2329 | Survey of serious adverse events and safety evaluation of oral anticancer drug treatment in Japan: A retrospective study. <i>Molecular and Clinical Oncology</i> , 2021, 14, 12. | 0.4 | 1 |
| 2330 | Predicting mutation status in lung adenocarcinoma: development and validation of a computed tomography-based radiomics signature. <i>American Journal of Cancer Research</i> , 2021, 11, 546-560. | 1.4 | 6 |
| 2332 | Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant Brain Metastasis and Spinal Cord Metastasis Models. <i>Frontiers in Pharmacology</i> , 2021, 12, 750031. | 1.6 | 2 |
| 2333 | OUP accepted manuscript. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 53-64. | 0.6 | 0 |
| 2334 | Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188645. | 3.3 | 52 |
| 2335 | Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 751209. | 1.3 | 10 |
| 2336 | Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. <i>Journal of Modern Oncology</i> , 2021, 23, 369-402. | 0.1 | 5 |
| 2337 | A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 8695-8705. | 0.9 | 8 |
| 2338 | Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial. <i>Journal of Neuro-Oncology</i> , 2021, 155, 307-317. | 1.4 | 9 |
| 2339 | Impact of Dose Reduction of Afatinib Used in Patients With Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 781084. | 1.6 | 3 |
| 2340 | A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naïve metastatic non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 105-115. | 1.1 | 10 |
| 2341 | First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002). <i>Scientific Reports</i> , 2021, 11, 23140. | 1.6 | 15 |
| 2342 | The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells. <i>Cancers</i> , 2021, 13, 6005. | 1.7 | 22 |
| 2343 | First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study. <i>Investigational New Drugs</i> , 2022, 40, 430-437. | 1.2 | 8 |
| 2344 | Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients. <i>Medicina (Lithuania)</i> , 2021, 57, 1252. | 0.8 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2346 | KRAS mutation: from undruggable to druggable in cancer. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 386. | 7.1 | 255 |
| 2347 | Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non-small cell lung cancer. <i>European Journal of Cancer</i> , 2022, 160, 227-234. | 1.3 | 5 |
| 2348 | Afatinib for the treatment of advanced non-small-cell lung cancer harboring an epidermal growth factor receptor exon 18 E709_T710delinsD mutation: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 562. | 0.4 | 4 |
| 2349 | Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 5639. | 1.7 | 13 |
| 2350 | Comparison of afatinib and osimertinib effect on overall survival in first-line drug treatment of EGFR-positive metastatic non-small cell lung cancer: network meta-analysis. <i>Journal of Modern Oncology</i> , 2021, 23, 408-417. | 0.1 | 0 |
| 2351 | Nicht-kleinzelliges Lungenkarzinom: Wandel und Möglichkeiten der molekularen Diagnostik. , 0, , . | | 0 |
| 2352 | Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea. <i>Translational Lung Cancer Research</i> , 2021, 10, 4353-4367. | 1.3 | 7 |
| 2353 | Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110598. | 1.4 | 6 |
| 2354 | Indian subset analysis of a phase iii open-label study of afatinib in epidermal growth factor receptor tyrosine kinase inhibitor-naïve patients with epidermal growth factor receptor mutation positive non-small cell lung cancer. <i>Oncology Journal of India</i> , 2021, 5, 116. | 0.1 | 1 |
| 2355 | Potential applications of clickable probes in EGFR activity visualization and prediction of EGFR-TKI therapy response for NSCLC patients. <i>European Journal of Medicinal Chemistry</i> , 2022, 230, 114100. | 2.6 | 3 |
| 2356 | Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations. <i>Healthbook TIMES Oncology Hematology</i> , 2020, , . | 0.1 | 3 |
| 2357 | Survey of serious adverse events and safety evaluation of oral anticancer drug treatment in Japan: A retrospective study. <i>Molecular and Clinical Oncology</i> , 2020, 14, 12. | 0.4 | 7 |
| 2358 | Pretreatment Neutrophil-to-Lymphocyte Ratio and Smoking History as Prognostic Factors in Advanced Non-small Cell Lung Cancer Patients Treated with Osimertinib. <i>Tuberculosis and Respiratory Diseases</i> , 2022, 85, 155-164. | 0.7 | 5 |
| 2359 | The co-mutation of EGFR and tumor-related genes leads to a worse prognosis and a higher level of tumor mutational burden in Chinese non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2022, 14, 185-193. | 0.6 | 7 |
| 2360 | Identification and characterization of post-translational modifications: Clinical implications. <i>Molecular Aspects of Medicine</i> , 2022, 86, 101066. | 2.7 | 34 |
| 2361 | Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR T790M mutation in non-small cell lung cancer cells. <i>Cancer Medicine</i> , 2022, 11, 944-955. | 1.3 | 5 |
| 2362 | Liquid Biopsy and Tissue Biopsy Comparison with Digital PCR and IHC/FISH for HER2 Amplification Detection in Breast Cancer Patients. <i>Journal of Cancer</i> , 2022, 13, 744-751. | 1.2 | 10 |
| 2363 | Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG). <i>Oncologist</i> , 2022, 27, 255-265. | 1.9 | 13 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2364 | Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors. <i>Molecules</i> , 2022, 27, 819. | 1.7 | 32 |
| 2365 | Complications following novel therapies for non-small cell lung cancer. <i>Journal of Internal Medicine</i> , 2022, 291, 732-754. | 2.7 | 6 |
| 2366 | Molecularly directed therapy of advanced/metastatic non-small cell lung cancer (CME article). <i>International Journal of Cancer Care and Delivery</i> , 2022, 2, . | 0.0 | 0 |
| 2368 | A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China. <i>Targeted Oncology</i> , 2022, 17, 1-13. | 1.7 | 6 |
| 2369 | Switch to EGFR-TKI after upfront platinum doublet induction therapy in non-small cell lung cancer (NSCLC) patients with EGFR (Epidermal Growth Factor Receptor) mutation: A multicentre retrospective study. <i>Cancer Treatment and Research Communications</i> , 2022, 31, 100526. | 0.7 | 1 |
| 2370 | Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma. <i>Cancers</i> , 2022, 14, 674. | 1.7 | 10 |
| 2371 | Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 37-44. | 2.3 | 7 |
| 2372 | Cytology-Based Specimen Triage for Epidermal Growth Factor Receptor Mutation Testing of Malignant Pleural Effusions in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 810124. | 1.3 | 2 |
| 2373 | Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF). <i>Cancers</i> , 2022, 14, 769. | 1.7 | 9 |
| 2374 | Efficacy of targeted therapies for oncogene-driven lung cancer in early single-arm versus late phase randomized clinical trials: A comparative analysis. <i>Cancer Treatment Reviews</i> , 2022, 104, 102354. | 3.4 | 2 |
| 2375 | Biomarker subset analysis of a phase IIIb, open-label study of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with EGFRm+ non-small-cell lung cancer. <i>Future Oncology</i> , 2022, 18, 1485-1497. | 1.1 | 0 |
| 2376 | Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study. <i>Lung Cancer</i> , 2022, 167, 41-48. | 0.9 | 18 |
| 2377 | A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2022, 166, 98-106. | 0.9 | 1 |
| 2378 | Predicting EGFR mutation status by a deep learning approach in patients with non-small cell lung cancer brain metastases. <i>Journal of Neuro-Oncology</i> , 2022, 157, 63-69. | 1.4 | 10 |
| 2379 | Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. <i>Cancer Discovery</i> , 2022, 12, 1233-1247. | 7.7 | 60 |
| 2380 | The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors. <i>Frontiers in Oncology</i> , 2022, 12, 843299. | 1.3 | 6 |
| 2381 | Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer. <i>Scientific Reports</i> , 2022, 12, 2167. | 1.6 | 18 |
| 2383 | Neurological complications of lung cancer. , 2022, , 243-276. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2384 | Efficacy of Prophylactic Traditional Chinese Medicine on Skin Toxicity of Afatinib in EGFR Mutation-Positive Advanced Lung Adenocarcinoma: A Single-Center, Prospective, Double-Blinded, Randomized-Controlled Pilot Trial. <i>Integrative Cancer Therapies</i> , 2022, 21, 153473542210866. | 0.8 | 4 |
| 2385 | Target therapy in cancer treatment. , 2022, , . | | 0 |
| 2386 | Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210791. | 1.4 | 10 |
| 2387 | ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. <i>Annals of Oncology</i> , 2022, 33, 466-487. | 0.6 | 67 |
| 2388 | Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI. <i>Cancers</i> , 2022, 14, 977. | 1.7 | 12 |
| 2389 | The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib. <i>Clinical Drug Investigation</i> , 2022, 42, 221-235. | 1.1 | 1 |
| 2390 | Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study. <i>Journal of Thoracic Oncology</i> , 2022, 17, 708-717. | 0.5 | 11 |
| 2391 | Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis. <i>Future Oncology</i> , 2022, 18, 2007-2028. | 1.1 | 3 |
| 2392 | Cancer cachexia as a determinant of efficacy of first-line pembrolizumab in patients with advanced non-small cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2022, 16, 91. | 0.4 | 7 |
| 2393 | MARIPOSA: phase 3 study of first-line amivantamab plus osimertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. <i>Future Oncology</i> , 2022, 18, 639-647. | 1.1 | 44 |
| 2394 | Changes in the concentration of EGFR-mutated plasma DNA in the first hours of targeted therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer. <i>International Journal of Clinical Oncology</i> , 2022, , 1. | 1.0 | 0 |
| 2395 | Assisting Multitargeted Ligand Affinity Prediction of Receptor Tyrosine Kinases Associated Nonsmall Cell Lung Cancer Treatment with Multitasking Principal Neighborhood Aggregation. <i>Molecules</i> , 2022, 27, 1226. | 1.7 | 3 |
| 2396 | Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers. <i>Molecular Cancer</i> , 2022, 21, 61. | 7.9 | 6 |
| 2397 | Evaluation of Progression-Free Survival and Overall Survival of Epidermal Growth Factor Receptor-Positive Metastatic Lung Adenocarcinoma Patients Treated with Erlotinib. <i>Medical Journal of the Islamic Republic of Iran</i> , 0, , . | 0.9 | 0 |
| 2398 | A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma. <i>Translational Lung Cancer Research</i> , 2022, 11, 238-249. | 1.3 | 7 |
| 2399 | Predicting EGFR mutation status in lung adenocarcinoma presenting as ground-glass opacity: utilizing radiomics model in clinical translation. <i>European Radiology</i> , 2022, 32, 5869-5879. | 2.3 | 17 |
| 2400 | A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib. <i>Clinical Lung Cancer</i> , 2022, 23, 300-310. | 1.1 | 12 |
| 2401 | Metabolic complete tumor response in a patient with epidermal growth factor receptor mutant non-small cell lung cancer treated with a reduced dose of afatinib. <i>Journal of International Medical Research</i> , 2022, 50, 030006052110588. | 0.4 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2402 | Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring EGFR Mutations. <i>Anticancer Research</i> , 2022, 42, 2145-2157. | 0.5 | 10 |
| 2403 | Establishment of prognostic nomograms for predicting the progression free survival of EGFR sensitizing mutation, advanced lung cancer patients treated with EGFR-TKIs. <i>Thoracic Cancer</i> , 2022, 13, 1289-1298. | 0.8 | 1 |
| 2404 | ORIENT-31 as the Sakigake "Charging Samurai" Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the "Meiji Modernization" of Post-3G EGFR TKI Progression?. <i>Lung Cancer: Targets and Therapy</i> , 2022, Volume 13, 13-21. | 1.3 | 2 |
| 2405 | Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM). <i>Annals of Oncology</i> , 2022, 33, 602-615. | 0.6 | 46 |
| 2406 | Aumolertinib: A Review in Non-Small Cell Lung Cancer. <i>Drugs</i> , 2022, 82, 577-584. | 4.9 | 9 |
| 2407 | ¹⁸ F-Fluorodeoxyglucose PET/CT for Early Prediction of Outcomes in Patients with Advanced Lung Adenocarcinomas and EGFR Mutations Treated with First-Line EGFR-TKIs. <i>Cancers</i> , 2022, 14, 1507. | 1.7 | 3 |
| 2408 | Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model. <i>Oncogene</i> , 2022, 41, 2470-2479. | 2.6 | 7 |
| 2409 | Oral targeted therapy dose adaptation in older patients with cancer: A real-life French cohort. <i>British Journal of Clinical Pharmacology</i> , 2022, , . | 1.1 | 0 |
| 2410 | Synthesis and Biological Activity of 3,9-Diazatetraasteranes as Novel EGFR Tyrosine Kinase Inhibitors. <i>Russian Journal of General Chemistry</i> , 2022, 92, 446-456. | 0.3 | 5 |
| 2411 | Imaging of Oligometastatic Disease. <i>Cancers</i> , 2022, 14, 1427. | 1.7 | 4 |
| 2412 | Remodeling of dermal adipose tissue alleviates cutaneous toxicity induced by anti-EGFR therapy. <i>ELife</i> , 2022, 11, . | 2.8 | 2 |
| 2413 | Primary Tumor Resection for Stage IV Non-small-cell Lung Cancer Without Progression After First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment: A Retrospective Case-Control Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 4873-4884. | 0.7 | 5 |
| 2414 | EGFR-mutated advanced lung cancer. Data from a single institution, the Hospital of Leon, in Spain. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 854-860. | 0.5 | 1 |
| 2415 | A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the Netherlands. <i>European Journal of Cancer</i> , 2022, 165, 195-204. | 1.3 | 5 |
| 2416 | Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100322. | 0.6 | 3 |
| 2417 | Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 865-875. | 1.2 | 1 |
| 2418 | Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations. <i>ESMO Open</i> , 2022, 7, 100398. | 2.0 | 7 |
| 2419 | Novel targeted therapies for advanced non-small lung cancer. <i>Seminars in Oncology</i> , 2022, 49, 326-336. | 0.8 | 9 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 2420 | Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance. <i>Frontiers in Oncology</i> , 2022, 12, 853501. | 1.3 | 2 |
| 2421 | TP53 Co-Mutations in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy. <i>Frontiers in Oncology</i> , 2022, 12, 860563. | 1.3 | 12 |
| 2422 | Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 111-126. | 1.0 | 2 |
| 2423 | Incidence and risk factors of drug-induced liver injury. <i>Liver International</i> , 2022, 42, 1999-2014. | 1.9 | 35 |
| 2424 | Front-Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-15. | 0.5 | 7 |
| 2425 | Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence. <i>Journal of Oncology</i> , 2021, 2021, 1-16. | 0.6 | 1 |
| 2426 | EGFR-D770G and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios. <i>Cells</i> , 2021, 10, 3561. | 1.8 | 7 |
| 2427 | Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec. <i>Current Oncology</i> , 2021, 28, 5179-5191. | 0.9 | 5 |
| 2428 | Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. <i>MedComm</i> , 2021, 2, 692-729. | 3.1 | 38 |
| 2429 | The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management. <i>Cancer Cell International</i> , 2021, 21, 675. | 1.8 | 9 |
| 2430 | The value of anticancer drugs – a regulatory view. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 207-215. | 12.5 | 14 |
| 2431 | Association of Stage Shift and Population Mortality Among Patients With Non-Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2021, 4, e2137508. | 2.8 | 41 |
| 2432 | Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer. <i>Npj Precision Oncology</i> , 2021, 5, 102. | 2.3 | 11 |
| 2433 | Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models. <i>Frontiers in Pharmacology</i> , 2021, 12, 750031. | 1.6 | 26 |
| 2435 | Exceptional response to afatinib in a patient with persistent G719A EGFR-mutant NSCLC. <i>Lung Cancer Management</i> , 2022, 11, LMT54. | 1.5 | 3 |
| 2436 | Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC. <i>Scientific Reports</i> , 2022, 12, 6367. | 1.6 | 7 |
| 2437 | Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020). <i>Thoracic Cancer</i> , 2022, 13, 1471-1478. | 0.8 | 5 |
| 2438 | EGFR signaling pathway as therapeutic target in human cancers. <i>Seminars in Cancer Biology</i> , 2022, 85, 253-275. | 4.3 | 61 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2439 | Alternating Therapy with Osimertinib and Afatinib for Treatment-Naive Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Single-Group, Open-Label Phase 2 Trial (WJOG10818L). <i>Lung Cancer</i> , 2022, 168, 38-45. | 0.9 | 5 |
| 2440 | Targeting mutations in cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, . | 3.9 | 56 |
| 2441 | A Review of the Correlation Between Epidermal Growth Factor Receptor Mutation Status and 18F-FDG Metabolic Activity in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 780186. | 1.3 | 8 |
| 2442 | An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer. <i>Nature Cancer</i> , 2022, 3, 402-417. | 5.7 | 65 |
| 2443 | Impact of pre-existing interstitial lung abnormal shadow on lung injury development and severity in patients of non-small cell lung cancer treated with osimertinib. <i>Cancer Medicine</i> , 2022, , . | 1.3 | 4 |
| 2444 | Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications. <i>Lung Cancer</i> , 2022, 168, 10-20. | 0.9 | 6 |
| 2461 | The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan. <i>Targeted Oncology</i> , 2022, 17, 295-306. | 1.7 | 7 |
| 2462 | Combining plasma extracellular vesicle Let-7b-5p, miR-184 and circulating miR-22-3p levels for NSCLC diagnosis and drug resistance prediction. <i>Scientific Reports</i> , 2022, 12, 6693. | 1.6 | 21 |
| 2485 | Patient reported outcomes from LUX-Lung 3: first-line afatinib is superior to chemotherapy-would patients agree?. <i>Annals of Palliative Medicine</i> , 2014, 3, 19-21. | 0.5 | 5 |
| 2487 | Beyond epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) testing in advanced non-small cell lung cancer: Is the picture as ROS1 as it appears?. <i>Lung India</i> , 2017, 34, 405. | 0.3 | 3 |
| 2489 | Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for EGFR-mutated Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2022, 42, 2583-2590. | 0.5 | 5 |
| 2490 | Effects of cigarette smoking on metabolic activity of lung cancer on baseline ¹⁸ F-FDG PET/CT. <i>PeerJ</i> , 2022, 10, e13352. | 0.9 | 0 |
| 2491 | Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib. <i>Scientific Reports</i> , 2022, 12, 7002. | 1.6 | 5 |
| 2492 | Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series. <i>Frontiers in Pharmacology</i> , 2022, 13, 912153. | 1.6 | 4 |
| 2493 | Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 497-530. | 2.3 | 530 |
| 2494 | Treatment pattern and outcomes in de novo T790M-mutated non-small cell lung cancer. <i>Ecancermedalscience</i> , 0, 16, . | 0.6 | 3 |
| 2495 | Efficacy of first-line treatments in the elderly and non-elderly patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: a network meta-analysis. <i>BMC Cancer</i> , 2022, 22, 514. | 1.1 | 1 |
| 2496 | Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report. <i>Journal of Geriatric Oncology</i> , 2022, 13, 1071-1083. | 0.5 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 2497 | The relationship between medication literacy and skin adverse reactions in non-small-cell lung cancer patients undergoing targeted EGFR-TKI therapy. <i>BMC Cancer</i> , 2022, 22, 491. | 1.1 | 6 |
| 2498 | Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 499-514. | 12.5 | 140 |
| 2499 | Sex and Gender Differences in Anticancer Treatment Toxicity: A Call for Revisiting Drug Dosing in Oncology. <i>Endocrinology</i> , 2022, 163, . | 1.4 | 21 |
| 2500 | The Controversial Role of IL-33 in Lung Cancer. <i>Frontiers in Immunology</i> , 2022, 13, . | 2.2 | 5 |
| 2501 | Characteristics of Genomic Alterations in Pericardial Effusion of Advanced Non-small Cell Lung Cancer. <i>Frontiers in Genetics</i> , 2022, 13, . | 1.1 | 0 |
| 2502 | Critical points in the management of EGFR-mutated non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2021, . | 0.6 | 0 |
| 2503 | Serum protein level as a predictor of therapeutic response and adverse effects associated with afatinib use. <i>Journal of Thoracic Disease</i> , 2022, 14, 1880-1889. | 0.6 | 1 |
| 2504 | Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer. <i>PLoS ONE</i> , 2022, 17, e0267362. | 1.1 | 6 |
| 2505 | The Value of Radiotherapy for Advanced Non-Small Cell Lung Cancer With Oncogene Driver-Mutation. <i>Frontiers in Oncology</i> , 2022, 12, . | 1.3 | 1 |
| 2506 | Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, . | 3.9 | 15 |
| 2508 | Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis. <i>Cancers</i> , 2022, 14, 2519. | 1.7 | 8 |
| 2509 | Individualized Treatment for Advanced Non-Small Cell Lung Cancer: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2022, 12, . | 1.3 | 2 |
| 2510 | Efficacy and Safety of Rezivertinib (BPI-7711) in Patients with Locally Advanced or Metastatic/Recurrent & EGFR T790M Mutated NSCLC: A Phase IIb Study. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 0 |
| 2511 | Improving the tolerability of osimertinib by identifying its toxic limit. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211032. | 1.4 | 16 |
| 2512 | Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients. <i>Thoracic Cancer</i> , 2022, 13, 1888-1897. | 0.8 | 8 |
| 2513 | Prevalence of highly actionable mutations among Indian patients with advanced non-small cell lung cancer: A systematic review and meta-analysis. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2023, 19, 158-171. | 0.7 | 0 |
| 2514 | Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib. <i>BMC Cancer</i> , 2022, 22, . | 1.1 | 2 |
| 2515 | Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study. <i>Journal of Thoracic Oncology</i> , 2022, 17, 1098-1108. | 0.5 | 51 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2516 | AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer. <i>Scientific Reports</i> , 2022, 12, . | 1.6 | 8 |
| 2517 | Evaluation of Treatment Efficacy of Tyrosine Kinase Inhibitors in Rare Single EGFR Exon 21 L861Q Mutation: Single Center Experience. , 2022, 23, 290-295. | | 0 |
| 2518 | Local thermal ablative therapies for extracranial oligometastatic disease of non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 0, , . | 0.7 | 2 |
| 2519 | A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study. <i>Targeted Oncology</i> , 2022, 17, 271-281. | 1.7 | 3 |
| 2520 | Prognostic outcome of treatment modalities for epidermal growth factor receptor-mutated advanced lung cancer. <i>Korean Journal of Internal Medicine</i> , 0, , . | 0.7 | 0 |
| 2521 | Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study. <i>Lancet Respiratory Medicine</i> , the, 2022, 10, 1019-1028. | 5.2 | 57 |
| 2522 | Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study. <i>Journal of Thoracic Oncology</i> , 2022, 17, 1205-1215. | 0.5 | 12 |
| 2523 | Afatinib 30 mg in the treatment of common and uncommon EGFR-mutated advanced lung adenocarcinomas: a retrospective, single-center, longitudinal study. <i>Journal of Thoracic Disease</i> , 2021, . | 0.6 | 0 |
| 2524 | A narrative review of deep learning applications in lung cancer research: from screening to prognostication. <i>Translational Lung Cancer Research</i> , 2022, 11, 1217-1229. | 1.3 | 8 |
| 2525 | Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials. <i>Translational Lung Cancer Research</i> , 2022, 11, 953-963. | 1.3 | 7 |
| 2526 | Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492211032. | 0.6 | 2 |
| 2527 | Uncovering the Molecular Basis for the Better Gefitinib Sensitivity of EGFR with Complex Mutations over Single Rare Mutation: Insights from Molecular Simulations. <i>Molecules</i> , 2022, 27, 3844. | 1.7 | 4 |
| 2528 | Ảnh hưởng của sự kết hợp giữa các thuốc điều trị bằng EGFR trong ung thư phổi không tế bào nhỏ. <i>Nghiên Cứu Y Học</i> , 2022, 155, 75-83. | 0.0 | 0 |
| 2529 | PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients. <i>Scientific Reports</i> , 2022, 12, . | 1.6 | 13 |
| 2530 | Impact of Smoking Status in Combination Treatment with EGFR Tyrosine Kinase Inhibitors and Anti-Angiogenic Agents in Advanced Non-Small Cell Lung Cancer Harboring Susceptible EGFR Mutations: Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 3366. | 1.0 | 2 |
| 2531 | Expanded Application of a Photoaffinity Probe to Study Epidermal Growth Factor Receptor Tyrosine Kinase with Functional Activity. <i>Analytical Chemistry</i> , 2022, 94, 10118-10126. | 3.2 | 2 |
| 2532 | Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6936. | 1.8 | 8 |
| 2533 | Real-world treatment patterns of metastatic non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors. <i>Cancer Medicine</i> , 2023, 12, 159-169. | 1.3 | 8 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2534 | Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting. <i>Thoracic Cancer</i> , 2022, 13, 2057-2063. | 0.8 | 4 |
| 2535 | Loop-Mediated Isothermal Amplification as Point-of-Care Testing for EGFR-Mutated Lung Adenocarcinoma. <i>Micromachines</i> , 2022, 13, 897. | 1.4 | 2 |
| 2536 | Whole-Exome Sequencing Uncovers Specific Genetic Variation Difference Based on Different Modes of Drug Resistance in Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 0 |
| 2538 | Erlotinib with or without bevacizumab as a first-line therapy for patients with advanced nonsquamous epidermal growth factor receptor-positive non-small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study. <i>Thoracic Cancer</i> , 2022, 13, 2192-2200. | 0.8 | 5 |
| 2539 | EGFR mutation types and abundance were associated with the overall survival of advanced lung adenocarcinoma patients receiving first-line tyrosine kinase inhibitors. <i>Journal of Thoracic Disease</i> , 2022, 14, 2254-2267. | 0.6 | 4 |
| 2540 | Cost-effectiveness of osimertinib versus placebo in resected EGFR-mutated non-small cell lung cancer in China. <i>Cancer Medicine</i> , 0, , . | 1.3 | 2 |
| 2541 | Development and Optimization of Osimertinib-loaded Biodegradable Polymeric Nanoparticles Enhance In-vitro Cytotoxicity in Mutant EGFR NSCLC Cell Models and In-vivo Tumor Reduction in H1975 Xenograft Mice Models. <i>AAPS PharmSciTech</i> , 2022, 23, . | 1.5 | 4 |
| 2543 | Overall Survival Benefits of First-Line Treatments for Asian Patients with Advanced Epidermal Growth Factor Receptor-Mutated NSCLC Harboring Exon 19 Deletion: A Systematic Review and Network Meta-Analysis. <i>Cancers</i> , 2022, 14, 3362. | 1.7 | 1 |
| 2544 | Treating advanced lung cancer in older veterans with comorbid conditions and frailty. <i>Seminars in Oncology</i> , 2022, , . | 0.8 | 0 |
| 2545 | Clinically-meaningful improvements in therapy for unresectable NSCLC. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 927-937. | 1.1 | 6 |
| 2546 | Emerging strategies to overcome resistance to third-generation EGFR inhibitors. <i>Journal of Hematology and Oncology</i> , 2022, 15, . | 6.9 | 48 |
| 2547 | The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer. <i>Cell Death and Disease</i> , 2022, 13, . | 2.7 | 3 |
| 2548 | Singapore Cancer Network (SCAN) Guidelines for the Use of Systemic Therapy in Advanced Non-Small Cell Lung Cancer. <i>Annals of the Academy of Medicine, Singapore</i> , 2015, 44, 449-462. | 0.2 | 2 |
| 2549 | Host-Related Factors as Targetable Drivers of Immunotherapy Response in Non-Small Cell Lung Cancer Patients. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 6 |
| 2550 | Double-dose icotinib may induce the emergence of the EGFR exon 20 T790M mutation in non-small cell lung cancer patients harboring EGFR-sensitive mutation. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 1 |
| 2551 | Lazertinib: on the Way to Its Throne. <i>Yonsei Medical Journal</i> , 2022, 63, 799. | 0.9 | 7 |
| 2552 | The Therapy of Osimertinib for EGFR Mutation-Non-small Cell Lung Cancer. , 0, 6, 219-229. | | 0 |
| 2553 | The Prognostic Value of Periostin Expression in Non-Small Cell Lung Cancer: A Meta-Analysis. <i>Medical Science Monitor</i> , 0, 28, . | 0.5 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2554 | Case Report: Two Patients With EGFR Exon 20 Insertion Mutated Non-Small Cell Lung Cancer Precision Treatment Using Patient-Derived Xenografts in Zebrafish Embryos. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 1 |
| 2555 | Cholesterol homeostasis and cancer: a new perspective on the low-density lipoprotein receptor. <i>Cellular Oncology (Dordrecht)</i> , 2022, 45, 709-728. | 2.1 | 12 |
| 2556 | Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 5 |
| 2557 | Response to Afatinib in a Common EGFR-Mutated Lung Adenocarcinoma with a Very Rare Combination of Compound Mutations. <i>Turkish Thoracic Journal</i> , 2022, 23, 364-365. | 0.2 | 0 |
| 2558 | Sotorasib and other drugs comparison in treating non-small cell lung cancer. , 0, 8, 675-686. | | 0 |
| 2559 | AZD4625 is a Potent and Selective Inhibitor of KRASG12C. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1535-1546. | 1.9 | 2 |
| 2560 | Rare EGFR E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC patients. <i>Lung Cancer</i> , 2022, 172, 117-123. | 0.9 | 0 |
| 2561 | The Effect of Intrathoracic Lesion Location on Initial Tyrosine Kinase Inhibitor Response in Advanced Oncogene-Addicted Non-Small Cell Lung Cancer: A Comparison Between RECIST 1.1 and a Novel Method of Response Assessment (MAX). <i>Clinical Lung Cancer</i> , 2022, 23, e501-e509. | 1.1 | 0 |
| 2562 | A Case of Osimertinib-Induced Eosinophilic Pneumonia. <i>Clinical Lung Cancer</i> , 2022, , . | 1.1 | 1 |
| 2563 | Retrospective analysis of independent predictors of progression-free survival in patients with <sc><i>EGFR</i> mutation-positive</sc> advanced non-small cell lung cancer receiving first-line osimertinib. <i>Thoracic Cancer</i> , 2022, 13, 2741-2750. | 0.8 | 5 |
| 2564 | The nomogram for the prediction of overall survival in patients with metastatic lung adenocarcinoma undergoing primary site surgery: A retrospective population-based study. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 2 |
| 2565 | Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated <i>EGFR</i>. <i>Journal of Clinical Oncology</i> , 2022, 40, 3587-3592. | 0.8 | 26 |
| 2566 | Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 3 |
| 2567 | T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review. <i>Medicine (United Tj ETQq1 1 0.7843 14rgBT /Overlock 10</i> | | |
| 2568 | Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 4 |
| 2569 | <i>EGFR</i>-mutant NSCLC: monitoring the molecular evolution of tumors in 2022. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 1115-1125. | 1.1 | 2 |
| 2570 | Clinical Validation of Companion Diagnostics for the Selection of Patients with Non-Small Cell Lung Cancer Tumors Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutations for Treatment with Amivantamab. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 1181-1188. | 1.2 | 2 |
| 2571 | The Ethanolic Extract of <i>Trichosanthes Kirilowii</i> Root Exerts anti-Cancer Effects in Human Non-Small Cell Lung Cancer Cells Resistant to EGFR TKI. <i>Nutrition and Cancer</i> , 2023, 75, 376-387. | 0.9 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2572 | Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study. <i>Journal of Thoracic Oncology</i> , 2022, 17, 1297-1305. | 0.5 | 21 |
| 2573 | Computed tomography-based radiomics quantification predicts epidermal growth factor receptor mutation status and efficacy of first-line targeted therapy in lung adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 2 |
| 2574 | Deep learning analysis to predict EGFR mutation status in lung adenocarcinoma manifesting as pure ground-glass opacity nodules on CT. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 3 |
| 2575 | A case of multiple primary lung adenocarcinoma with a <i>CD74</i> – <i>ENRG1</i> fusion protein and <i>HER2</i> mutation benefit from combined target therapy. <i>Thoracic Cancer</i> , 2022, 13, 3063-3067. | 0.8 | 4 |
| 2576 | Influence of esomeprazole on the bioavailability of afatinib: A pharmacokinetic cross-over study in patients with non-small cell lung cancer. <i>Biomedicine and Pharmacotherapy</i> , 2022, 155, 113695. | 2.5 | 1 |
| 2577 | Design, synthesis and biological evaluation of novel macrocyclic derivatives bearing aniline pyrimidine scaffolds as EGFR-TKIs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 75, 128970. | 1.0 | 1 |
| 2578 | A High Number of Co-Occurring Genomic Alterations Detected by NGS is Associated with Worse Clinical Outcomes in Advanced EGFR-Mutant Lung Adenocarcinoma: Data from LATAM Population. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 0 |
| 2579 | Translational Research in Lung Cancer. <i>Medical Radiology</i> , 2022, , . | 0.0 | 0 |
| 2580 | Targeted Therapies in Non-small Cell Lung Cancer. <i>Medical Radiology</i> , 2022, , . | 0.0 | 1 |
| 2581 | Temporal Pattern of Cardiac Adverse Events Associated with EGFR-TKIs in Lung Cancer Patients: A Pharmacovigilance Analysis. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 0 |
| 2582 | Substanzen gegen molekulare Zielstrukturen. <i>Springer Reference Medizin</i> , 2022, , 1-14. | 0.0 | 0 |
| 2583 | Clinical trial design in the era of precision medicine. <i>Genome Medicine</i> , 2022, 14, . | 3.6 | 68 |
| 2584 | A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11). <i>Clinical Lung Cancer</i> , 2022, 23, e536-e539. | 1.1 | 7 |
| 2585 | A novel EGFR exon 21 indel mutation in lung adenocarcinoma and response to dacomitinib: A case report. <i>Medicine (United States)</i> , 2022, 101, e30269. | 0.4 | 0 |
| 2586 | Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2023, 55, 112-122. | 1.3 | 1 |
| 2587 | Design, Synthesis and Antitumor Activities of Novel Quinazolinone Derivatives as Potential EGFR Inhibitors. <i>Chemical and Pharmaceutical Bulletin</i> , 2022, 70, 637-641. | 0.6 | 3 |
| 2589 | Endobronchial Ultrasound-guided Sampling of Centrally Located Intrapulmonary Tumors Provides Suitable Material for Diagnostic and Molecular Testing. <i>Journal of Bronchology and Interventional Pulmonology</i> , 0, Publish Ahead of Print, . | 0.8 | 1 |
| 2590 | EGFR-TKI re-administration after osimertinib failure in T790M mutation loss cases with re-biopsy. <i>Investigational New Drugs</i> , 2022, 40, 1342-1349. | 1.2 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 2591 | EGFR T790M testing through repeated liquid biopsy over time: a real-world multicentric retrospective experience. <i>Journal of Thoracic Disease</i> , 2022, 14, 3364-3375. | 0.6 | 1 |
| 2592 | A Machine Learning-Based Predictive Model of Epidermal Growth Factor Mutations in Lung Adenocarcinomas. <i>Cancers</i> , 2022, 14, 4664. | 1.7 | 6 |
| 2593 | Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations. <i>Medicinal Chemistry Research</i> , 2022, 31, 1647-1662. | 1.1 | 9 |
| 2594 | From organoids to bedside: Advances in modeling, decoding and targeting of colorectal cancer. <i>International Journal of Cancer</i> , 2023, 152, 1304-1313. | 2.3 | 4 |
| 2595 | Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 3 |
| 2596 | A case of crescentic glomerulonephritis induced by afatinib for lung adenocarcinoma. <i>CEN Case Reports</i> , 0, , . | 0.5 | 1 |
| 2597 | High levels of <i>AXL</i> expression in untreated <i>EGFR</i> -mutated non-small cell lung cancer negatively impacts the use of osimertinib. <i>Cancer Science</i> , 2023, 114, 606-618. | 1.7 | 9 |
| 2598 | Synthesis and Biological Evaluation of 3,9-Dioxatetraasteranes as Potential Inhibitors of Epidermal Growth Factor Receptor. <i>Letters in Drug Design and Discovery</i> , 2024, 21, 552-558. | 0.4 | 0 |
| 2599 | Prognostic analysis and risk stratification of lung adenocarcinoma undergoing EGFR-TKI therapy with time-serial CT-based radiomics signature. <i>European Radiology</i> , 2023, 33, 825-835. | 2.3 | 10 |
| 2600 | Identification of Immuno-Targeted Combination Therapies Using Explanatory Subgroup Discovery for Cancer Patients with EGFR Wild-Type Gene. <i>Cancers</i> , 2022, 14, 4759. | 1.7 | 1 |
| 2601 | Dynamic Assessment of Tissue and Plasma EGFR-Activating and T790M Mutations with Droplet Digital PCR Assays for Monitoring Response and Resistance in Non-Small Cell Lung Cancers Treated with EGFR-TKIs. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11353. | 1.8 | 6 |
| 2602 | Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): clinical experience of the Galician Lung Cancer Group. <i>Cancer Treatment and Research Communications</i> , 2022, , 100646. | 0.7 | 0 |
| 2603 | Liquid biopsy for detecting epidermal growth factor receptor mutation among patients with non-small cell lung cancer treated with afatinib: a multicenter prospective study. <i>BMC Cancer</i> , 2022, 22, . | 1.1 | 2 |
| 2604 | Applications of covalent chemistry in targeted protein degradation. <i>Chemical Society Reviews</i> , 2022, 51, 9243-9261. | 18.7 | 14 |
| 2605 | First-line therapeutic strategy for patients with advanced non-small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232211257. | 1.1 | 2 |
| 2606 | Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutations. <i>Therapeutic Advances in Respiratory Disease</i> , 2022, 16, 175346662211327. | 1.0 | 6 |
| 2607 | Nanoencapsulation of tyrosine kinase inhibitors for oncological therapeutics. , 2022, , 251-267. | | 0 |
| 2608 | Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue. , 2022, , . | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2609 | Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies. <i>Acta Oncologica</i> , 2022, 61, 1347-1353. | 0.8 | 2 |
| 2610 | New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1626-1644. | 1.3 | 10 |
| 2612 | Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell Lung Cancer (NSCLC) – A Single Center, Retrospective Observational Study. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12511. | 1.8 | 2 |
| 2613 | Prognostic Value of Circulating Tumor DNA (ctDNA) in Oncogene-Driven NSCLC: Current Knowledge and Future Perspectives. <i>Cancers</i> , 2022, 14, 4954. | 1.7 | 5 |
| 2614 | Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON study. <i>Journal of Geriatric Oncology</i> , 2023, 14, 101394. | 0.5 | 1 |
| 2615 | <sc>TAS2940</sc>, a novel <sc>brainâ€penetrable panâ€ERBB</sc> inhibitor, for tumors with <i>HER2</i> and <i>EGFR</i> aberrations. <i>Cancer Science</i> , 2023, 114, 654-664. | 1.7 | 3 |
| 2616 | Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2022, 14, 5095. | 1.7 | 5 |
| 2617 | Landscape of the clinical development of China innovative anti-lung cancer drugs. , 2023, 1, 67-75. | | 2 |
| 2618 | Comparison of the Efficacy of EGFR-TKIs Combined with Antiangiogenic Agents between Patients with Exon 19 Deletion and Patients with Exon 21 Leu858 Arg Mutation: A Systematic Review and Meta-Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-9. | 0.6 | 0 |
| 2619 | Advanced Lung Cancer Patientsâ€™ Use of EGFR Tyrosine Kinase Inhibitors and Overall Survival: Real-World Evidence from Quebec, Canada. <i>Current Oncology</i> , 2022, 29, 8043-8073. | 0.9 | 1 |
| 2621 | Hazard Function Analysis of Recurrence in Patients with Curatively Resected Lung Cancer: Results from the Japanese Lung Cancer Registry in 2010. <i>Cancers</i> , 2022, 14, 5119. | 1.7 | 0 |
| 2623 | Preclinical Study of a Biparatopic METxMET Antibodyâ€Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC. <i>Clinical Cancer Research</i> , 2023, 29, 221-232. | 3.2 | 12 |
| 2624 | Interventional pulmonology use of cell-free DNA assay for metastatic nonâ€small cell lung cancer: the UC Davis experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2022, 16, 175346662211353. | 1.0 | 0 |
| 2625 | Emerging therapies for non-small cell lung cancer harboring EGFR exon 20 insertion mutations: narrative review. <i>Annals of Translational Medicine</i> , 2022, . | 0.7 | 0 |
| 2626 | Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 1 |
| 2627 | Realâ€world outcomes of <sc>antiâ€EGFR</sc> therapy in advanced nonâ€small cell lung cancer <sc>EGFR</sc> mutated in Peru. <i>Thoracic Cancer</i> , 2023, 14, 61-67. | 0.8 | 2 |
| 2628 | The effect of <sc>EGFRâ€TKIs</sc> on survival in advanced nonâ€smallâ€cell lung cancer with <sc>EGFR</sc> mutations: A realâ€world study. <i>Cancer Medicine</i> , 0, , . | 1.3 | 2 |
| 2629 | Segmentectomy for clinically earlyâ€stage primary squamous cell carcinoma of the lung. <i>Thoracic Cancer</i> , 2022, 13, 3477-3485. | 0.8 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2630 | Absence of copy number gain of <i>EGFR</i> : A possible predictive marker of long-term response to afatinib. <i>Cancer Science</i> , 2023, 114, 1045-1055. | 1.7 | 5 |
| 2631 | A fluorogenic probe for predicting treatment response in non-small cell lung cancer with <i>EGFR</i> -activating mutations. <i>Nature Communications</i> , 2022, 13, . | 5.8 | 10 |
| 2632 | A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced <i>EGFR</i> -mutant lung adenocarcinoma: Data from LATAM population. <i>Lung Cancer</i> , 2022, 174, 133-140. | 0.9 | 5 |
| 2633 | The impact of population-based <i>EGFR</i> testing in non-squamous metastatic non-small cell lung cancer in Alberta, Canada. <i>Lung Cancer</i> , 2023, 175, 60-67. | 0.9 | 1 |
| 2634 | Combating acquired resistance to osimertinib in <i>EGFR</i> -mutant lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211440. | 1.4 | 7 |
| 2635 | Synergistic Effect of HAD-B1 and Afatinib Against Gefitinib Resistance of Non-Small Cell Lung Cancer. <i>Integrative Cancer Therapies</i> , 2022, 21, 153473542211443. | 0.8 | 3 |
| 2636 | MicroRNAs and Drug Resistance in Non-Small Cell Lung Cancer: Where Are We Now and Where Are We Going. <i>Cancers</i> , 2022, 14, 5731. | 1.7 | 1 |
| 2637 | Pharmacokinetics of gefitinib in elderly patients with <i>EGFR</i> -mutated advanced non-small cell lung cancer: a prospective study. <i>BMC Pulmonary Medicine</i> , 2022, 22, . | 0.8 | 2 |
| 2638 | The mechanism of action of different generations of <i>EGFR</i> -inhibitors in malignant lung tumors. Literature review and data synthesis. <i>Journal of Modern Oncology</i> , 2022, 24, 340-344. | 0.1 | 0 |
| 2639 | Ảnh hưởng của quá trình truyền tải thuốc ung thư phổi không tế bào nhỏ mang đột biến gen EGFR đối với hiệu quả điều trị bằng gefitinib. <i>Tap Chi Nghien Cuu Y Hoc</i> , 2022, 159, 178-186. | 0.0 | 0 |
| 2641 | Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon <i>EGFR</i> mutations: Real-world data from Taiwan. <i>Thoracic Cancer</i> , 2023, 14, 12-23. | 0.8 | 8 |
| 2642 | Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. <i>Journal of Modern Oncology</i> , 2022, 24, 269-304. | 0.1 | 2 |
| 2643 | CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer. <i>Frontiers of Medicine</i> , 0, , . | 1.5 | 1 |
| 2644 | Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia. <i>Biomedicines</i> , 2022, 10, 3008. | 1.4 | 0 |
| 2645 | PROTAC therapy as a new targeted therapy for lung cancer. <i>Molecular Therapy</i> , 2023, 31, 647-656. | 3.7 | 13 |
| 2646 | Mechanisms of <i>EGFR</i> -TKI-Induced Apoptosis and Strategies Targeting Apoptosis in <i>EGFR</i> -Mutated Non-Small Cell Lung Cancer. <i>Genes</i> , 2022, 13, 2183. | 1.0 | 3 |
| 2647 | Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit. <i>Annals of Oncology</i> , 2023, 34, 431-439. | 0.6 | 7 |
| 2648 | Possible heart failure caused by osimertinib in a lung cancer patient. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 1015-1020. | 0.5 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2649 | Considerations for the Utility of Real-World Evidence Beyond Trial Data in Advanced NSCLC: The Case of Frontline Tyrosine Kinase Inhibitors. <i>Cancer Management and Research</i> , 0, Volume 14, 3421-3435. | 0.9 | 1 |
| 2650 | Emerging Antibodies in Cancer Therapy. <i>Advanced NanoBiomed Research</i> , 2023, 3, . | 1.7 | 1 |
| 2651 | Reversible Drug Resistance Mechanisms in Non-small Cell Lung Cancer. <i>Yakugaku Zasshi</i> , 2022, 142, 1321-1326. | 0.0 | 0 |
| 2652 | The survival after discontinuation of <i>EGFR</i> TKIs due to intolerable adverse events in patients with <i>EGFR</i> -mutated non-small cell lung cancer. <i>Thoracic Cancer</i> , 2023, 14, 348-356. | 0.8 | 3 |
| 2653 | A systematic review of epidermal growth factor receptor tyrosine kinase inhibitor-induced heart failure and its management. <i>The Egyptian Journal of Internal Medicine</i> , 2022, 34, . | 0.3 | 1 |
| 2654 | Endobronchial ultrasound-guided rebiopsy of non-small cell lung cancer with acquired resistance after <i>EGFR</i> tyrosine kinase inhibitor treatment. <i>Thoracic Cancer</i> , 0, . | 0.8 | 1 |
| 2655 | Successful Dasatinib Treatment of Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinoma and <i>BCR-ABL1</i> -Positive Chronic Myeloid Leukemia: A Case Report. <i>Case Reports in Oncology</i> , 2022, 15, 1081-1087. | 0.3 | 1 |
| 2656 | Consolidative high-dose thoracic radiotherapy for limited metastatic nonsmall cell lung cancer: Focusing on oligo-progressive disease. <i>Asia-Pacific Journal of Clinical Oncology</i> , 0, . | 0.7 | 0 |
| 2657 | Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer. <i>Molecular Biomedicine</i> , 2022, 3, . | 1.7 | 8 |
| 2658 | Therapeutic strategies for <i>EGFR</i> -mutated non-small cell lung cancer patients with osimertinib resistance. <i>Journal of Hematology and Oncology</i> , 2022, 15, . | 6.9 | 46 |
| 2659 | Non-small cell lung cancer with <i>EGFR</i> (<i>L858R</i> and <i>E709X</i>) and <i>CNNB1</i> mutations responded to afatinib. <i>Thoracic Cancer</i> , 0, . | 0.8 | 1 |
| 2660 | Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15056. | 1.8 | 32 |
| 2661 | Spinal Metastases and the Evolving Role of Molecular Targeted Therapy, Chemotherapy, and Immunotherapy. <i>Neurospine</i> , 2022, 19, 978-993. | 1.1 | 3 |
| 2662 | Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1699-1707. | 2.0 | 2 |
| 2663 | Osimertinib in NSCLC With Atypical <i>EGFR</i> -Activating Mutations: A Retrospective Multicenter Study. <i>JTO Clinical and Research Reports</i> , 2023, 4, 100459. | 0.6 | 4 |
| 2664 | Pharmacokinetics of Afatinib after Intravenous and Oral Administrations in Rats Using Validated UPLC MS/MS Assay. <i>Journal of Chromatographic Science</i> , 2024, 62, 249-256. | 0.7 | 0 |
| 2665 | Discovery of HCD3514 as a potent <i>EGFR</i> inhibitor against C797S mutation <i>in vitro</i> and <i>in vivo</i> . <i>Journal of Cancer</i> , 2023, 14, 152-162. | 1.2 | 0 |
| 2667 | <i>BRAF</i> RNA is prognostic and widely expressed in lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2023, 12, 27-41. | 1.3 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2668 | Importancia del test de mutación del receptor del factor de crecimiento epidérmico en cáncer de pulmón de células no pequeñas. , 2015, 20, . | | 0 |
| 2669 | The surgical resection of the primary tumor increases survival in patients with EGFR-mutant advanced non-small cell lung cancer: a tertiary center cohort study. Scientific Reports, 2022, 12, . | 1.6 | 0 |
| 2671 | Apoptosis signaling in EGFR inhibitor resistance in NSCLC. , 2023, , 71-88. | | 0 |
| 2672 | Examination of the effectiveness of local therapy for oligorecurrence of EGFR-mutated NSCLC. Thoracic Cancer, 2023, 14, 766-772. | 0.8 | 4 |
| 2673 | Relationship Between Osimertinib Concentration and Clinical Response in Japanese Patients With Non-small Cell Lung Cancer. Anticancer Research, 2023, 43, 725-732. | 0.5 | 1 |
| 2674 | Interactions between natural products and cancer treatments: underlying mechanisms and clinical importance. Cancer Chemotherapy and Pharmacology, 2023, 91, 103-119. | 1.1 | 11 |
| 2675 | Deep learning for predicting epidermal growth factor receptor mutations of non-small cell lung cancer on PET/CT images. Quantitative Imaging in Medicine and Surgery, 2023, 13, 1286-1299. | 1.1 | 3 |
| 2676 | The beginning of a new era in induction treatment for operable non-small cell lung cancer: a narrative review. Journal of Thoracic Disease, 2023, 15, 747-758. | 0.6 | 2 |
| 2677 | Comparison of gefitinib plus chemotherapy versus gefitinib alone for advanced non-small cell lung cancer: A meta analysis. Clinics, 2023, 78, 100152. | 0.6 | 3 |
| 2678 | Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592211461. | 1.4 | 5 |
| 2679 | Káēt quáē sáēng thām vā yáē;u táē tiān lēáēng trān báēnh nhāēn ung thē° pháēi khāēng táē; bāo náēgiaēōāē;in muāē™n k tyrosine kinase thāē; háē† 1, 2 Áiāēu tráē phāēc Áāē“ paclitaxel - carboplatin. Tap Chi Nghien Cuu Y Hoc, 2023, 160, 266-274. | | 0 |
| 2680 | Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study. BMC Cancer, 2023, 23, . | 1.1 | 3 |
| 2681 | Targeted Therapy for Non-Small Cell Lung Cancer. Hematology/Oncology Clinics of North America, 2023, , . | 0.9 | 0 |
| 2682 | Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study. European Journal of Cancer, 2023, 185, 83-93. | 1.3 | 10 |
| 2683 | NCOA-RET fusion as a secondary resistance mechanism to osimertinib in complex EGFR-mutated lung adenocarcinoma: Case report and review of literature. Current Problems in Cancer Case Reports, 2023, 10, 100232. | 0.1 | 0 |
| 2684 | Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data. Cancers, 2023, 15, 629. | 1.7 | 7 |
| 2685 | The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations. JTO Clinical and Research Reports, 2023, 4, 100462. | 0.6 | 1 |
| 2686 | Targeted Therapy: Molecular Pathology and Targets of Gallbladder Cancer. , 2023, , 269-290. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2687 | Unmet Medical Needs in Non-Small-Cell Lung Cancer Treatment: How to Design Pre-Emptive Combination Therapies. <i>European Medical Journal Oncology</i> , 0, , 48-53. | 0.0 | 0 |
| 2688 | The efficacy and safety of PD-1 inhibitors for EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor failure: a retrospective real-world cohort study. <i>Annals of Translational Medicine</i> , 2023, 11, 157-157. | 0.7 | 2 |
| 2689 | NGHIÃŠN Cá»U Äá»C Äá»M LÃ,M SÃENG VÃ€ Cá»N LÃ,M SÃENG Bá»†NH NHÃ,N UNG THÃE PHÃ»I KHÃ»NG Tá»BÃ€ NHÃ»Ž GIA»Äá»EU TRÃ»Š ÄÃCH EGFR THÃ»4 Há»† 1, 2. <i>Y Hoc Viet Nam</i> , 2023, 522, . | 0.0 | 0 |
| 2690 | Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain. <i>BMC Pulmonary Medicine</i> , 2023, 23, . | 0.8 | 1 |
| 2691 | CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations. <i>Frontiers in Oncology</i> , 0, 13, . | 1.3 | 3 |
| 2692 | Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan. <i>Targeted Oncology</i> , 2023, 18, 195-207. | 1.7 | 7 |
| 2693 | Applications of radiomics-based analysis pipeline for predicting epidermal growth factor receptor mutation status. <i>BioMedical Engineering OnLine</i> , 2023, 22, . | 1.3 | 1 |
| 2694 | Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions. <i>Frontiers of Medicine</i> , 2023, 17, 18-42. | 1.5 | 8 |
| 2695 | Factors Affecting the Comprehension of Outpatients Receiving Cancer Chemotherapy. <i>Biological and Pharmaceutical Bulletin</i> , 2023, 46, 505-510. | 0.6 | 0 |
| 2696 | Expert Consensus on the Diagnosis and Treatment of Anticancer Drug-Induced Interstitial Lung Disease. <i>Current Medical Science</i> , 2023, 43, 1-12. | 0.7 | 1 |
| 2697 | Infections in lung cancer patients undergoing immunotherapy and targeted therapy: An overview on the current scenario. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 184, 103954. | 2.0 | 3 |
| 2698 | Treatment Patterns, Testing Practices, and Outcomes in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer in Poland: A Descriptive Analysis of National, Multicenter, Real-World Data from the REFLECT Study. <i>Cancers</i> , 2023, 15, 1581. | 1.7 | 0 |
| 2699 | Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC). <i>Frontiers in Oncology</i> , 0, 13, . | 1.3 | 2 |
| 2700 | Chemotherapy-Induced Oral Complications and Prophylaxis Strategies. <i>Cancer Investigation</i> , 2023, 41, 432-455. | 0.6 | 0 |
| 2701 | Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors. <i>BMC Cancer</i> , 2023, 23, . | 1.1 | 5 |
| 2702 | Adjuvant EGFR-TKI therapy in resected EGFR-mutation positive non-small cell lung cancer: A real-world study. <i>Frontiers in Oncology</i> , 0, 13, . | 1.3 | 0 |
| 2703 | Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations. <i>Clinical Cancer Research</i> , 2023, 29, 2123-2130. | 3.2 | 6 |
| 2704 | Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer. <i>Cancers</i> , 2023, 15, 1766. | 1.7 | 6 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2705 | Residual neural network with mixed loss based on batch training technique for identification of EGFR mutation status in lung cancer. Multimedia Tools and Applications, 0, , . | 2.6 | 0 |
| 2706 | TÁC DỤNG KHẢ NĂNG MONG MUỐN CÁI A PHÁC ẮC PACLITAXEL ẮC CARBOPLATIN TRONG ẮC ẮC TRẮNG LUNG THỂ PHÁC ẮC KHẢ NĂNG NHẢY GIẢI ẮC ẮC MUỐN ẮC ẮC TRI ẮC ẮC SAU ẮC ẮC TRẮNG THU ẮC ẮC EGFR TYROSINE KINASE. Y Hoc Viet Nam, 2023, 524, . | 0.4 | 0 |
| 2707 | Trends in antineoplastic drug use, cost and prescribing patterns among patients with lung cancer in nine major cities of China, 2016 ẮC ẮC 2020: a retrospective observational study based on inpatient and outpatient hospital data. BMJ Open, 2023, 13, e069645. | 0.8 | 2 |
| 2708 | CT Radiomics Predict EGFR-T790M Resistance Mutation in Advanced Non-Small Cell Lung Cancer Patients After Progression on First-line EGFR-TKI. Academic Radiology, 2023, 30, 2574-2587. | 1.3 | 3 |
| 2709 | Efficacy of different platforms in detecting <i>EGFR</i> mutations using cerebrospinal fluid <sc>cell-free DNA</sc> from <sc>non-small</sc> <sc>cell</sc> lung cancer patients with leptomeningeal metastases. Thoracic Cancer, 2023, 14, 1251-1259. | 0.8 | 5 |
| 2710 | Regional differences in epidermal growth factor receptor-tyrosine kinase inhibitor therapy in lung cancer treatment using a national database in Japan. Scientific Reports, 2023, 13, . | 1.6 | 0 |
| 2711 | Ultra-rapid Idylla ẮC EGFR mutation screening followed by next-generation sequencing: An integrated solution to molecular diagnosis of non-small cell lung cancer. Frontiers in Oncology, 0, 13, . | 1.3 | 0 |
| 2712 | Structure ẮC Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017 ẮC Present). Pharmaceuticals, 2023, 16, 534. | 1.7 | 7 |
| 2713 | The Emerging Role of Radiotherapy in Oligoprogressive Non-Small Cell Lung Cancer. Surgical Oncology Clinics of North America, 2023, , . | 0.6 | 0 |
| 2714 | A systematic review of genetic ancestry as a risk factor for incidence of non-small cell lung cancer in the US. Frontiers in Genetics, 0, 14, . | 1.1 | 3 |
| 2716 | Concomitant TP53 mutation in early-stage resected EGFR-mutated non-small cell lung cancer: a narrative approach in a genetically admixed Brazilian cohort. Brazilian Journal of Medical and Biological Research, 0, 56, . | 0.7 | 1 |
| 2717 | The Use of Cytotoxic Drugs as First Line Chemotherapy for EGFR (+) Nonsquamous NSCLC: A Network Meta-Analysis. Disease Markers, 2023, 2023, 1-8. | 0.6 | 2 |
| 2718 | Detection of EGFR mutations in early-stage lung adenocarcinoma by machine learning-based radiomics. Translational Cancer Research, 2023, . | 0.4 | 0 |
| 2719 | Comparison of the Incidence Rate of Radiation Pneumonitis Observed in Patients with Advanced Lung Adenocarcinoma Treated with Simultaneous Thoracic Radiotherapy and 1G/2G/3G EGFR-TKIs. Cancer Management and Research, 0, Volume 15, 351-362. | 0.9 | 1 |
| 2720 | Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations. Cancer Immunology, Immunotherapy, 0, , . | 2.0 | 1 |
| 2721 | Personalized treatment for patients with lung cancer. Deutsches Ärzteblatt International, 0, , . | 0.6 | 0 |
| 2722 | Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial. European Journal of Cancer, 2023, 188, 8-19. | 1.3 | 0 |
| 2725 | Tissue Acquisition in Patients with Suspected Lung Cancer: Techniques Available and Sampling Adequacy for Molecular Testing. , 2023, , 307-325. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2733 | Role and mechanistic actions of protein kinase inhibitors as an effective drug target for cancer and COVID. Archives of Microbiology, 2023, 205, . | 1.0 | 2 |
| 2759 | Evaluation des Nutzens. , 2023, , 37-179. | | 0 |
| 2761 | Combination of Stereotactic Ablative Radiotherapy and Systemic Therapy in Oligoprogressive Non-small Cell Lung Cancer. , 2023, , . | | 0 |
| 2772 | Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials. Signal Transduction and Targeted Therapy, 2023, 8, . | 7.1 | 11 |
| 2791 | Prognosis and Prognostic Factors of Lung Cancer. , 2023, , 1-16. | | 0 |
| 2795 | Pulmonary Complications of Lung Cancer Treatment. Respiratory Medicine, 2023, , 229-254. | 0.1 | 0 |
| 2820 | Lung Cancer in Elderly: Patient-Centered Approach for Optimal Delivery of Care. , 2024, , 1-17. | | 0 |
| 2844 | Lung Cancer in Elderly: Patient-Centered Approach for Optimal Delivery of Care. , 2024, , 869-884. | | 0 |